WO2022120194A1 - Polymer nanoparticle and dna nanostructure compositions and methods for non-viral delivery - Google Patents
Polymer nanoparticle and dna nanostructure compositions and methods for non-viral delivery Download PDFInfo
- Publication number
- WO2022120194A1 WO2022120194A1 PCT/US2021/061846 US2021061846W WO2022120194A1 WO 2022120194 A1 WO2022120194 A1 WO 2022120194A1 US 2021061846 W US2021061846 W US 2021061846W WO 2022120194 A1 WO2022120194 A1 WO 2022120194A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- block copolymer
- composition
- methacrylate
- dna
- raft block
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
- A61K47/6455—Polycationic oligopeptides, polypeptides or polyamino acids, e.g. for complexing nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
- A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
- A61K47/6933—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained by reactions only involving carbon to carbon, e.g. poly(meth)acrylate, polystyrene, polyvinylpyrrolidone or polyvinylalcohol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
- A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
- A61K47/6935—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F293/00—Macromolecular compounds obtained by polymerisation on to a macromolecule having groups capable of inducing the formation of new polymer chains bound exclusively at one or both ends of the starting macromolecule
- C08F293/005—Macromolecular compounds obtained by polymerisation on to a macromolecule having groups capable of inducing the formation of new polymer chains bound exclusively at one or both ends of the starting macromolecule using free radical "living" or "controlled" polymerisation, e.g. using a complexing agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y30/00—Nanotechnology for materials or surface science, e.g. nanocomposites
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y35/00—Methods or apparatus for measurement or analysis of nanostructures
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y40/00—Manufacture or treatment of nanostructures
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F2438/00—Living radical polymerisation
- C08F2438/03—Use of a di- or tri-thiocarbonylthio compound, e.g. di- or tri-thioester, di- or tri-thiocarbamate, or a xanthate as chain transfer agent, e.g . Reversible Addition Fragmentation chain Transfer [RAFT] or Macromolecular Design via Interchange of Xanthates [MADIX]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/16—Aptamers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
- C12N2310/531—Stem-loop; Hairpin
Definitions
- the invention relates to polymer nanoparticle and DNA nanostructure delivery compositions for non-viral delivery, and methods therefor. More particularly, the invention relates to polymer nanoparticle delivery compositions, such as reversible addition-fragmentation chain transfer (RAFT) polymer compositions, and DNA nanostructure delivery compositions, such as DNA origami compositions, for the delivery, for example, of more than one payload, or for the delivery of a nucleic acid construct payload of 3 kB or more, and methods therefor.
- polymer nanoparticle delivery compositions such as reversible addition-fragmentation chain transfer (RAFT) polymer compositions
- DNA nanostructure delivery compositions such as DNA origami compositions
- Genetic medicines including gene therapy, gene silencing, splicing regulators, and nuclease based gene editors
- Genetic medicines are poised to produce revolutionary treatments, including vaccines, infectious disease treatments, antimicrobial treatments, antiviral treatments, and most notably, genetic disease treatments.
- the in vivo delivery of these genetic medicine pay loads to the specific tissues and cells that need to be treated, while avoiding tissues and cells that can reduce the efficacy or safety of the genetic medicine, poses a significant challenge. Additional challenges include the ability to deliver large genetic payloads or multiple payloads.
- Adeno-associated viruses are the most widely used tool for genetic medicine delivery, but AAVs are not able to deliver large genetic payloads or multiple payloads (such as the clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 system), and they sometimes trigger unwanted immune responses, including the generation of anti-AAV antibodies, a cell mediated response. Some of the immune responses caused by AAV in patients are potentially fatal immune responses.
- CRISPR clustered regularly interspaced short palindromic repeats
- CRISPR/Cas9 Therapeutics based on the CRISPR/Cas9 system have an exceptional potential to treat a number of genetic diseases due to the capability of this system for precise and programmable gene editing.
- Gene editing and repair using the CRISPR/Cas9 system has two main mechanisms, including non-homologous end joining (NHEJ) which repairs the site of cut by inducing random indel mutation, and homology-directed repair (HDR), which repairs the cut site based on a pre-existing template. Because a pre-designed template can be used for HDR-directed repair, therapies based on this mechanism can be tailored to cure a large number of different genetic diseases.
- NHEJ non-homologous end joining
- HDR homology-directed repair
- HDR repair requires the delivery of CRISPR/Cas9, small guide RNA (sgRNA) and a donor DNA strand at the same time to a particular location.
- sgRNA small guide RNA
- This requirement becomes particularly limiting for in vivo applications because ensuring co-delivery of multiple large molecules to the same targeted location is currently not feasible.
- the Cas9 enzyme sequence and guide RNA complex is too large to fit into AAVs.
- non-viral delivery systems including gene delivery systems.
- the current state-of-the-art non-viral gene delivery systems such as liposomes, have many drawbacks such as poor biocompatibility and the inability to easily engineer or functionalize them. Additional concerns are that such non-viral gene delivery systems are easily degraded by various enzymes as they pass through intracellular or intercellular compartments, and these systems have not been able to package multiple large pay loads.
- the inventors have designed polymer nanoparticle (e.g., RAFT polymer) and DNA nanostructure delivery compositions (e.g., DNA origami nanostructures). These compositions have the advantage of being biocompatible, non-toxic, and can be programmed in many ways.
- the polymer nanoparticle and DNA nanostructure delivery compositions can be programmed to have functional groups that enable them to evade early degradation, that enable them to evade immune responses, and that enable intracellular imaging and targeted and controlled delivery of therapeutic genes.
- these non-viral delivery compositions can enhance the stability, safety, and/or efficacy of genetic medicine payloads by providing immune evasion, tissue- directed intracellular delivery, and the ability to deliver large genetic payloads or multiple payloads.
- a DNA nanostructure delivery composition comprising: i) a single stranded DNA scaffold and ii) one or more oligonucleotides that bind through complementary base pairing with a segment of the DNA scaffold, wherein the one or more oligonucleotides cause the DNA scaffold to fold, and wherein the composition comprises more than one payload for delivery or a nucleic acid construct payload of 3 kB or more.
- composition of clause 1 wherein the more than one payload comprises nucleic acids.
- composition of clause 2 wherein the nucleic acids comprise DNA or RNA.
- composition of clause 2 wherein the nucleic acids comprise a ribonucleoprotein.
- composition of clause 2 wherein the payload nucleic acids comprise a short guide RNA (sgRNA) and a donor DNA strand.
- sgRNA short guide RNA
- composition of clause 1 wherein the payloads comprise a CRISPR associated enzyme.
- composition of clause 7 wherein the targeted enzyme is a CRISPR associated enzyme.
- composition of clause 1 wherein the payloads comprise a CRISPR associated enzyme, an sgRNA, and a donor DNA strand.
- composition of clause 1 wherein the payloads comprise CRISPR/Cas9, an sgRNA, and a donor DNA strand.
- composition of clause 1 wherein the payloads comprise a coding sequence for Cas9, an sgRNA, and a donor DNA strand in the form of a plasmid.
- composition of clause 1 wherein the payloads consist of one molecule each of CRISPR/Cas9, an sgRNA, and a donor DNA strand.
- composition of clause 1 wherein the nucleic acid construct payload of 3 kB or more comprises a CAR-T DNA construct.
- composition of clause 1 wherein the payloads comprise an antisense oligonucleotide.
- nucleic acid construct payload is of a size selected from the group consisting of 3 kB or more, 3.5 kB or more, 4 kB or more, 4.5 kB or more, 5 kB or more, 5.5 kB or more, 6 kB or more, 6.5 kB or more, 7 kB or more, 7.5 kB or more, 8 kB or more, and 8.5 kB or more.
- composition of clause 1 wherein the payloads comprise a reverse transcriptase.
- composition of clause 1 wherein the DNA scaffold and the one or more oligonucleotides comprise M13 bacteriophage DNA.
- composition of clause 2 wherein the one or more oligonucleotides comprise overhangs that bind through complementary base paring with the pay load nucleic acids.
- composition of clause 1 further comprising a pharmaceutically acceptable carrier.
- composition of clause 26 wherein the pharmaceutically acceptable carrier is for parenteral administration or topical administration.
- composition of clause 28 wherein the one or more polymers comprise polyethylene glycol.
- composition of clause 28 wherein the one or more polymers comprise polyethylene glycol poly-L-lysine.
- composition of clause 28 wherein the one or more polymers comprise polyethylenimine .
- composition of clause 28 wherein the one or more polymers comprise polyethylene glycol poly-L-lysine and polyethylenimine.
- the DNA nanostructure further comprises a targeting component for targeting to cells.
- composition of clause 33 wherein the targeting component is a nucleotide that has a three-dimensional structure capable of binding a target cell receptor.
- composition of clause 34 wherein the nucleotide is an RNA that forms a ‘stem- and-loop’ structure.
- a method for gene therapy comprising administering to a patient a DNA nanostructure delivery composition comprising: i) a single stranded DNA scaffold and ii) one or more oligonucleotides that bind through complementary base pairing with a segment of the DNA scaffold, wherein the one or more oligonucleotides cause the DNA scaffold to fold, and wherein the composition comprises more than one payload for delivery or a nucleic acid construct payload of 3 kB or more.
- nucleic acids comprise DNA or RNA.
- nucleic acids comprise a ribonucleoprotein.
- the payload nucleic acids comprise a short guide RNA (sgRNA) and a donor DNA strand.
- sgRNA short guide RNA
- the payloads comprise a CRISPR associated enzyme, an sgRNA, and a donor DNA strand.
- the payloads comprise CRISPR/Cas9.
- the payloads comprise CRISPR/Cas9, an sgRNA, and a donor DNA strand.
- the payloads comprise a coding sequence for Cas9, an sgRNA, and a donor DNA strand in the form of a plasmid.
- nucleic acid construct payload of 3 kB or more comprises a CAR-T DNA construct.
- nucleic acid construct payload is of a size selected from the group consisting of 3 kB or more, 3.5 kB or more, 4 kB or more, 4.5 kB or more, 5 kB or more, 5.5 kB or more, 6 kB or more, 6.5 kB or more, 7 kB or more, 7.5 kB or more, 8 kB or more, and 8.5 kB or more.
- the targeting component is a nucleotide that has a three-dimensional structure capable of binding a target cell receptor.
- nucleotide is an RNA that forms a ‘stem-and- loop’ structure.
- the cancer is selected from the group consisting of lung cancer, bone cancer, pancreatic cancer, skin cancer, uterine cancer, ovarian cancer, endometrial cancer, rectal cancer, stomach cancer, colon cancer, breast cancer, cancer of the esophagus, cancer of the endocrine system, prostate cancer, leukemia, lymphoma, mesothelioma, cancer of the bladder, cancer of the kidney, neoplasms of the central nervous system, brain cancer, and adenocarcinoma.
- a method for targeting a DNA nanostructure delivery composition to cells of a patient comprising administering to the patient: i) a single stranded DNA scaffold and ii) one or more oligonucleotides that bind through complementary base pairing with a segment of the DNA scaffold, wherein the one or more oligonucleotides cause the DNA scaffold to fold, wherein the composition comprises more than one payload for delivery or a nucleic acid construct payload of 3 kB or more, and wherein the DNA nanostructure comprises a targeting component for targeting to the cells of the patient.
- nucleic acids comprise DNA or RNA.
- nucleic acids comprise a ribonucleoprotein.
- the payload nucleic acids comprise a short guide RNA (sgRNA) and a donor DNA strand.
- sgRNA short guide RNA
- the payloads comprise a CRISPR associated enzyme, an sgRNA, and a donor DNA strand.
- the payload comprises CRISPR/Cas9 and Cas9 is fused with a deaminase.
- the payloads comprise a coding sequence for Cas9, an sgRNA, and a donor DNA strand in the form of a plasmid.
- nucleic acid construct payload of 3 kB or more comprises a CAR-T DNA construct.
- nucleic acid construct payload is of a size selected from the group consisting of 3 kB or more, 3.5 kB or more, 4 kB or more, 4.5 kB or more, 5 kB or more, 5.5 kB or more, 6 kB or more, 6.5 kB or more, 7 kB or more, 7.5 kB or more, 8 kB or more, and 8.5 kB or more.
- the targeting component is a nucleotide that has a three-dimensional structure capable of binding a target cell receptor.
- nucleotide is an RNA that forms a ‘stem-and- loop’ structure.
- a method comprising: synthesizing a diverse set of non-viral gene delivery compositions, wherein each non- viral gene delivery composition differs from each other non-viral gene delivery composition of the diverse set with respect to at least one of a set of composition characteristics, simultaneously testing one or more quality attributes of each of the non-viral gene delivery composition of the diverse set, and creating, using results of the testing, a predictive model that correlates the composition characteristics with the quality attributes.
- composition characteristics comprise one or more of molecular weight, degree of branching, number of ionizable groups, core-to-corona molecular weight ratio, hydrophilicity, hydrophobicity, propensity for aggregation, size, pKa, logP, and surface charge.
- each of the non-viral gene delivery compositions of the diverse set is a DNA nanostructure delivery composition according to one of clauses 1-36.
- a RAFT block copolymer comprising a. a first terminus comprising a first capping unit derived from a first chain transfer agent in a RAFT copolymerization process; b. a first block prepared from one or more monomer units covalently attached to the first reactive functional unit, and having a molecular weight (M n ) in the range of about 20 kDa to about 40 kDa and a degree of polymerization in the range of about 300 to about 400; c.
- M n molecular weight
- a second block prepared from one or more monomer units covalently attached to the first block, and having a molecular weight (M n )in the range of about 5 kDa to about 20 kDa and a degree of polymerization in the range of about 400 to about 500; and d.
- M n molecular weight
- RAFT block copolymer has one or more of an overall molecular weight (Mn) in the range of about 25 kDa to about 60 kDa, and overall degree of polymerization in the range of about 700 to about 900, a target size in the range of about of about 10 to about 60 nm, and a maximum corona- to-core ratio (CCR) of about 1.5 to about 3.5.
- Mn overall molecular weight
- CCR maximum corona- to-core ratio
- each chain transfer agent is independently selected from the group consisting of bis(carboxymethyl)trithiocarbonate, bis(2-amino-2-oxoethyl) trithiocarbonate, bis[4-(2- hydroxyethoxycarbonyl)benzyl] trithiocarbonate, 4-cyano-4-(ethylsulfanylthiocarbonyl) sulfanylvpentanoic acid, 4-cyano-4-((phenylcarbonothioyl)thio)pentanoic acid, and 4-cyano-4- [(dodecylsulfanylthiocarbonyl)sulfanyl] pentanoic acid.
- a method of preparing a RAFT block copolymer comprising: i. contacting a first chain transfer agent, a first initiator and one or more monomer units to provide a first block; ii. contacting a second chain transfer agent, a second initiator and one or more monomer units to provide a second block iii. contacting the first block and the second block under conditions capable of coupling the blocks to provide the RAFT block copolymer.
- the first chain transfer agent is a diamino or dihydroxy chain transfer agent
- the second chain transfer agent is a dicarboxylic acid chain transfer agent.
- step (i) The method of any one of clauses 128 to 133, wherein the one or more monomer units in step (i) are independently selected from the group consisting of 2-dimethylaminoethyl acrylate, 2-(diethylamino) ethyl methacrylate, 2-(diisopropylamino) ethyl methacrylate, butyl methacrylate, ethyl acrylic acid, propyl acrylic acid, (hydroxyethyl)methacrylate, and methyl methacrylate.
- step (i) is one of 2-dimethylaminoethyl acrylate, 2-(diethylamino) ethyl methacrylate, 2- (diisopropylamino) ethyl methacrylate, butyl methacrylate, ethyl acrylic acid, propyl acrylic acid, (hydroxyethyl)methacrylate, or methyl methacrylate.
- step (ii) are independently selected from the group consisting of 2-dimethylaminoethyl acrylate, 2-(diethylamino) ethyl methacrylate, 2-(diisopropylamino) ethyl methacrylate, butyl methacrylate, ethyl acrylic acid, propyl acrylic acid, (hydroxyethyl)methacrylate, and methyl methacrylate.
- step (ii) are two different monomer units independently selected from the group consisting of 2-dimethylaminoethyl acrylate, 2-(diethylamino) ethyl methacrylate, 2-(diisopropylamino) ethyl methacrylate, butyl methacrylate, ethyl acrylic acid, propyl acrylic acid, (hydroxyethyl)methacrylate, and methyl methacrylate.
- step (ii) are three different monomer units independently selected from the group consisting of 2-dimethylaminoethyl acrylate, 2-(diethylamino) ethyl methacrylate, 2-(diisopropylamino) ethyl methacrylate, butyl methacrylate, ethyl acrylic acid, propyl acrylic acid, (hydroxyethyl)methacrylate, and methyl methacrylate.
- step (ii) are 2-dimethylaminoethyl acrylate, butyl methacrylate, and propyl acrylic acid; or 2-dimethylaminoethyl acrylate and butyl methacrylate; or 2-dimethylaminoethyl acrylate, butyl methacrylate, and ethyl acrylic acid.
- RAFT block copolymer has one or more of an overall molecular weight (M n ) in the range of about 25 kDa to about 60 kDa, and overall degree of polymerization in the range of about 700 to about 900, a target size in the range of about of about 10 to about 60 nm, and a maximum corona-to-core ratio (CCR) of about 1.5 to about 3.5.
- M n overall molecular weight
- CCR maximum corona-to-core ratio
- a method of preparing a library of RAFT block copolymers comprising: i. providing an array of reaction mixtures in a multiwell plate, wherein each well comprises a mixture of a first chain transfer agent, a first initiator, one or more monomer units, and optionally a solvent or solvent mixture; ii. reacting the mixture in each well under conditions that promote RAFT copolymerization to provide a series of first block copolymers in the wells of the multiwell plate; iii. quenching the reactions in the wells of the multiwell plate; iv. purifying the first block copolymer in each well of the multiwell plate; v. optionally characterizing the first block copolymer in each well of the multiwell plate; vi.
- step (vii) optionally purifying the first block copolymer in each well of the multiwell plate; vii. contacting to the first block copolymer in each well of the multiwell plate with a second array of reaction mixtures comprising a second chain transfer agent, a second initiator, and one or more monomer units, and optionally a solvent or solvent mixture; viii. reacting the components of step (vii) under conditions that promote RAFT copolymerization to provide a series of RAFT block copolymers in the wells of the multiwell plate; ix. quenching the reactions in the wells of the multiwell plate; x. purifying the RAFT block copolymer in each well of the multiwell plate; and xi. optionally characterizing the RAFT block copolymer in each well of the multiwell plate.
- step (i) is independently selected from the group consisting of 2-dimethylaminoethyl acrylate, 2- (diethylamino) ethyl methacrylate, 2-(diisopropylamino) ethyl methacrylate, butyl methacrylate, ethyl acrylic acid, propyl acrylic acid, (hydroxyethyl)methacrylate, and methyl methacrylate.
- step (i) is one of 2-dimethylaminoethyl acrylate, 2-(diethylamino) ethyl methacrylate, 2- (diisopropylamino) ethyl methacrylate, butyl methacrylate, ethyl acrylic acid, propyl acrylic acid, (hydroxyethyl)methacrylate, or methyl methacrylate.
- step (vii) The method of any one of clauses 141 to 143, wherein the one or more monomer units in step (vii) are independently selected from the group consisting of 2-dimethylaminoethyl acrylate, 2-(diethylamino) ethyl methacrylate, 2-(diisopropylamino) ethyl methacrylate, butyl methacrylate, ethyl acrylic acid, propyl acrylic acid, (hydroxyethyl)methacrylate, and methyl methacrylate.
- step (vii) The method of any one of clauses 141 to 144, wherein the one or more monomer units in step (vii) are two different monomer units independently selected from the group consisting of 2-dimethylaminoethyl acrylate, 2-(diethylamino) ethyl methacrylate, 2-(diisopropylamino) ethyl methacrylate, butyl methacrylate, ethyl acrylic acid, propyl acrylic acid, (hydroxyethyl)methacrylate, and methyl methacrylate.
- the one or more monomer units in step (vii) are two different monomer units independently selected from the group consisting of 2-dimethylaminoethyl acrylate, 2-(diethylamino) ethyl methacrylate, 2-(diisopropylamino) ethyl methacrylate, butyl methacrylate, ethyl acrylic acid, propyl acrylic acid, (hydroxyeth
- step (vii) The method of any one of clauses 141 to 145, wherein the one or more monomer units in step (vii) are three different monomer units independently selected from the group consisting of 2-dimethylaminoethyl acrylate, 2-(diethylamino) ethyl methacrylate, 2- (diisopropylamino) ethyl methacrylate, butyl methacrylate, ethyl acrylic acid, propyl acrylic acid, (hydroxyethyl)methacrylate, and methyl methacrylate.
- the one or more monomer units in step (vii) are three different monomer units independently selected from the group consisting of 2-dimethylaminoethyl acrylate, 2-(diethylamino) ethyl methacrylate, 2- (diisopropylamino) ethyl methacrylate, butyl methacrylate, ethyl acrylic acid, propyl acrylic acid, (hydroxyeth
- step (vii) The method of any one of clauses 141 to 146, wherein the one or more monomer units in step (vii) are 2-dimethylaminoethyl acrylate, butyl methacrylate, and propyl acrylic acid; or 2-dimethylaminoethyl acrylate and butyl methacrylate; or 2-dimethylaminoethyl acrylate, butyl methacrylate, and ethyl acrylic acid.
- first and second chain transfer are each independently selected from the group consisting of bis(carboxymethyl)trithiocarbonate, bis(2-amino-2-oxoethyl) trithiocarbonate, bis[4-(2- hydroxyethoxycarbonyl)benzyl] trithiocarbonate, 4-cyano-4-(ethylsulfanylthiocarbonyl) sulfanylvpentanoic acid, 4-cyano-4-((phenylcarbonothioyl)thio)pentanoic acid, and 4-cyano-4- [(dodecylsulfanylthiocarbonyl)sulfanyl] pentanoic acid.
- (x) are carried out via filtration, diafiltration, or dialysis in a multiwell format.
- a composition comprising a RAFT block copolymer according to any one of clauses 118 to 127 or a RAFT block copolymer prepared according to the method of any one of clauses 128 to 156.
- a RAFT block copolymer conjugate comprising a RAFT block copolymer according to any one of clauses 118 to 127 or a RAFT block copolymer prepared according to the method of any one of clauses 128 to 156, and further comprising a biomolecule, drug, or label covalently attached to the RAFT block copolymer through a functional group on one of the first or second chain transfer agents that is incorporated into the RAFT block copolymer.
- a method of preparing a RAFT block copolymer conjugate comprising a RAFT block copolymer according to any one of clauses 118 to 127 or a RAFT block copolymer prepared according to the method of any one of clauses 128 to 156 and a biomolecule, drug, or label, wherein the RAFT block copolymer and the biomolecule, drug, or label are covalently attached through a functional group on one of the first or second chain transfer agents that is incorporated into the RAFT block copolymer.
- a RAFT block copolymer complex comprising a RAFT block copolymer according to any one of clauses 118 to 127 or a RAFT block copolymer prepared according to the method of any one of clauses 128 to 156, and further comprising a payload complexed to the RAFT block copolymer through electrostatic interaction.
- sgRNA short guide RNA
- the RAFT block copolymer complex of clause 167 wherein the payload comprises a reverse transcriptase.
- the RAFT block copolymer complex of clause 167 further comprising a pharmaceutically acceptable carrier.
- the RAFT block copolymer complex of clause 167 further comprising a targeting component for targeting to cells.
- a method for gene therapy comprising administering to a patient a RAFT block copolymer of any one of clauses 167 to 188.
- a method for targeting a polymer nanoparticle composition to cells of a patient comprising administering to the patient a RAFT block copolymer of any one of clauses 167 to 188.
- each of the non-viral gene delivery compositions of the diverse set is a RAFT block copolymer according to one of clauses 118-127.
- Fig. 1A shows a schematic of a DNA nanostructure showing a central cavity to encapsulate a CRISPR RNP.
- Fig. IB shows the designed dimensions.
- Fig. 1C and Fig. ID show measured dimensions of the DNA nanostructure as measured with DynaPro and ZetaSizer.
- Fig. IE shows a TEM image showing one to one encapsulation of Cas9 RNP (arrows) in the DNA nanostructure and uptake in HEK 293 cells.
- Fig. IF shows results of an MTT assay to study cytotoxicity of the empty DNA nanostructrure.
- Fig. 1G and Fig. 1H show results demonstrating concentration dependent uptake of the DNA nanostructure and that EGFP Cas9 colocalizes with the cell nucleus indicating nuclear delivery.
- Fig. 2 shows a schematic of the input parameters for polymer nanoparticle synthesis and the highly tunable output characteristics.
- Fig. 3 shows the results of a cytotoxicity assay for polymer nanoparticle compositions.
- Fig. 4 shows delivery of polymer nanoparticle compositions to HEK-293 cells.
- Fig. 5A shows a side view of a DNA nanostructure delivery composition with a capsule with lid, designed to have a height of 23.4 nm and a width of 26 nm.
- Fig. 5B shows the transverse view of the design, with a length of 60 nm.
- the cavity has dimensions of 13 nm in height and 15.6 nm in width and is designed to encapsulate CRISPR RNP.
- the cylindrical structures represent helix “bundles”.
- Fig. 6 is a chart showing polymer library size (diameter) data for Libraries 0006 (left most bar), 0007 (left-center bar), 0009 (right-center bar), and 0011 (right most bar) prepared as described herein.
- Fig. 7A-C are charts showing polymer Library Block 1 Molecular Weight (Mw) Data for Block 12 of Libraries 0006 (Fig. 7A), 0007 (Fig. 7B), and 0008 (Fig. 7C) prepared as described herein and measured as weight average molecular weight.
- Fig. 8A-B are charts showing polymer Library Block 1 Molecular Weight (Mw) Data for Block 12 of Libraries 0009 (Fig. 8A) and 0011 (Fig. 8B) prepared as described herein and measured as weight average molecular weight.
- Fig. 9A-C are cartoons showing a 96-well plate having, in each well, the completed Block 1 polymer of varying molecular weights for each of library 0001 (Fig. 9A), 0003 (Fig. 9B), and 0005 (Fig. 9C).
- Fig. 10A-C are graphs showing MTT assay results for the completed Block 1 polymer of varying molecular weights for each of library 0001 (Fig. 10A), 0003 (Fig. 10B), and 0005 (Fig. 10C).
- the invention relates to polymer nanoparticle and DNA nanostructure delivery compositions for non-viral delivery, and methods therefor. More particularly, the invention relates to polymer nanoparticle delivery compositions, such as reversible addition-fragmentation chain transfer (RAFT) polymer compositions, and DNA nanostructure delivery compositions, such as DNA origami compositions, for the delivery of more than one payload, or for the delivery of a nucleic acid construct payload of 3 kB or more, and methods therefor.
- polymer nanoparticle delivery compositions such as reversible addition-fragmentation chain transfer (RAFT) polymer compositions
- DNA nanostructure delivery compositions such as DNA origami compositions
- a DNA nanostructure delivery composition comprising: i) a single stranded DNA scaffold and ii) one or more oligonucleotides that bind through complementary base pairing with a segment of the DNA scaffold, wherein the one or more oligonucleotides cause the DNA scaffold to fold, and wherein the composition comprises more than one payload for delivery or a nucleic acid construct payload of 3 kB or more.
- composition of clause 1 wherein the more than one payload comprises nucleic acids.
- composition of clause 2 wherein the nucleic acids comprise DNA or RNA.
- composition of clause 2 wherein the nucleic acids comprise a ribonucleoprotein.
- composition of clause 2 wherein the payload nucleic acids comprise a short guide RNA (sgRNA) and a donor DNA strand.
- sgRNA short guide RNA
- composition of clause 1 wherein the payloads comprise a CRISPR associated enzyme.
- composition of clause 7 wherein the targeted enzyme is a CRISPR associated enzyme.
- composition of clause 1 wherein the payloads comprise a CRISPR associated enzyme, an sgRNA, and a donor DNA strand.
- composition of clause 1 wherein the payloads comprise CRISPR/Cas9, an sgRNA, and a donor DNA strand.
- composition of clause 1 wherein the payloads comprise a coding sequence for Cas9, an sgRNA, and a donor DNA strand in the form of a plasmid.
- composition of clause 1 wherein the payloads consist of one molecule each of CRISPR/Cas9, an sgRNA, and a donor DNA strand.
- nucleic acid construct payload of 3 kB or more comprises a CAR-T DNA construct.
- the payloads comprise an antisense oligonucleotide.
- nucleic acid construct payload is of a size selected from the group consisting of 3 kB or more, 3.5 kB or more, 4 kB or more, 4.5 kB or more, 5 kB or more, 5.5 kB or more, 6 kB or more, 6.5 kB or more, 7 kB or more, 7.5 kB or more, 8 kB or more, and 8.5 kB or more.
- composition of clause 1 wherein the payloads comprise a reverse transcriptase.
- composition of clause 1 wherein the DNA scaffold and the one or more oligonucleotides comprise M13 bacteriophage DNA.
- composition of clause 2 wherein the one or more oligonucleotides comprise overhangs that bind through complementary base paring with the pay load nucleic acids.
- composition of clause 1 further comprising a pharmaceutically acceptable carrier.
- composition of clause 26 wherein the pharmaceutically acceptable carrier is for parenteral administration or topical administration.
- composition of clause 28 wherein the one or more polymers comprise polyethylene glycol.
- composition of clause 28 wherein the one or more polymers comprise polyethylene glycol poly-L-lysine.
- composition of clause 28 wherein the one or more polymers comprise polyethylenimine .
- composition of clause 28 wherein the one or more polymers comprise polyethylene glycol poly-L-lysine and polyethylenimine.
- composition of clause 1 wherein the DNA nanostructure further comprises a targeting component for targeting to cells.
- composition of clause 33 wherein the targeting component is a nucleotide that has a three-dimensional structure capable of binding a target cell receptor.
- composition of clause 34 wherein the nucleotide is an RNA that forms a ‘stem- and-loop’ structure.
- a method for gene therapy comprising administering to a patient a DNA nanostructure delivery composition comprising: i) a single stranded DNA scaffold and ii) one or more oligonucleotides that bind through complementary base pairing with a segment of the DNA scaffold, wherein the one or more oligonucleotides cause the DNA scaffold to fold, and wherein the composition comprises more than one payload for delivery or a nucleic acid construct payload of 3 kB or more.
- nucleic acids comprise DNA or RNA.
- nucleic acids comprise a ribonucleoprotein.
- the payload nucleic acids comprise a short guide RNA (sgRNA) and a donor DNA strand.
- sgRNA short guide RNA
- the payloads comprise a CRISPR associated enzyme, an sgRNA, and a donor DNA strand. 47. The method of clause 37 wherein the payloads comprise CRISPR/Cas9.
- the payloads comprise a coding sequence for Cas9, an sgRNA, and a donor DNA strand in the form of a plasmid.
- nucleic acid construct payload of 3 kB or more comprises a CAR-T DNA construct.
- nucleic acid construct payload is of a size selected from the group consisting of 3 kB or more, 3.5 kB or more, 4 kB or more, 4.5 kB or more, 5 kB or more, 5.5 kB or more, 6 kB or more, 6.5 kB or more, 7 kB or more, 7.5 kB or more, 8 kB or more, and 8.5 kB or more.
- the targeting component is a nucleotide that has a three-dimensional structure capable of binding a target cell receptor.
- nucleotide is an RNA that forms a ‘stem-and- loop’ structure.
- the cancer is selected from the group consisting of lung cancer, bone cancer, pancreatic cancer, skin cancer, uterine cancer, ovarian cancer, endometrial cancer, rectal cancer, stomach cancer, colon cancer, breast cancer, cancer of the esophagus, cancer of the endocrine system, prostate cancer, leukemia, lymphoma, mesothelioma, cancer of the bladder, cancer of the kidney, neoplasms of the central nervous system, brain cancer, and adenocarcinoma.
- a method for targeting a DNA nanostructure delivery composition to cells of a patient comprising administering to the patient: i) a single stranded DNA scaffold and ii) one or more oligonucleotides that bind through complementary base pairing with a segment of the DNA scaffold, wherein the one or more oligonucleotides cause the DNA scaffold to fold, wherein the composition comprises more than one payload for delivery or a nucleic acid construct payload of 3 kB or more, and wherein the DNA nanostructure comprises a targeting component for targeting to the cells of the patient.
- nucleic acids comprise DNA or RNA.
- nucleic acids comprise a ribonucleoprotein.
- the payload nucleic acids comprise a short guide RNA (sgRNA) and a donor DNA strand.
- sgRNA short guide RNA
- the payloads comprise a CRISPR associated enzyme, an sgRNA, and a donor DNA strand.
- the payload comprises CRISPR/Cas9 and Cas9 is fused with a deaminase.
- the payloads comprise a coding sequence for Cas9, an sgRNA, and a donor DNA strand in the form of a plasmid.
- nucleic acid construct payload of 3 kB or more comprises a CAR-T DNA construct.
- nucleic acid construct payload is of a size selected from the group consisting of 3 kB or more, 3.5 kB or more, 4 kB or more, 4.5 kB or more, 5 kB or more, 5.5 kB or more, 6 kB or more, 6.5 kB or more, 7 kB or more, 7.5 kB or more, 8 kB or more, and 8.5 kB or more.
- the targeting component is a nucleotide that has a three-dimensional structure capable of binding a target cell receptor.
- nucleotide is an RNA that forms a ‘stem-and- loop’ structure.
- a method comprising: synthesizing a diverse set of non-viral gene delivery compositions, wherein each non- viral gene delivery composition differs from each other non-viral gene delivery composition of the diverse set with respect to at least one of a set of composition characteristics, simultaneously testing one or more quality attributes of each of the non-viral gene delivery composition of the diverse set, and creating, using results of the testing, a predictive model that correlates the composition characteristics with the quality attributes.
- composition characteristics comprise one or more of molecular weight, degree of branching, number of ionizable groups, core-to-corona molecular weight ratio, hydrophilicity, hydrophobicity, propensity for aggregation, size, pKa, logP, and surface charge.
- each of the non-viral gene delivery compositions of the diverse set is a DNA nanostructure delivery composition according to one of clauses 1-36.
- a RAFT block copolymer comprising a. a first terminus comprising a first capping unit derived from a first chain transfer agent in a RAFT copolymerization process; b. a first block prepared from one or more monomer units covalently attached to the first reactive functional unit, and having a molecular weight (M n ) in the range of about 20 kDa to about 80 kDa and a degree of polymerization in the range of about 20 to about 400; c.
- M n molecular weight
- a second block prepared from one or more monomer units covalently attached to the first block, and having a molecular weight (M n )in the range of about 5 kDa to about 80 kDa and a degree of polymerization in the range of about 10 to about 500; and d.
- M n molecular weight
- RAFT block copolymer has one or more of an overall molecular weight (Mn) in the range of about 25 kDa to about 160 kDa, and overall degree of polymerization in the range of about 30 to about 900, a size in the range of about of about 10 to about 60 nm, and a maximum corona- to-core ratio (CCR) of about 1 to about 4.
- Mn overall molecular weight
- CCR maximum corona- to-core ratio
- each chain transfer agent is independently selected from the group consisting of bis(carboxymethyl)trithiocarbonate, bis(2-amino-2-oxoethyl) trithiocarbonate, bis[4-(2- hydroxyethoxycarbonyl)benzyl] trithiocarbonate, 4-cyano-4-(ethylsulfanylthiocarbonyl) sulfanylvpentanoic acid, 4-cyano-4-((phenylcarbonothioyl)thio)pentanoic acid, and 4-cyano-4- [(dodecylsulfanylthiocarbonyl)sulfanyl] pentanoic acid.
- a method of preparing a RAFT block copolymer comprising: i. contacting a first chain transfer agent, a first initiator and one or more monomer units to provide a first block; ii. contacting a second chain transfer agent, a second initiator and one or more monomer units to provide a second block iii. contacting the first block and the second block under conditions capable of coupling the blocks to provide the RAFT block copolymer.
- the first chain transfer agent is a diamino or dihydroxy chain transfer agent
- the second chain transfer agent is a dicarboxylic acid chain transfer agent.
- step (i) The method of any one of clauses 128 to 133, wherein the one or more monomer units in step (i) are independently selected from the group consisting of 2-dimethylaminoethyl acrylate, 2-(diethylamino) ethyl methacrylate, 2-(diisopropylamino) ethyl methacrylate, butyl methacrylate, ethyl acrylic acid, propyl acrylic acid, (hydroxyethyl)methacrylate, and methyl methacrylate.
- step (i) is one of 2-dimethylaminoethyl acrylate, 2-(diethylamino) ethyl methacrylate, 2- (diisopropylamino) ethyl methacrylate, butyl methacrylate, ethyl acrylic acid, propyl acrylic acid, (hydroxyethyl)methacrylate, or methyl methacrylate.
- step (ii) are independently selected from the group consisting of 2-dimethylaminoethyl acrylate, 2-(diethylamino) ethyl methacrylate, 2-(diisopropylamino) ethyl methacrylate, butyl methacrylate, ethyl acrylic acid, propyl acrylic acid, (hydroxyethyl)methacrylate, and methyl methacrylate.
- step (ii) are two different monomer units independently selected from the group consisting of 2-dimethylaminoethyl acrylate, 2-(diethylamino) ethyl methacrylate, 2-(diisopropylamino) ethyl methacrylate, butyl methacrylate, ethyl acrylic acid, propyl acrylic acid, (hydroxyethyl)methacrylate, and methyl methacrylate.
- step (ii) are three different monomer units independently selected from the group consisting of 2-dimethylaminoethyl acrylate, 2-(diethylamino) ethyl methacrylate, 2-(diisopropylamino) ethyl methacrylate, butyl methacrylate, ethyl acrylic acid, propyl acrylic acid, (hydroxyethyl)methacrylate, and methyl methacrylate.
- step (ii) are 2-dimethylaminoethyl acrylate, butyl methacrylate, and propyl acrylic acid; or 2-dimethylaminoethyl acrylate and butyl methacrylate; or 2-dimethylaminoethyl acrylate, butyl methacrylate, and ethyl acrylic acid.
- RAFT block copolymer has one or more of an overall molecular weight (M n ) in the range of about 25 kDa to about 160 kDa, and overall degree of polymerization in the range of about 30 to about 900, a size in the range of about of about 10 to about 60 nm, and a maximum corona- to-core ratio (CCR) of about 1 to about 4.
- M n overall molecular weight
- CCR maximum corona- to-core ratio
- a method of preparing a library of RAFT block copolymers comprising: i. providing an array of reaction mixtures in a multiwell plate, wherein each well comprises a mixture of a first chain transfer agent, a first initiator, one or more monomer units, and optionally a solvent or solvent mixture; ii. reacting the mixture in each well under conditions that promote RAFT copolymerization to provide a series of first block copolymers in the wells of the multiwell plate; iii. quenching the reactions in the wells of the multiwell plate; iv. purifying the first block copolymer in each well of the multiwell plate; v. optionally characterizing the first block copolymer in each well of the multiwell plate; vi.
- step (vii) optionally purifying the first block copolymer in each well of the multiwell plate; vii. contacting to the first block copolymer in each well of the multiwell plate with a second array of reaction mixtures comprising a second chain transfer agent, a second initiator, and one or more monomer units, and optionally a solvent or solvent mixture; viii. reacting the components of step (vii) under conditions that promote RAFT copolymerization to provide a series of RAFT block copolymers in the wells of the multiwell plate; ix. quenching the reactions in the wells of the multiwell plate; x. purifying the RAFT block copolymer in each well of the multiwell plate; and xi. optionally characterizing the RAFT block copolymer in each well of the multiwell plate.
- step (i) is independently selected from the group consisting of 2-dimethylaminoethyl acrylate, 2- (diethylamino) ethyl methacrylate, 2-(diisopropylamino) ethyl methacrylate, butyl methacrylate, ethyl acrylic acid, propyl acrylic acid, (hydroxyethyl)methacrylate, and methyl methacrylate.
- step (i) is one of 2-dimethylaminoethyl acrylate, 2-(diethylamino) ethyl methacrylate, 2- (diisopropylamino) ethyl methacrylate, butyl methacrylate, ethyl acrylic acid, propyl acrylic acid, (hydroxyethyl)methacrylate, or methyl methacrylate.
- step (vii) The method of any one of clauses 141 to 143, wherein the one or more monomer units in step (vii) are independently selected from the group consisting of 2-dimethylaminoethyl acrylate, 2-(diethylamino) ethyl methacrylate, 2-(diisopropylamino) ethyl methacrylate, butyl methacrylate, ethyl acrylic acid, propyl acrylic acid, (hydroxyethyl)methacrylate, and methyl methacrylate.
- step (vii) The method of any one of clauses 141 to 144, wherein the one or more monomer units in step (vii) are two different monomer units independently selected from the group consisting of 2-dimethylaminoethyl acrylate, 2-(diethylamino) ethyl methacrylate, 2-(diisopropylamino) ethyl methacrylate, butyl methacrylate, ethyl acrylic acid, propyl acrylic acid, (hydroxyethyl)methacrylate, and methyl methacrylate.
- the one or more monomer units in step (vii) are two different monomer units independently selected from the group consisting of 2-dimethylaminoethyl acrylate, 2-(diethylamino) ethyl methacrylate, 2-(diisopropylamino) ethyl methacrylate, butyl methacrylate, ethyl acrylic acid, propyl acrylic acid, (hydroxyeth
- step (vii) The method of any one of clauses 141 to 145, wherein the one or more monomer units in step (vii) are three different monomer units independently selected from the group consisting of 2-dimethylaminoethyl acrylate, 2-(diethylamino) ethyl methacrylate, 2- (diisopropylamino) ethyl methacrylate, butyl methacrylate, ethyl acrylic acid, propyl acrylic acid, (hydroxyethyl)methacrylate, and methyl methacrylate.
- the one or more monomer units in step (vii) are three different monomer units independently selected from the group consisting of 2-dimethylaminoethyl acrylate, 2-(diethylamino) ethyl methacrylate, 2- (diisopropylamino) ethyl methacrylate, butyl methacrylate, ethyl acrylic acid, propyl acrylic acid, (hydroxyeth
- step (vii) The method of any one of clauses 141 to 146, wherein the one or more monomer units in step (vii) are 2-dimethylaminoethyl acrylate, butyl methacrylate, and propyl acrylic acid; or 2-dimethylaminoethyl acrylate and butyl methacrylate; or 2-dimethylaminoethyl acrylate, butyl methacrylate, and ethyl acrylic acid.
- first and second chain transfer are each independently selected from the group consisting of bis(carboxymethyl)trithiocarbonate, bis(2-amino-2-oxoethyl) trithiocarbonate, bis[4-(2- hydroxyethoxycarbonyl)benzyl] trithiocarbonate, 4-cyano-4-(ethylsulfanylthiocarbonyl) sulfanylvpentanoic acid, 4-cyano-4-((phenylcarbonothioyl)thio)pentanoic acid, and 4-cyano-4- [(dodecylsulfanylthiocarbonyl)sulfanyl] pentanoic acid.
- (x) are carried out via filtration, diafiltration, or dialysis in a multiwell format.
- a composition comprising a RAFT block copolymer according to any one of clauses 118 to 127 or a RAFT block copolymer prepared according to the method of any one of clauses 128 to 156.
- a RAFT block copolymer conjugate comprising a RAFT block copolymer according to any one of clauses 118 to 127 or a RAFT block copolymer prepared according to the method of any one of clauses 128 to 156, and further comprising a biomolecule, drug, or label covalently attached to the RAFT block copolymer through a functional group on one of the first or second chain transfer agents that is incorporated into the RAFT block copolymer.
- a method of preparing a RAFT block copolymer conjugate comprising a RAFT block copolymer according to any one of clauses 118 to 127 or a RAFT block copolymer prepared according to the method of any one of clauses 128 to 156 and a biomolecule, drug, or label, wherein the RAFT block copolymer and the biomolecule, drug, or label are covalently attached through a functional group on one of the first or second chain transfer agents that is incorporated into the RAFT block copolymer.
- a RAFT block copolymer complex comprising a RAFT block copolymer according to any one of clauses 118 to 127 or a RAFT block copolymer prepared according to the method of any one of clauses 128 to 156, and further comprising a payload complexed to the RAFT block copolymer through electrostatic interaction.
- sgRNA short guide RNA
- the RAFT block copolymer complex of clause 167 wherein the payload comprises a reverse transcriptase.
- the RAFT block copolymer complex of clause 167 further comprising a pharmaceutically acceptable carrier.
- the RAFT block copolymer complex of clause 167 further comprising a targeting component for targeting to cells.
- a method for gene therapy comprising administering to a patient a RAFT block copolymer of any one of clauses 167 to 188.
- a method for targeting a polymer nanoparticle composition to cells of a patient comprising administering to the patient a RAFT block copolymer of any one of clauses 167 to 188.
- each of the non-viral gene delivery compositions of the diverse set is a RAFT block copolymer according to one of clauses 118-127.
- the polymer nanoparticle or DNA nanostructure delivery compositions described herein may comprise any non-viral composition for in vivo delivery of the payloads.
- the polymer nanoparticle or nanostructure DNA delivery compositions described herein may be selected from the group comprising: polymer nanoparticles, reversible addition-fragmentation chain transfer (RAFT) polymers, polyplexes, micelles, polymersomes, dendrimers, emulsion, synthetic virus-like particles, carbon nanotubes, emulsions, and any DNA nanostructure delivery composition, such as DNA origami structures.
- RAFT reversible addition-fragmentation chain transfer
- polymer nanoparticle compositions e.g., RAFT copolymers
- DNA nanostructure delivery compositions the two platforms have a high degree of tunability in structure and function, opportunities to protect payloads from adverse reactions or degradation by the immune system, and cell targeting via surface charge, particle size, or conjugation with various aptamers.
- These delivery systems also lend themselves to computer aided design, and they both have suitable pathways to robust, commercial scale manufacturing processes with higher yields and fewer purification steps than viral manufacturing processes.
- a DNA nanostructure delivery composition is provided.
- a DNA nanostructure delivery composition e.g., a DNA origami structure
- a delivery platform is programmable and offers an opportunity for precise scale-up and manufacturing.
- the biologic and non-viral nature of the DNA nanostructure delivery composition reduces the chance of adverse immune reactions.
- control of each nucleotide that forms a part of the DNA nanostructure delivery composition allows for the precise design and modification of the structure, including suitable chemical moieties which can make in vivo delivery and endosomal escape possible.
- the DNA nanostructure delivery composition can undergo selfbase pairing (i.e., a DNA origami structure) to fold into structures that can form the single-stranded DNA scaffold that can encapsulate a payload.
- selfbase pairing i.e., a DNA origami structure
- the DNA nanostructure delivery composition can comprise i) a single stranded DNA scaffold and ii) one or more oligonucleotides that bind through complementary base pairing with a segment of the DNA scaffold, wherein the one or more oligonucleotides cause the DNA scaffold to fold.
- the one or more oligonucleotides can comprise overhangs that bind through complementary base paring with the payload nucleic acids.
- the overhangs can be located within a cavity within the DNA scaffold, and the cavity can be covered by a lid and a hinge allowing the payloads to be completely enclosed within the cavity when the lid is shut.
- the lid can further comprise oligonucleotide strands that bind through complementary base pairing with other oligonucleotide strands attached to the DNA scaffold when the lid is in the closed position.
- DNA nanostructure delivery compositions e.g., DNA origami structures
- DNA origami structures are described in U.S. Patent No. 9,765,341, incorporated herein by reference.
- complementary base pairing refers to the ability of purine and pyrimidine nucleotide sequences to associate through hydrogen bonding to form doublestranded nucleic acid molecules. Guanine and cytosine, adenine and thymine, and adenine and uracil are complementary and can associate through hydrogen bonding resulting in the formation of double-stranded nucleic acid molecules when two nucleic acid molecules have “complementary” sequences.
- the complementary sequences can be DNA or RNA sequences.
- the complementary DNA or RNA sequences are referred to as a “complement.”
- the polymer nanoparticle composition e.g., RAFT polymer
- the polymer nanoparticle composition e.g., RAFT polymer
- DNA nanostructure delivery compositions of the invention can comprise more than one payload for delivery to target cells, or a nucleic acid construct payload of 3 kB or more for delivery to target cells.
- the nucleic acid construct payload of 3 kB or more can be DNA or RNA.
- the DNA scaffold and the one or more oligonucleotides can comprise M13 bacteriophage DNA.
- the DNA nanostructure delivery composition further comprises a targeting component for targeting to cells.
- the targeting component can be a nucleotide that is an RNA that forms a ‘stem-and-loop’ structure.
- the DNA nanostructure delivery composition can be designed so that the polynucleotide strands fold into three-dimensional structures via a series of highly tuned ‘stem-and-loop’ configurations.
- the DNA nanostructure delivery composition can have a high affinity for protein receptors expressed on specific cells resulting in targeting of the DNA nanostructure delivery composition and the payload to the specific cells.
- the polynucleotide that binds to the target cell receptor can bind in conjunction with a peptide aptamer.
- the DNA nanostructure delivery composition can be folded so that, in the presence of certain biomarkers such as cell receptors, microRNA, DNA, RNA or an antigen, the self-base pairs are disrupted and the DNA nanostructure delivery composition can unfold, resulting in the triggered release of the payload only in the presence of the specific biomarker.
- biomarkers such as cell receptors, microRNA, DNA, RNA or an antigen
- a lock-and-key mechanism for triggered opening of a DNA nanostructure delivery composition e.g., a DNA origami construct
- a DNA origami construct has been demonstrated previously (Andersen, et al., Nature, Vol. 459, pages 73- 76(2009)), incorporated by reference herein.
- the use of the DNA nanostructure delivery composition to create three-dimensional structures that target cells and tissues allows for more efficient delivery of payloads with fewer side effects, since the DNA nanostructure delivery composition can have low immunogenicity, and the payload will be released only in the presence of RNA or peptide biomarkers, for example, that exist in the cytosol of target cells and tissues.
- DNA nanostructure delivery composition In the embodiment where a DNA nanostructure delivery composition is used, computer aided design tools can predict the nucleotide sequence necessary to produce highly engineered DNA nanostructure delivery compositions. For gene delivery, these DNA nanostructure delivery compositions offer the advantages of encapsulation efficiency, as the size and shape of the structure can be tailored to fit the cargo. In another aspect, loading efficiency can be increased by incorporating nucleic acid payloads into the encapsulating DNA nanostructure delivery composition itself.
- the non-viral delivery vehicles needed for translation of gene editing treatments can be synthesized with repeatable, versatile and scalable methods to meet GMP requirements.
- lipid nanoparticles have been used for most non-viral nucleic acid delivery vehicles in clinical trials.
- polymer nanoparticles have been less commonly used for clinical nucleic acid delivery, polymer synthesis methods provide these types of scalable manufacturing benefits in ways that cannot be matched by other biomaterials such as lipids.
- Recently, methods of producing cationic block copolymer nanoparticles using reversible- addition fragmentation chain transfer (RAFT) polymerization have been standardized to demonstrate rigor and reproducibility necessary for commercial scale nanocarrier production. Given the robustness, versatility and sophistication of the RAFT copolymerization process, it is an attractive route to synthesizing non- viral delivery vehicle alternatives to AAVs.
- RAFT reversible- addition fragmentation chain transfer
- polymer nanoparticle delivery vehicles are designed using cationic polymers that form complexes with negatively charged nucleic acids and enhance interaction with the negative resting potential of the cellular membrane.
- the same positive surface charge may also lead to cytotoxicity in high enough doses.
- the RAFT copolymers prepared according to the methods described herein have been shown to be well tolerated by cells as provided in the examples described herein.
- polymer nanoparticles may be used as delivery vehicles according to the present disclosure.
- the polymer nanoparticles may be made by RAFT copolymerization to synthesize a diverse set of block copolymers, and to screen their ability to form complexes with a payload.
- polymer nanoparticles e.g., RAFT copolymers
- payloads may be combined with the polymer nanoparticles or DNA nanostructure delivery compositions using any or all of covalent bonds, electrostatic interactions, and ligand affinity interactions.
- covalent bonding methods include the use of EDC/NHS to form stable amide bonds between the payload and the polymer nanoparticles for improved stability (both “on the shelf’ and in vivo), ease of separation and extraction, and sensitive detection.
- electrostatic bonding methods include the use of cationic polymer nanoparticles or DNA nanostructure delivery compositions that electrostatically complex with the payload.
- ligand affinity bonding includes the use of ligands such as avidin and biotin, both covalently bonded to the polymer nanoparticles or DNA nanostructure delivery compositions and the payload via EDC/NHS chemistry to yield the stable combination of the payload and the polymer nanoparticles or DNA nanostructure delivery compositions.
- ligands such as avidin and biotin
- RAFT copolymerization may be achieved using chain transfer agents (CTAs) containing one or more terminal carboxyl groups in order to obtain carboxy terminated polymers with ends available for bonding to the payload via the methods described above.
- CTAs chain transfer agents
- the resulting mono or di-carboxy terminated polymer is dispersed in a low pH (e.g., a pH of less than 6) buffer, both ends of the polymer are exposed and available for labeling via EDC/NHS chemistry.
- a physiological pH ⁇ pH 7
- the core blocks self-assemble, encapsulating the payload in the hydrophobic core, to be released and exposed upon acidification in the endosomal compartment of a cell.
- RAFT copolymers as prepared herein can be described by the following structure: CTACap-[Block l] m -[Block 2] n -CTACap where each CTACap is a capping unit derived from the chain transfer agent(s) used in the process for preparing the RAFT copolymer.
- the CTA used for preparing each of Block 1 and Block 2 can be the same or different.
- the CTA used to prepare each of Block 1 and Block 2 is the same (e.g. macroCTA).
- the CTA used to prepare each of Block 1 and Block 2 is different.
- the CTA used to prepare one or both of Block 1 and Block 2 comprises a functional group for the covalent attachment of a biomolecule, drug, or label to the RAFT copolymer.
- the covalent attachment can be via an ester or an amide bond.
- the covalent attachment can be via EDC-NHS chemistry.
- the first capping unit is of the formula wherein * represents a point of covalent attachment to the first block.
- the second capping unit is of the formula wherein * represents a point of covalent attachment to the second block, and R is -SC2-C12 alkyl or C 6 H 5 ,
- the RAFT copolymer can be complexed with a biological molecule, such as a DNA molecule, via electrostatic interaction.
- each of Block 1 and Block 2 can comprise one or more monomer units polymerized using a RAFT polymerization process. It will be appreciated that the identity of the monomer units is not particularly limited so long as the monomer units being used are compatible with a RAFT polymerization process.
- Suitable monomer units include but are not limited to 2-dimethylaminoethyl acrylate (DMAEMA), 2-(diethylamino) ethyl methacrylate (DEAEMA), 2-(diisopropylamino) ethyl methacrylate, butyl methacrylate (BMA), ethyl acrylic acid (EAA), propyl acrylic acid (PAA), (hydroxyethyl)methacrylate (HEMA), and methyl methacrylate (MMA), Acrylic acid (AA), Aminoethyl methacrylate (AEM), 2-(2- aminoethylamino) ethyl methacrylate (AEAEMA), N-(2- Aminoethyl) methacrylamide (AEMA), 3- amino-2-hydroxypropyl methacrylate (AEAHPMA), 3 -aminopropyl methacrylamide (AHPMA), Amidoamine (AMA), N-(3-Aminopropyl)methacrylamide
- the monomer units used to make Block 1 and/or Block 2 of RAFT copolymers as described herein are selected from the group consisting of 2-(dimethylamino) ethyl acrylate (DMAEEA), 2-(diethylamino) ethyl methacrylate (DEAEEA), 2-(diisopropylamino) ethyl methacrylate (DIEAMA), butyl methacrylate (BMA), ethyl acrylic acid (EAA), propyl acrylic acid (PAA), (hydroxyethyl)methacrylate, and methyl methacrylate (MMA).
- DMAEEA 2-(dimethylamino) ethyl acrylate
- DEAEEA 2-(diethylamino) ethyl methacrylate
- DIEAMA 2-(diisopropylamino) ethyl methacrylate
- BMA butyl methacrylate
- EAA ethyl acrylic acid
- the RAFT copolymers provided herein can be described by the formula:
- RAFT copolymer as described herein having a single monomer in Block 1 of 25 units and 3 different monomers in Block 2 having an average monomer unit ratio of 20:10:5 for a total n of 35, can be described by the general formula
- the polymers prepared using a RAFT polymerization are random polymers having a distribution of units and hence molecular weights. Therefore, the cartoon representation of Block 2 in the example above is a random copolymer comprising 35 monomer units of B2M1, B2M2, and B2M3 in the ratio described above.
- the polymer nanoparticle composition or the DNA nanoparticle delivery composition can be coated with one or more polymers to protect the compositions from immune responses or to enhance endosomal escape.
- the one or more polymers comprise polyethylene glycol.
- the one or more polymers comprise polyethylene glycol poly-L-lysine.
- the one or more polymers comprise polyethylenimine.
- the one or more polymers comprise polyethylene glycol poly-L-lysine and polyethylenimine.
- a RAFT block copolymer as described herein has one or more of an overall molecular weight (M n ) in the range of about 25 kDa to about 160 kDa, and overall degree of polymerization in the range of about 30 to about 900, a size in the range of about of about 10 to about 60 nm, and a maximum corona-to-core ratio (CCR) of about 1 to about 4.
- M n overall molecular weight
- CCR maximum corona-to-core ratio
- the size is in the range of about of about 10 to about 50 nm, about 15 to about 45 nm, about 20 to about 40 nm, or about 25 to about 35 nm.
- the maximum corona-to-core ratio (CCR) is less than 4, or less than 3, about 1 to about 3.8, about 1.2 to about 3.5, about 1.5 to about 3, about 1.5 to about 2.5, or about 1 to about 2.
- the first block can be prepared from one or more monomer units and have a molecular weight (Mn) in the range of about 20 kDa to about 80 kDa and a degree of polymerization in the range of about 20 to about 400.
- the first block molecular weight (M n ) is in the range of about 25 kDa to about 60 kDa, or about 30 kDa to about 55 kDa, about 30 kDa to about 50 kDa, or about 30 kDa to about 40 kDa, and the like.
- the first block degree of polymerization is in the range of about 30 to about 350, about 50 to about 300, about 70 to about 250, about 80 to about 240, about 100 to about 200, and the like.
- the second block can be prepared from one or more monomer units, and can have a molecular weight (M n )in the range of about 1 kDa to about 80 kDa and a degree of polymerization in the range of about 3 to about 500.
- the second block molecular weight (M n ) is in the range of about 10 kDa to about 70 kDa, about 15 kDa to about 65 kDa, about 20 kDa to about 60 kDa, about 25 kDa to about 55 kDa, about 30 kDa to about 50 kDa, about 35 kDa to about 45 kDa, about 5 kDa to about 15 kDa, and the like.
- the second block degree of polymerization is in the range of about 10 to about 500, about 12 to about 450, 20 to about 400, about 25 to about 350, about 50 to about 300, about 100 to about 250, about 150 to about 200, about 5 to about 50, about 5 to about 20, and the like.
- RAFT polymerization is generally known in the art.
- Suitable reagents, monomers, and conditions for RAFT polymerization previously investigated can be used in the copolymers, methods, and compositions described herein, such as those described in United States Patent Nos. 9,006,193, 9,464,300, and 9,476,063, the disclosures of each of which are incorporated by reference in their entirety. It will be appreciated that a variety of solvents can be used in the RAFT polymerization method steps and purification steps described herein.
- Suitable solvents include, but are not limited to, 2-Chloroethanol, Acetic Acid (Glacial), Acetone, Acetonitrile, Acetophenone, Aniline, Benzaldehyde, Benzyl Acetate, Carbon disulfide, Cyclohexane, Cyclohexanol, Di(ethylene glycol), Di(propylene glycol), Diacetone alcohol, Diethyl ether, Dimethylsulfoxide, Ethanol, Ethyl acetate, Ethylene glycol, Formaldehyde (37% solution), Formamide, Formic acid, Formic acid (96%), Hexanelsobutanol, Isopropanol, Isopropyl acetate, Isopropyl ether, m-Cresol, Methanol, Methyl acetate, Methyl ethyl ketone, Mineral Oil, N,N- Dimethylformamide, n-Butanol, n-Octane,
- Illustrative payloads for the polymer nanoparticle or nanostructure DNA delivery compositions described herein can include any one or a combination of compositions selected from the group comprising: nucleic acids (e.g., DNA or RNA), pDNA, oligodeoxyribonucleic acids (ODNs), dsDNA, ssDNA, antisense oligonucleotides, antisense RNA, siRNA, messenger RNA, guide RNA (e.g., small guide RNA), ribonucleoproteins, donor DNA strands used in the CRISPR/Cas9 system, and enzymes, such as CRISPR-associated enzymes, e.g., Cas9, enzymes used in other gene editing systems, such as ZFNs, custom designed homing endonucleases, TALENS systems, other gene editing endonucleases, and reverse transcriptase.
- nucleic acids e.g., DNA or RNA
- ODNs oligodeoxyribon
- CAR-T cells are T cells expressing chimeric antigen receptors (CARs).
- the CAR is a genetically engineered receptor that is designed to target a specific antigen, for example, a tumor antigen. This targeting can result in cytotoxicity against the tumor, for example, such that CAR-T cells expressing CARs can target and kill tumors via the specific tumor antigens.
- CARs can comprise a recognition region, e.g., a single chain fragment variable (scFv) region derived from an antibody for recognition and binding to the antigen expressed by the tumor, an activation signaling domain, e.g., the CD3 ⁇ chain of T cells can serve as a T cell activation signal in CARs, and a co- stimulation domain (e.g., CD137, CD28 or CD134) to achieve prolonged activation of T cells in vivo.
- scFv single chain fragment variable
- an activation signaling domain e.g., the CD3 ⁇ chain of T cells can serve as a T cell activation signal in CARs
- a co- stimulation domain e.g., CD137, CD28 or CD134
- the payload can be a nucleic acid construct (e.g., DNA or RNA) with a size selected from the group consisting of 3 kB or more, 3.1 kB or more, 3.2 kB or more, 3.3 kB or more, 3.4 kB or more, 3.5 kB or more, 3.6 kB or more, 3.7 kB or more, 3.8 kB or more, 3.9 kB or more, 4 kB or more, 4.1 kB or more, 4.2 kB or more, 4.3 kB or more, 4.4 kB or more, 4.5 kB or more, 4.6 kB or more, 4.7 kB or more, 4.8 kB or more, 4.9 kB or more, 5 kB or more, 5.1 kB or more, 5.2 kB or more, 5.3 kB or more, 5.4 kB or more, 5.5 kB or more, 5.6 kB or more,
- the payload can be any one or more of the components of the CRISPR RNP system including a CRIS PR- associated enzyme (e.g., Cas9), a short guide RNA (sgRNA), and a donor DNA strand.
- a CRIS PR-associated enzyme e.g., Cas9
- sgRNA short guide RNA
- the payload can comprise an sgRNA used for targeting an enzyme to a specific genomic sequence.
- the targeted enzyme can be a CRISPR-associated enzyme.
- the payload can comprise one molecule each of CRISPR/Cas9, an sgRNA, and a donor DNA strand in the polymer nanoparticle or DNA nanostructure delivery compositions described herein.
- the payloads can be nucleic acids used for homology directed repair or as transposable elements.
- the payloads can be any of the payloads described herein in the form of a plasmid construct.
- the DNA nanostructure delivery composition described herein can encapsulate a payload that is used for gene editing.
- the CRISPR/Cas9 system can be the payload and can be used for gene editing.
- another gene editing system can be the payload, such as ZFNs, custom designed homing endonucleases, and TALENS systems.
- the Cas9 endonuclease is capable of introducing a double strand break into a DNA target sequence.
- the Cas9 endonuclease is guided by the guide polynucleotide (e.g., sgRNA) to recognize and optionally introduce a double strand break at a specific target site into the genome of a cell.
- the guide polynucleotide e.g., sgRNA
- the Cas9 endonuclease can unwind the DNA duplex in close proximity to the genomic target site and can cleave both target DNA strands upon recognition of a target sequence by a guide polynucleotide (e.g., sgRNA), but only if the correct protospacer-adjacent motif (PAM) is approximately oriented at the 3' end of the target.
- a guide polynucleotide e.g., sgRNA
- PAM protospacer-adjacent motif
- the donor DNA strand can then be incorporated into the genomic target site.
- the CRISPR/Cas9 system for gene editing is well-known in the art.
- the payload may include DNA segments that serve as nuclear localization signals, enhancing nuclear delivery of the polymer nanoparticles (e.g., RAFT copolymers) or DNA nanostructure delivery compositions upon endosomal escape.
- the payload may include a nucleotide sequence designed to bind as an aptamer to endosomal receptors, enhancing intracellular trafficking of the polymer nanoparticles (e.g., RAFT copolymers) or DNA nanostructure delivery compositions.
- a DNA nanostructure delivery composition (e.g., DNA origami) is provided to package the Cas9 protein, the sgRNA and the single stranded donor DNA strand together in one nanostructure to ensure co-delivery of all the components to a particular location at the same time.
- the single stranded nature of the sgRNA and the donor DNA strand can be used to convert these components into constitutive parts of the DNA nanostructure delivery composition (e.g., the DNA origami structure) such that they get delivered together and dissociate at the same time from the DNA nanostructure delivery composition upon reaching the target site (e.g., a target cell).
- the DNA nanostructure delivery composition can deliver either a plasmid or the ribonucleoprotein (RNP) form of CRISPR/Cas 9.
- a method for gene therapy comprises administering to a patient a DNA nanostructure delivery composition comprising i) a single stranded DNA scaffold and ii) one or more oligonucleotides that bind through complementary base pairing with a segment of the DNA scaffold, wherein the one or more oligonucleotides cause the DNA scaffold to fold, and wherein the composition comprises more than one payload for delivery or a nucleic acid construct payload of 3 kB or more.
- the method comprises administering to the patient a polymer nanoparticle composition, such as a RAFT copolymer composition.
- a method for targeting a DNA nanostructure delivery composition to cells of a patient comprises administering to the patient i) a single stranded DNA scaffold and ii) one or more oligonucleotides that bind through complementary base pairing with a segment of the DNA scaffold, wherein the one or more oligonucleotides cause the DNA scaffold to fold, wherein the composition comprises more than one payload for delivery or a nucleic acid construct payload of 3 kB or more, and wherein the DNA nanostructure comprises a targeting component for targeting to the cells of the patient.
- the targeting method comprises administering to the patient a polymer nanoparticle composition, such as a RAFT copolymer composition.
- compositions described herein may be formulated as pharmaceutical compositions for parenteral or topical administration.
- Such pharmaceutical compositions and processes for making the same are known in the art for both humans and nonhuman mammals. See, e.g., REMINGTON: THE SCIENCE AND PRACTICE OF PHARMACY, (1995) A. Gennaro, et al., eds., 19 th ed., Mack Publishing Co. Additional active ingredients may be included in the compositions.
- the polymer nanoparticle composition or the DNA nanostructure delivery composition may be administered, for example, directly into the blood stream of a patient, into muscle, into an internal organ, or can be administered in a topical formulation.
- suitable routes for such parenteral administration include intravenous, intraarterial, intraperitoneal, intrathecal, epidural, intracerebroventricular, intraurethral, intrasternal, intracranial, intratumoral, intramuscular and subcutaneous delivery.
- means for parenteral administration include needle (including microneedle) injectors, needle-free injectors and infusion techniques.
- parenteral formulations are typically aqueous solutions which may contain carriers or excipients such as salts, carbohydrates and buffering agents (preferably at a pH of from 3 to 9), but they may be more suitably formulated as a sterile nonaqueous solution or as a dried form to be used in conjunction with a suitable vehicle such as sterile, pyrogen-free water or sterile saline.
- a suitable vehicle such as sterile, pyrogen-free water or sterile saline.
- the preparation under sterile conditions, by lyophilization to produce a sterile lyophilized powder for a parenteral formulation may readily be accomplished using standard pharmaceutical techniques well-known to those skilled in the art.
- the solubility of the composition used in the preparation of a parenteral formulation may be increased by the use of appropriate formulation techniques, such as the incorporation of solubility-enhancing agents.
- compositions for parenteral administration comprise: a) a pharmaceutically active amount of the polymer nanoparticle composition or the DNA nanostructure delivery composition; b) a pharmaceutically acceptable pH buffering agent to provide a pH in the range of about pH 4.5 to about pH 9; c) an ionic strength modifying agent in the concentration range of about 0 to about 300 millimolar; and d) water soluble viscosity modifying agent in the concentration range of about 0.25% to about 10% total formula weight or any combinations of a), b), c) and d) are provided.
- the pH buffering agents for use in the compositions and methods herein described are those agents known to the skilled artisan and include, for example, acetate, borate, carbonate, citrate, and phosphate buffers, as well as hydrochloric acid, sodium hydroxide, magnesium oxide, monopotassium phosphate, bicarbonate, ammonia, carbonic acid, hydrochloric acid, sodium citrate, citric acid, acetic acid, disodium hydrogen phosphate, borax, boric acid, sodium hydroxide, diethyl barbituric acid, and proteins, as well as various biological buffers, for example, TAPS, Bicine, Tris, Tricine, HEPES, TES, MOPS, PIPES, cacodylate, or MES.
- acetate, borate, carbonate, citrate, and phosphate buffers as well as hydrochloric acid, sodium hydroxide, magnesium oxide, monopotassium phosphate, bicarbonate, ammonia, carbonic acid, hydrochloric acid, sodium citrate,
- the ionic strength modulating agents include those agents known in the art, for example, glycerin, propylene glycol, mannitol, glucose, dextrose, sorbitol, sodium chloride, potassium chloride, and other electrolytes.
- Useful viscosity modulating agents include but are not limited to, ionic and nonionic water soluble polymers; crosslinked acrylic acid polymers such as the “carbomer” family of polymers, e.g., carboxypolyalkylenes that may be obtained commercially under the Carbopol® trademark; hydrophilic polymers such as polyethylene oxides, polyoxyethylene-polyoxypropylene copolymers, and polyvinylalcohol; cellulosic polymers and cellulosic polymer derivatives such as hydroxypropyl cellulose, hydroxyethyl cellulose, hydroxypropyl methylcellulose, hydroxypropyl methylcellulose phthalate, methyl cellulose, carboxymethyl cellulose, and etherified cellulose; gums such as tragacanth and xanthan gum; sodium alginate; gelatin, hyaluronic acid and salts thereof, chitosans, gellans or any combination thereof.
- non-acidic viscosity modulating agents such as
- the solubility of the compositions described herein used in the preparation of a parenteral formulation may be increased by the use of appropriate formulation techniques, such as the incorporation of solubility-enhancing agents.
- compositions described herein may be administered topically.
- a variety of dose forms and bases can be applied to the topical preparations, such as an ointment, cream, gel, gel ointment, plaster (e.g. cataplasm, poultice), solution, powders, and the like.
- These preparations may be prepared by any conventional method with conventional pharmaceutically acceptable carriers or diluents as described below.
- vaseline higher alcohols, beeswax, vegetable oils, polyethylene glycol, etc.
- fats and oils waxes, higher fatty acids, higher alcohols, fatty acid esters, purified water, emulsifying agents etc.
- gel formulations conventional gelling materials such as polyacrylates (e.g. sodium poly acrylate), hydroxypropyl cellulose, hydroxypropyl methyl cellulose, polyvinyl alcohol, polyvinylpyrrolidone, purified water, lower alcohols, polyhydric alcohols, polyethylene glycol, and the like are used.
- an emulsifying agent preferably nonionic surfactants
- an oily substance e.g. liquid paraffin, triglycerides, and the like
- a plaster such as cataplasm or poultice can be prepared by spreading a gel preparation as mentioned above onto a support (e.g. fabrics, nonwoven fabrics).
- paraffins, squalane, lanolin, cholesterol esters, higher fatty acid esters, and the like may optionally be used.
- antioxidants such as BHA, BHT, propyl gallate, pyrogallol, tocopherol, etc. may also be incorporated.
- the dosage of the polymer nanoparticle composition or the DNA nanostructure delivery composition can vary significantly depending on the patient condition, or the disease state being treated, the route of administration and tissue distribution, and the possibility of co-usage of other therapeutic treatments.
- the effective amount to be administered to a patient is based on body surface area, patient weight or mass, and physician assessment of patient condition.
- the polymer nanoparticle composition or the DNA nanostructure delivery composition can be administered to a patient with a disease or a disorder selected from the group consisting of cancer, a muscular disorder, a pulmonary disorder, a skin disorder, a neurological disease, neurofibromatosis 1 (NF1), and a hemoglobinopathy.
- a disease or a disorder selected from the group consisting of cancer, a muscular disorder, a pulmonary disorder, a skin disorder, a neurological disease, neurofibromatosis 1 (NF1), and a hemoglobinopathy.
- the cancer is selected from the group consisting of lung cancer, bone cancer, pancreatic cancer, skin cancer, uterine cancer, ovarian cancer, endometrial cancer, rectal cancer, stomach cancer, colon cancer, breast cancer, cancer of the esophagus, cancer of the endocrine system, prostate cancer, leukemia, lymphoma, mesothelioma, cancer of the bladder, cancer of the kidney, neoplasms of the central nervous system, brain cancer, and adenocarcinoma.
- the skin disorder is a Staphlococcus aureus infection.
- the muscular disorder is muscular dystrophy (e.g., Duchenne Muscular Dystrophy).
- the polymer nanoparticle composition and the DNA nanostructure delivery composition are not cytotoxic to the cells of the patient.
- the gene therapy may result in the inactivation of a pathogen (i.e., a microorganism) rather than altering the genome of the patient.
- a method comprising synthesizing a diverse set of non-viral gene delivery compositions, wherein each non-viral gene delivery composition differs from each other non-viral gene delivery composition of the diverse set with respect to at least one of a set of composition characteristics, simultaneously testing one or more quality attributes of each of the non-viral gene delivery composition of the diverse set, and creating, using results of the testing, a predictive model that correlates the composition characteristics with the quality attributes.
- the composition characteristics can comprise one or more of molecular weight, degree of branching, number of ionizable groups, core- to-corona molecular weight ratio, hydrophilicity, hydrophobicity, propensity for aggregation, size, pKa, logP, and surface charge.
- the quality attributes can comprise one or more of cytotoxicity, immunogenicity, transfection efficiency, zeta potential, size, pKa, logP, and loading efficiency.
- the diverse set can comprises hundreds or thousands of non-viral gene delivery compositions.
- each of the non-viral gene delivery compositions of the diverse set can be a DNA nanostructure delivery composition according to one of clauses 1-36 or 118-154 or a RAFT block copolymer according to one of clauses 118-127 above, above.
- high-throughput testing, and machine learning data analysis can accelerate the design-build-test-learn (DBTL) cycle for development of CRISPR- based therapeutics.
- the polymer nanoparticle composition or the DNA nanostructure delivery composition may be labelled to enhance downstream separation.
- this may include covalently bonding the polymer nanoparticle composition or the DNA nanostructure delivery composition to a magnetic nanoparticle (e.g., superparamagnetic iron oxide), to polyhistidine tags for metal ion chromatography, and/or to fluorescent labels for fluorescent assisted separation (such as with FACS).
- the labels may be used to track the polymer nanoparticle composition or the DNA nanostructure delivery composition in vivo.
- Possible “endpoints” include, but are not limited to, quantitative presence in various physiological tissue, post administration, measured via, for example, fluorescence.
- the labels allow for rapid in vivo screening of many non- viral nanoparticle variants with parallel determination of quantitative bio-distribution, and rapid in vitro screening of many non-viral nanoparticle variants for stability, cytotoxicity, immunogenicity, and efficacy.
- This embodiment allows for the construction of a large library of non-viral delivery vehicles that can be drawn from for use as delivery vehicles for genetic medicines, including gene therapies, genetic vaccines, gene editing, and gene regulators.
- a large library of similar, but unique polymer nanoparticle compositions or the DNA nanostructure delivery compositions may be constructed for use in a high-throughput screening process to identify targeting components that bind to specific targets.
- This rapid screening platform can quickly determine an effective targeting molecule that can be used for targeted delivery to a specific cell or tissue, or for use as a neutralizing molecule for a pathogen.
- references in the specification to “one embodiment,” “an embodiment,” “an illustrative embodiment,” etc., indicate that the embodiment described may include a particular feature, structure, or characteristic, but every embodiment may or may not necessarily include that particular feature, structure, or characteristic. Moreover, such phrases are not necessarily referring to the same embodiment. Further, when a particular feature, structure, or characteristic is described in connection with an embodiment, it is submitted that it is within the knowledge of one skilled in the art to effect such feature, structure, or characteristic in connection with other embodiments whether or not explicitly described.
- items included in a list in the form of “at least one A, B, and C” can mean (A); (B); (C); (A and B); (A and C); (B and C); or (A, B, and C).
- items listed in the form of “at least one of A, B, or C” can mean (A); (B); (C); (A and B); (A and C); (B and C); or (A, B, and C).
- DNA nanostructure delivery compositions uses nucleic acids themselves (the DNA origami structure) to encapsulate the CRISPR RNP construct.
- a singlestranded DNA scaffold is used and is grown and isolated in the M13 phage and combined with oligonucleotide staples that pair with the scaffold at pre-programed segments to form highly controlled and tuned three-dimensional structures.
- computer aided design (CAD) tools can predict the sequences in oligonucleotide staples necessary to produce highly engineered nanostructures, resulting in the possibility of a virtual library of nanoparticles from which to begin a custom delivery vehicle design.
- CAD computer aided design
- these DNA nanostructures offer significant advantages, including precise tuning of the size and shape of the structure to match the cargo.
- nanoparticles can be functionalized with nucleic acid aptamers for targeted binding to specific cell and tissue types.
- the inventors have designed a novel DNA origami delivery platform customized for the delivery, for example, of CRISPR RNP (Fig. 5). Loading efficiency can be further increased by strategically incorporating overhangs in the origami sequence to bind the guide and repair DNA constructs within the encapsulating nanostructure itself.
- highly specific targeted delivery can be achieved with the incorporation of “lock and key” mechanisms into the nucleotide sequence as discussed herein.
- DNA scaffolds can be produced in high yield using cell density fermentation of Escherichia coli libraries.
- Oligonucleotides used as the “staples” for the origami structure can be produced synthetically and then cloned in large numbers using PCR.
- two delivery vehicle platforms polymer nanoparticles and DNA origami to encapsulate and deliver CRISPR RNPs have been developed.
- the processing steps for each platform include several critical processing parameters (CPPs) that can be tuned to produce desirable critical quality attributes (CQAs).
- CCPs critical processing parameters
- CQAs critical quality attributes
- several desired CQA outputs include decreasing the cytotoxicity and immunogenicity of the delivery vehicles while enhancing their uptake by and subsequent transfection efficiency.
- the size, hydrophilicity and hydrophobicity, propensity for aggregation, and zeta potential of these delivery vehicles with and without their cargo can be characterized. Then, a series of in vitro assays can be run in parallel to identify how changes in the CPPs affect cytotoxicity, immunogenicity, and transfection efficiency of the delivery vehicles.
- the inventors have established machine learning to analyze large data sets and build models which can be applied to the exploration of nanocarrier design spaces. This framework will be set up to build a suitability surface for optimization of the CQAs via a machine learning algorithm. This system will accelerate the design of nanocarriers capable of efficiently delivering CRISPR/Cas9 gene editing tools, for example, to cells.
- DNA nanostructures can be used to encapsulate RNP, to demonstrate triggered release in cells in vitro, and to assess efficacy in vivo using an animal model.
- the design shown in Fig. 5 can be used to encapsulate a Cas9/gRNA RNP that is delivered to a HEK-293 reporter cell in vitro.
- the cell can be modified with a GFP reporter with a stop codon preceding it.
- the gRNA is targeted to disrupt the stop codon, leading to a GFP signal indicating successful gene editing.
- the nanostructure can be tagged with a Cy5 red fluorescent label and tracked using the IVIS to determine biodistribution.
- DNA nanostructures were fabricated, loaded with CRISPR/Cas9 and coated with polyethylene glycol (PEG)-Poly-L-Lysine to protect the structures from degradation and clearance in vivo and polyethylenimine (PEI) to enhance endosomal escape.
- PEG polyethylene glycol
- PEI polyethylenimine
- the encapsulation of a CRISPR/Cas9 RNP in a DNA nanostructure with one-to-one precision demonstrates the unique capability of DNA nanostructures (e.g., DNA origami structures) to produce nanostructures with a high degree of predictability (i.e., fabricated structures looked exactly as designed) and structural control. Only one molecule of Cas9 RNP was encapsulated per structure. This is not possible with any other delivery vector currently available.
- HDR-mediated gene editing experiments will use the same DNA nanostructures which in addition to having the CRISPR RNP also have two HDR donor DNA strand oligos per DNA nanostructure for an in vivo study.
- the DNA nanostructures will be labeled with Cy5.5 dye for biodistribution and toxicity analysis.
- the non-viral delivery vehicles needed for translation of gene editing treatments can be synthesized with repeatable, versatile and scalable methods to meet GMP requirements.
- lipid nanoparticles have been used for most non-viral nucleic acid delivery vehicles in clinical trials.
- polymer nanoparticles have been less commonly used for clinical nucleic acid delivery, polymer synthesis methods provide scalable manufacturing benefits in ways that cannot be matched by other biomaterials such as lipids.
- RAFT reversible- addition fragmentation chain transfer
- RAFT copolymerization process is an attractive route for synthesizing non-viral delivery vehicle alternatives to AAVs. It has recently been demonstrated that these RAFT copolymers can be synthesized in multiplex, high-throughput arrays in multi-well plates. These methods are being used for the encapsulation and delivery of pDNA encoding for Cas9 and gRNA editing systems to somatic cell lines. As is the case with lipid nanoparticles, polymer nanoparticle delivery vehicles are designed using cationic polymers that form complexes with negatively charged nucleic acids and enhance interaction with the negative resting potential of the cellular membrane. However, the same positive surface charge may also lead to cytotoxicity in high enough doses. To address this concern, the inventors have conducted cytotoxicity assays (Fig. 3 - see Example 4). [0013] 3A: PREPARATION OF RAFT COPOLYMERS
- Block 1 reagents were combined in a round bottom flask, purged with argon, and heated to 60 °C for 6 hours using a heating mantle.
- the reaction product was purified using four 80:20 pentane:ether precipitation washes and centrifugation cycles and dried in vacuo.
- the Block 1 product was used as the macroRAFT agent for Block 2, and the calculated reagent volumes (as calculated based on theoretical molecular weight information for Block 1) were combined in a round bottom for the Block 2 reaction.
- the reaction mixture was argon purged before being heated at 60 °C for 24 hours.
- the reaction product was purified using the same purification process and dried in vacuo.
- the resulting polymer was dialyzed in deionized water for 4 days with multiple water changes each day. Finally, the dialyzed material was lyophilized for 4 days and stored at room temperature for experimental use. Size was measured using a Malvern Zetasizer Nano. Molecular weights for Blocks 1 and 2 were measured, and molecular weight for Block 1 was measured internally using a DynaPro Plate Reader III. All molecular weights are reported in this example as number average molecular weight (M n ).
- GPC Data was obtained using a TDA-305 Tetra Detector System by Malvern. Data acquisition and handling were made with OmniSec software.
- Block 1 140 (140 DMAEMAs)
- Block 2 52 (8 DMAEMAs, 6 PAAs, and 38 BMAs)
- Block 1 100% dimethylaminoethyl methacrylate
- Block 2 -17% dimethylaminoethyl methacrylate, -74% butyl methacrylate, and 9% propyl acrylic acid
- a RAFT copolymer (160 mg) prepared according to example 3 A was transferred into a 50 mL conical tube and reconstituted in MES buffer at 8 mg/mL. The sample was sonicated for 30 minutes. EDC reagent (10.5 mg) and Sulfo-NHS(29.7 mg) was added to the polymer. The sample was incubated for 15 minutes at room temperature to allow the reaction to occur. The reaction volume was transferred to Amicon ultra-4 centrifuge tubes (MWCO 30 kDa). (Max 3.5 mL/Tube) and centrifuged at 4,000 x g for 15 minutes.
- the filtrated was discarded and sterile PBS was added to the retentate to reconstitute to 8 mg/mL polymer.
- Avidin 36.9 mg was added to the reaction and incubated for 15 minutes at room temperature.
- the sample was transferred to an amicon ultra-4 centrifuge tubes (MWCO 30 kDa). (Max 3.5 mL/Tube) and centrifuged at 4,000 x g for 15 minutes.
- the filtrate was discarded and sterile PBS was added to the retentate to final concentration of 8 mg/mL polymer.
- An avidin stock solution was created at 205.8 pM by reconstituting 10 mg of avidin in 720 pL of PBS to prepare an Avidin calibration curve in triplicate.
- Dulbeccos PBS (322 pL) was added to wells A1-A3 of a 96 well plate.
- Stock Avidin (78 pL) was added to yield a 40 pM solution in wells A1-A3.
- Dulbeccos PBS 200 pL was added to remaining wells of columns 1-3 and a 2:1 serial dilution was performed from first row of wells.
- RAFT copolymers were prepared according to the general procedure provided in Example 3A above, and using a 96 well plate. All reagent amounts were determined according to the same method as described in Example 3A.
- Block 1 reagents were combined in wells of a polypropylene 96-well u- shaped bottom microplate (Greiner Bio-One) or in polypropylene Eppendorf microcentrifuge tubes (Sigma-Aldrich) and placed in a VWR 1400E Sheldon vacuum oven.
- a 20 mL glass vial was filled with approximately 10-15 mL of dimethylformamide, and the vial was placed in the oven to provide a source for atmosphere saturation.
- the oven was purged with argon at ⁇ 3 L/min for approximately 45 minutes, and heated to between 60 °C and 75 °C for 6 hours.
- reaction product solutions were transferred to 1.5 mL Eppendorf tubes (if necessary) and purified via four precipitation washes using an appropriate purification solvent solution (e.g., 80:20 pentane: ether, isopropyl alcohol, methanol, etc.) and centrifugation cycles and dried in vacuo.
- an appropriate purification solvent solution e.g. 80:20 pentane: ether, isopropyl alcohol, methanol, etc.
- the Block 1 product was used as the macroRAFT agent for Block 2, and the calculated reagent volumes (as calculated based on theoretical molecular weight information for Block 1) were combined in either a polypropylene 96-well u-shaped bottom microplate (Greiner Bio-One) or in polypropylene Eppendorf microcentrifuge tubes (Sigma- Aldrich) for the Block 2 reaction.
- the reaction mixtures were placed in a VWR 1400E Sheldon vacuum oven, which was argon purged at ⁇ 3 L/min for approximately 45 minutes before being heated to between 60 °C and 75 °C for 24 hours.
- the reaction products were purified using the same purification process as used for Block 1 library materials and dried in vacuo.
- the resulting polymers were resuspended in either acetone or chloroform and aliquoted as needed for experimental use (these transfer solvents evaporated prior to material use), stored in a dry state at room temperature, or dissolved in deionized water, frozen, and lyophilized prior to experimental use. Size was measured using a Wyatt Technology DynaPro Plate Reader III. Molecular weights for Block 1 materials were measured using a DynaPro Plate Reader III. Nanoparticle sizes above the DynaPro Plate Reader III molar mass capability threshold prevented measurement of Block 2 molecular weights for these polymer libraries. All molecular weights for high-throughput polymer libraries are reported as weight average molecular weight (M w ).
- Diameter data is provided for Libraries 0006, 0007, 0009, and 0011 in Fig. 6. Diameter data is calculated as follows:
- Library Block 1 for libraries 0001, 0003, and 0005 were prepared in 96-well plates as shown in Figs. 9A-9C.
- MTT assay A standard methylthiazolyldiphenyl-tetrazolium bromide (MTT assay) was used to measure cell viability on day 3 (after ⁇ 30 hours of exposure to test doses). Approximately 2.4 ml of MTT in cell media at 5 mg/ml was used and 20 ul of the solution was added to each well of the cell plate. The plate was wrapped in foil and incubated for 3 hours. After 3 hours, the plate was removed from incubator and all media was aspirated off with a pipet. 200 ul of isopropanol was added to each well to dissolve the crystals. The plate was wrapped in foil and placed on an orbital shaker for ⁇ 5 minutes for full dissolution.
- the plate was then read in a plate reader at 560 nm and 670 nm.
- the background at 670 nm was subtracted from the absorbance at 560 nm.
- Cell viability is reported as a percentage of the absorbance read for cells that were given no treatment (i.e. were dispersed in media only).
- cytotoxicity results for DNA nanostructure delivery compositions are described in Example 2 and the results are Fig. IF.
- the results for polymer nanoparticle compositions are shown in Fig. 3.
- Polymer nanoparticle compositions were not cytotoxic at concentrations below ⁇ 73 nM.
- Lipofectamine was cytotoxic at concentrations above 0.28 vol % of the stock solution. This is equivalent to 0.625 pl per well, which is about 2 times the highest dose recommended by the manufacturer.
- the two negative controls (PBS and optimum) showed positive cell growth (near 110% cell proliferation ) above that of medium only.
- the two negative controls (9% and 33 % ethanol) showed almost complete cell death ( ⁇ 2% cell viability).
- MTT solution at a concentration of 5 mg/mL in media at a volume equivalent to 25 uL per a sample was prepared. Added 20 uL of MTT solution to each well of the cell plate, including 3 blank wells. Gently shook the plate to mix the solution. Placed lid or 96-well plate sticker over the plate. Wrapped plate with aluminum foil. Sprayed plate down with 70% ethanol and placed in cell incubator (37° C, 5% CO2) for 3-4 hours. After incubation, aspirated off the media from the wells using a Pasteur pipet and the vacuum in the laminar flow hood. Resuspended the formazan (MTT metabolic product) in 200 uL isopropanol.
- HEK-293T cells were seeded in a 96-well plate at 30,000 cells per well in 0.2 ml of media and left in an incubator at 37 degrees C overnight. The next day, a serial dilution of polymer nanoparticles was prepared in PBS. Lipofectamine 3000 reagent was prepared according to the manufacturer protocol. The pDNA was added to the dilutions of polymer nanoparticles and lipofectamine to yield 11 -fold higher concentrations of both components than those indicated in the images. To each well, 0.02 ml of each dilution was added, to yield an 11- fold dilution.
- the cells were incubated with the treatments overnight, and fluorescence images were captured with a GFP filter cube set (ex 475 nm, em 509 nm).
- the dose of polymer nanoparticles (Fig. 4C) showed the most fluorescence and corresponded to a polymer to DNA ratio of ⁇ 4, which is consistent with the previous convention. This shows that the polymer nanoparticle platform can be further optimized with our high-throughput platform to deliver genes to cells for treatments.
- Oligonucleotide staples can be designed for a single stranded DNA scaffold that Is produced from M13 bacteriophage DNA cloned in Escherichia coli using fermentation. These oligos can be designed to form, for example, a DNA nanostructure deliver composition (i.e. a DNA origami structure) with a cavity that is ⁇ 13 x 15 nm (the approximate dimensions of an RNP).
- the oliogo staples can be chosen to include overhangs with sticky ends that will bind to the gRNA of the RNP as well as the ends of the homology directed repair donor DNA strand.
- the lid on the hinge can be designed with sticky overhangs that will self-anneal after the RNP is loaded, resulting in a compact particle containing all the machinery needed in one particle to effectively deliver multiple payloads, such as the CRISPR RNP to a target cell. Fluorescence microscopy experiments can aid in understanding where the DNA nanostructures traffic within the cells. Using a DAPI (4',6-diamidino-2-phenylindole) blue fluorescent stain, the cell nuclei can be stained blue to examine the extent to which the RNPs co-localize within the nucleus.
- the surface of the DNA nanostructure can be designed with polyethylene glycol (PEG) polylysine moieties to reduce immunogenicity.
- PEG polyethylene glycol
- nucleotide “stem-and-loop” features can take on three-dimensional structures able to bind target cell receptors with or without the help of peptide aptamers.
- the folding of the DNA nanostructures can be confirmed via transmission electron microscopy (TEM).
- TEM transmission electron microscopy
- the loading of the RNP into the DNA nanostructure can be confirmed with a fluorescently labeled RNP (EGFP) and a fluorescence microscope.
- Particle size, surface charge, and aggregation state can be analyzed in a multi- well plate format via dynamic light scattering. Zeta potential can be analyzed with a Malvern zetasizer.
- the DNA nanostructures loaded with RNP can be assayed in the same array of 96-well plate assays as the polymer nanoparticle compositions.
- the RNP system can be used to produce green fluorescence in a line of HEK-293 cells that have been modified with a GFP reporter preceded by a stop codon.
- the gRNA in the RNP can target the stop codon, and when it is disrupted, the cells will report a green fluorescence.
- a similar test can be done with other cells.
- the RNP can simply be labeled with EGFP, and the co-localization of the DNA nanostructures in the cells can be evaluated via fluorescence microscopy with DAPI stained cells.
- THP-1 cells and RAW264 cells can be treated with the DNA nanostructures and the immune response can be quantified using ELISA assays for inflammatory cytokines as well as a Greiss assay for a rapid evaluation of inflammatory response associated with nitrous oxide production.
- the THP-1 cells do not have a strong nitrous oxide production read-out, but the RAW254 mouse cells are sensitive to the inflammation and produce a strong nitrous oxide signal.
- the bioactivity read-outs can be connected to the physical characteristics and the design parameters of the DNA nanostructures.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nanotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Crystallography & Structural Chemistry (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Polymers & Plastics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Condensed Matter Physics & Semiconductors (AREA)
- General Physics & Mathematics (AREA)
- Composite Materials (AREA)
- Materials Engineering (AREA)
- Analytical Chemistry (AREA)
- Manufacturing & Machinery (AREA)
- Medical Informatics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IL303390A IL303390A (en) | 2020-12-03 | 2021-12-03 | Compositions of polymer nanoparticles and DNA nanostructures and methods for non-viral transport |
| EP21901543.5A EP4255495A4 (en) | 2020-12-03 | 2021-12-03 | COMPOSITIONS OF POLYMERIC NANOPARTICLES AND DNA NANOSTRUCTURES AND METHODS FOR NON-VIRAL DELIVERY |
| AU2021391823A AU2021391823A1 (en) | 2020-12-03 | 2021-12-03 | Polymer nanoparticle and dna nanostructure compositions and methods for non-viral delivery |
| JP2023534084A JP2023553010A (ja) | 2020-12-03 | 2021-12-03 | 非ウイルス性送達のためのポリマーナノ粒子およびdnaナノ構造組成物ならびに方法 |
| CA3203975A CA3203975A1 (en) | 2020-12-03 | 2021-12-03 | Polymer nanoparticle and dna nanostructure compositions and methods for non-viral delivery |
| CN202180092894.XA CN116887866A (zh) | 2020-12-03 | 2021-12-03 | 聚合物纳米颗粒和dna纳米结构组合物及用于非病毒递送的方法 |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063121202P | 2020-12-03 | 2020-12-03 | |
| US63/121,202 | 2020-12-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2022120194A1 true WO2022120194A1 (en) | 2022-06-09 |
Family
ID=81849538
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US2021/061846 Ceased WO2022120194A1 (en) | 2020-12-03 | 2021-12-03 | Polymer nanoparticle and dna nanostructure compositions and methods for non-viral delivery |
Country Status (8)
| Country | Link |
|---|---|
| US (4) | US20220175812A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4255495A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023553010A (cg-RX-API-DMAC7.html) |
| CN (1) | CN116887866A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021391823A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3203975A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL303390A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022120194A1 (cg-RX-API-DMAC7.html) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12031128B2 (en) | 2021-04-07 | 2024-07-09 | Battelle Memorial Institute | Rapid design, build, test, and learn technologies for identifying and using non-viral carriers |
| US12109223B2 (en) | 2020-12-03 | 2024-10-08 | Battelle Memorial Institute | Polymer nanoparticle and DNA nanostructure compositions and methods for non-viral delivery |
| WO2025072893A1 (en) * | 2023-09-29 | 2025-04-03 | Battelle Memorial Institute | Polymer nanoparticle compositions for non-viral gene delivery |
| WO2025072751A1 (en) * | 2023-09-29 | 2025-04-03 | Battelle Memorial Institute | Polymer nanoparticle compositions for in vivo expression of polypeptides |
| WO2025072801A1 (en) * | 2023-09-29 | 2025-04-03 | Battelle Memorial Institute | Polymer nanoparticle compositions for non-viral gene delivery to the central nervous system |
| WO2025250979A1 (en) * | 2024-05-31 | 2025-12-04 | Battelle Memorial Institute | Polymer nanoparticle compositions for non-viral gene delivery |
| US12709747B2 (en) | 2023-09-27 | 2026-08-18 | Battelle Memorial Institute | Rapid design, build, test, and learn technologies for identifying and using non-viral carriers |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116343955B (zh) * | 2022-12-29 | 2026-03-24 | 中国工商银行股份有限公司 | 基于纳米材料的参数预测方法和装置、处理器及电子设备 |
| AU2024393766A1 (en) | 2023-12-08 | 2026-06-18 | Battelle Memorial Institute | Use of dna origami nanostructures for molecular information based data storage systems |
| WO2026035659A1 (en) * | 2024-08-05 | 2026-02-12 | Battelle Memorial Institute | Polymer nanoparticle compositions for non-viral gene delivery |
| US20260090998A1 (en) * | 2024-10-02 | 2026-04-02 | Battelle Memorial Institute | Methods of using polymer nanoparticle compositions for treating a disease |
| CN119666949B (zh) * | 2024-11-28 | 2026-02-27 | 昆明理工大学 | 一种电化学适配体传感器及其制备方法和应用 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120251583A1 (en) * | 2005-06-14 | 2012-10-04 | The California Institute Of Technology | Methods of making nucleic acid nanostructures |
| US20150104408A1 (en) * | 2012-04-18 | 2015-04-16 | Arrowhead Madison Inc. | Poly(acrylate) Polymers for In Vivo Nucleic Acid Delivery |
| WO2019126627A1 (en) * | 2017-12-22 | 2019-06-27 | Rensselaer Polytechnic Institute | Dna origami nanoparticle delivery of programmed chromosome breakage machinery |
| WO2019152957A1 (en) * | 2018-02-02 | 2019-08-08 | Arizona Board Of Regents On Behalf Of Arizona State University | Dna-chimeric antigen receptor t cells for immunotherapy |
| WO2020051507A1 (en) * | 2018-09-06 | 2020-03-12 | The Broad Institute, Inc. | Nucleic acid assemblies for use in targeted delivery |
Family Cites Families (573)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1198052A (en) | 1965-02-12 | 1970-07-08 | Ici Ltd | Polymer Dispersions |
| SE339105B (cg-RX-API-DMAC7.html) | 1966-02-23 | 1971-09-27 | Avisun Corp | |
| US3847857A (en) | 1967-11-02 | 1974-11-12 | Rohm & Haas | Stain resistant coating composition |
| US3562806A (en) | 1968-09-10 | 1971-02-09 | Eastman Kodak Co | Rumen stable medicament and/or nutrient compositions |
| US3678098A (en) | 1969-04-04 | 1972-07-18 | Rohm & Haas | Unsaturated quaternary monomers and polymers |
| GB1324087A (en) | 1969-07-18 | 1973-07-18 | Commw Scient Ind Res Org | Copolymers and veterinary compositions treated therewith |
| GB1284489A (en) | 1970-03-16 | 1972-08-09 | Ici Ltd | Thermoplastic polymer blends |
| US3744969A (en) | 1970-06-09 | 1973-07-10 | Rohm & Haas | Break resistant leather |
| US3829564A (en) | 1970-07-17 | 1974-08-13 | Commw Scient Ind Res Org | Coated products for veterinary use |
| US3706565A (en) | 1970-10-28 | 1972-12-19 | Eastman Kodak Co | Photographic compositions containing an admixture of organic and inorganic silver salts |
| US3706564A (en) | 1970-10-28 | 1972-12-19 | Eastman Kodak Co | Process for forming silver halide crystals in the presence of amphiphilic copolymers |
| GB1314285A (en) | 1970-12-16 | 1973-04-18 | Ici Australia Ltd | Explosive compositions |
| US4056559A (en) | 1971-04-23 | 1977-11-01 | Rohm And Haas Company | Novel polymers of alkyl methacrylates |
| IL45712A (en) | 1973-10-02 | 1977-10-31 | Hydrophilics Int Inc | Hydrophilic copolymer salt and its use |
| JPS5156886A (ja) | 1974-11-14 | 1976-05-18 | Unitika Ltd | Horiionkonpuretsukusuno seizoho |
| JPS5320051B2 (cg-RX-API-DMAC7.html) | 1975-02-28 | 1978-06-24 | ||
| US4036766A (en) | 1976-06-14 | 1977-07-19 | Texaco Inc. | Polymethacrylate additives and lube compositions thereof |
| US4237253A (en) | 1977-04-21 | 1980-12-02 | L'oreal | Copolymers, their process of preparation, and cosmetic compounds containing them |
| DE2861140D1 (en) | 1977-11-29 | 1981-12-17 | Bexford Ltd | Vesicular recording materials |
| KR830001200B1 (ko) | 1979-02-05 | 1983-06-21 | 이와마 가즈오 | 자기 헤드의 트랙킹 장치 |
| US4377481A (en) | 1980-11-14 | 1983-03-22 | Abcor, Inc. | Blended, polymeric, matrix membrane and process of making and using same |
| DE3271303D1 (en) | 1981-03-19 | 1986-07-03 | Ici Plc | Process for producing stable dispersions in water-dilutable liquid media of halogen-containing addition polymer, employing a polymeric dispersant, and waterborne coating compositions based on dispersions so made |
| SE8103843L (sv) | 1981-06-18 | 1982-12-19 | Astra Laekemedel Ab | Farmaceutisk mixtur |
| JPS57211146A (en) | 1981-06-23 | 1982-12-24 | Fuji Photo Film Co Ltd | Photopolymerizable composition |
| US4544621A (en) | 1982-05-19 | 1985-10-01 | Ciba Geigy Corporation | Photocrosslinkable water-soluble polymers, containing maleimidyl and quaternary ammonium groups process for their preparation and use thereof |
| US4559293A (en) | 1983-04-08 | 1985-12-17 | Kimoto & Co., Ltd. | Photosensitive recording material developable with aqueous neutral salt solution |
| NZ209347A (en) | 1983-09-09 | 1987-06-30 | Dulux Australia Ltd | Thermoplastic coating composition containing at least one acrylic polymer and at least two plasticisers |
| US4592816A (en) | 1984-09-26 | 1986-06-03 | Rohm And Haas Company | Electrophoretic deposition process |
| EP0199306B1 (en) | 1985-04-22 | 1992-03-11 | E.I. Du Pont De Nemours And Company | Wash-off film containing synthetic amphoteric polymers |
| EP0217137B1 (en) | 1985-08-29 | 1992-04-08 | E.I. Du Pont De Nemours And Company | Photopolymerizable composition of acrylic copolymer containing dicyclopentenyl acrylate or methacrylate |
| EP0243177B1 (en) | 1986-04-23 | 1993-07-07 | Sumitomo Chemical Company, Limited | Catalytic production of polyamide block copolymers |
| US5969046A (en) | 1986-11-18 | 1999-10-19 | Rohm And Haas Company | Reacting methylene and alkene components in presence of tertiary amine reacted with epoxide |
| US4755563A (en) | 1986-12-29 | 1988-07-05 | E. I. Du Pont De Nemours And Company | Block copolymer dispersants containing ionic moieties |
| JP2697818B2 (ja) | 1987-03-13 | 1998-01-14 | 株式会社リコー | 加熱定着用現像剤 |
| US4834799A (en) | 1987-10-27 | 1989-05-30 | Videojet Systems International, Inc. | Jet ink for vinyl substrate marking |
| JP2680594B2 (ja) | 1988-03-02 | 1997-11-19 | イー・アイ・デュポン・ドゥ・ヌムール・アンド・カンパニー | ブロツク共重合体分散剤 |
| US4925764A (en) | 1988-12-23 | 1990-05-15 | E. I. Du Pont De Nemours & Co. | Positive solid block toner |
| US4985160A (en) | 1989-02-08 | 1991-01-15 | E. I. Du Pont De Nemours And Company | Branched polymers as fuel oil additives |
| EP0473757A1 (en) | 1990-02-28 | 1992-03-11 | DowBrands Inc. | Ionizable polymer cleaning compositions and methods for cleaning stains |
| US5085698A (en) | 1990-04-11 | 1992-02-04 | E. I. Du Pont De Nemours And Company | Aqueous pigmented inks for ink jet printers |
| US5124381A (en) | 1990-11-08 | 1992-06-23 | Armstrong World Industries, Inc. | Acrylic polymer coating compositions for coats and films that have reduced surface resistivity |
| DE4110027C2 (de) | 1991-03-27 | 1996-08-29 | Lohmann Therapie Syst Lts | Verfahren zur Konfektionierung transdermaler therapeutischer Pflaster |
| US5141556A (en) | 1991-06-13 | 1992-08-25 | E. I. Du Pont De Nemours And Company | Penetrants for aqueous ink jet inks |
| US5205861A (en) | 1991-10-09 | 1993-04-27 | E. I. Du Pont De Nemours And Company | Aqueous ink jet inks containing alkylene oxide condensates of certain nitrogen heterocyclic compounds as cosolvents |
| US5180425A (en) | 1991-11-05 | 1993-01-19 | E. I. Du Pont De Nemours And Company | Aqueous ink jet inks containing polyol/alkylene oxide condensates as cosolvents |
| US5519081A (en) | 1991-11-15 | 1996-05-21 | Imperial Chemical Industries Plc | Polymerisable compositions |
| US5271765A (en) | 1992-02-03 | 1993-12-21 | E. I. Du Pont De Nemours And Company | Aqueous cationic dye-based ink jet inks |
| DE69325401T2 (de) | 1992-02-20 | 1999-11-25 | E.I. Du Pont De Nemours & Co., Inc. | Dreiblock-Polymer Dispersionsmittel enthaltende Wasserdispersionen |
| US5428383A (en) | 1992-08-05 | 1995-06-27 | Hewlett-Packard Corporation | Method and apparatus for preventing color bleed in a multi-ink printing system |
| US5310778A (en) | 1992-08-25 | 1994-05-10 | E. I. Du Pont De Nemours And Company | Process for preparing ink jet inks having improved properties |
| CA2104976A1 (en) | 1992-09-02 | 1994-03-03 | Stephan D. Daubney | Separation of plasma or serum from whole blood using a red blood cell binding component and a polymer containing multiple cationic sites |
| JPH06145262A (ja) | 1992-09-03 | 1994-05-24 | Rohm & Haas Co | 多段階ポリマーを含有する耐水性組成物 |
| US5310595A (en) | 1992-09-18 | 1994-05-10 | Minnesota Mining And Manufacturing Company | Water-based transparent image recording sheet for plain paper copiers |
| US5432035A (en) | 1992-12-18 | 1995-07-11 | Fujitsu Limited | Flash fixing color toner and process for producing the same |
| US5512418A (en) | 1993-03-10 | 1996-04-30 | E. I. Du Pont De Nemours And Company | Infra-red sensitive aqueous wash-off photoimaging element |
| US5620883A (en) | 1994-04-01 | 1997-04-15 | The Johns Hopkins University | Living cells microencapsulated in a polymeric membrane having two layers |
| US5418277A (en) | 1994-04-26 | 1995-05-23 | E. I. Du Pont De Nemours And Company | Aqueous ink jet inks containing fluorinated polymers |
| EP0753551B1 (en) | 1995-07-11 | 2000-02-09 | E.I. Du Pont De Nemours And Company | Ink set and process for alleviating bleed in printed elements |
| SG80553A1 (en) | 1995-07-20 | 2001-05-22 | Tanabe Seiyaku Co | Pharmaceutical preparation in form of coated capsule releasable at lower part of digestive tract |
| TW438608B (en) | 1995-08-02 | 2001-06-07 | Hisamitsu Pharmaceutical Co | A tablet containing anion exchange resin |
| US5518534A (en) | 1995-08-04 | 1996-05-21 | E. I. Du Pont De Nemours And Company | Ink set and process for alleviating bleed in printed elements |
| US5525450A (en) | 1995-09-01 | 1996-06-11 | Xerox Corporation | Liquid developer compositions with multiple block copolymers |
| DE69634697T2 (de) | 1995-10-25 | 2006-05-04 | Octoplus B.V. | Kationische polyacrylate und poly(alkyl)acrylate oder die entsprechende acrylamide zur verwendung in synthetischen transfektions-systemen |
| US7256020B2 (en) | 1996-11-29 | 2007-08-14 | Third Wave Technologies, Inc. | Methods and compositions for detecting target sequences |
| US5709714A (en) | 1996-03-11 | 1998-01-20 | Rohm And Haas Company | Method of treating leather with amphoteric polymers |
| US5698016A (en) | 1996-06-14 | 1997-12-16 | Cabot Corporation | Compositions of modified carbon products and amphiphilic ions and methods of using the same |
| JP4010585B2 (ja) | 1996-10-15 | 2007-11-21 | 久光製薬株式会社 | 陰イオン交換樹脂を含有する錠剤 |
| US6040358A (en) | 1996-12-27 | 2000-03-21 | E. I. Du Pont De Nemours And Company | Ink jet inks containing linear polymer additives |
| WO1998051749A1 (en) | 1997-05-12 | 1998-11-19 | The General Electric Company, Plc | Sedimentation free jet ink composition |
| US6004582A (en) | 1997-05-30 | 1999-12-21 | Laboratorios Phoenix U.S.A, Inc. | Multi-layered osmotic device |
| EP0886187B1 (en) | 1997-06-18 | 2003-10-15 | Canon Kabushiki Kaisha | Toner, two-component developer and image forming method |
| US6221402B1 (en) | 1997-11-20 | 2001-04-24 | Pfizer Inc. | Rapidly releasing and taste-masking pharmaceutical dosage form |
| KR100404534B1 (ko) | 1997-11-21 | 2003-11-05 | 더 프록터 앤드 갬블 캄파니 | 중합체성 거품 증진제를 포함하는 세제 조성물 및 이를 사용한 거품 용적과 거품 보유율의 증진방법 |
| JP2001524587A (ja) | 1997-11-21 | 2001-12-04 | ザ、プロクター、エンド、ギャンブル、カンパニー | 高分子泡改善剤を含んでなる液体洗剤組成物 |
| US6139856A (en) | 1997-12-11 | 2000-10-31 | Biomedical Development Corp. | Composition useful for providing one-step surgical preparation and drape |
| US6720387B1 (en) | 1998-02-18 | 2004-04-13 | 3M Innovative Properties Company | Hot-melt adhesive compositions comprising acidic polymer and basic polymer blends |
| EP0945148B1 (en) | 1998-03-26 | 2003-11-26 | Biomat B.V. | Endovascular stents with a polymeric coating |
| US6247808B1 (en) | 1998-04-22 | 2001-06-19 | Hewlett-Packard Company | Ink-jet printing system for improved print quality |
| US6022908A (en) | 1998-04-22 | 2000-02-08 | Hewlett-Packard Company | Printing liquids for improved print quality |
| JPH11335269A (ja) | 1998-05-19 | 1999-12-07 | Hisamitsu Pharmaceut Co Inc | 遺伝子関連医薬の経口投与固形製剤 |
| DE19918435A1 (de) | 1998-07-23 | 2000-01-27 | Roehm Gmbh | Überzugs- und Bindemittel für orale oder dermale Arzneiformen |
| US6004712A (en) | 1998-08-26 | 1999-12-21 | Xerox Corporation | Coated carrier |
| CA2347104A1 (en) | 1998-10-26 | 2000-04-05 | Tanabe Seiyaku Co., Ltd. | Sustained-release particles |
| DE69912078T2 (de) | 1998-12-10 | 2004-08-26 | E.I. Du Pont De Nemours And Co., Wilmington | Tintenstrahldrucktinten, die sternförmige Polymerzusätze enthalten |
| US6245421B1 (en) | 1999-02-04 | 2001-06-12 | Kodak Polychrome Graphics Llc | Printable media for lithographic printing having a porous, hydrophilic layer and a method for the production thereof |
| US6903064B1 (en) | 1999-05-26 | 2005-06-07 | Procter & Gamble Company | Detergent composition comprising polymeric suds volume and suds duration enhancers |
| US7241729B2 (en) | 1999-05-26 | 2007-07-10 | Rhodia Inc. | Compositions and methods for using polymeric suds enhancers |
| US6827795B1 (en) | 1999-05-26 | 2004-12-07 | Procter & Gamble Company | Detergent composition comprising polymeric suds enhancers which have improved mildness and skin feel |
| US6276273B1 (en) | 1999-06-11 | 2001-08-21 | Kodak Polychrome Graphics Llc | Surfactant-pretreated printing plate substrate, lithographic printing plate and method for production thereof |
| US6413306B1 (en) | 1999-10-07 | 2002-07-02 | E. I. Du Pont De Nemours And Company | Pigment dispersions containing ABC-block polymer dispersant |
| AU2764801A (en) | 2000-01-07 | 2001-07-24 | University Of Washington | Enhanced transport of agents using membrane disruptive agents |
| US6532871B1 (en) | 2000-01-27 | 2003-03-18 | Kodak Polychrome Graphics Llc | Method of controlling image resolution on a substrate using an autophobic fluid |
| US6471349B1 (en) | 2000-01-27 | 2002-10-29 | Kodak Polychrome Graphics Llc | Method to prepare a printing plate and printing plate |
| US6132917A (en) | 2000-03-29 | 2000-10-17 | Xerox Corporation | Coated carrier |
| US6251554B1 (en) | 2000-03-29 | 2001-06-26 | Xerox Corporation | Coated carrier |
| US6653056B2 (en) | 2000-07-12 | 2003-11-25 | E. I. Du Pont Nemours And Company | Process for patterning non-photoimagable ceramic tape |
| KR20020016069A (ko) | 2000-08-24 | 2002-03-04 | 민경윤 | 마크로라이드계 항생제의 경구투여용 조성물 및 이의 제조방법 |
| GB0102342D0 (en) | 2001-01-30 | 2001-03-14 | Smithkline Beecham Plc | Pharmaceutical formulation |
| HK1054195B (zh) | 2001-02-27 | 2005-09-09 | Evonik Röhm Gmbh | 用於提高了儲存穩定性的藥物製劑的包衣及粘合劑 |
| DE10110391A1 (de) | 2001-03-03 | 2002-09-26 | Lohmann Therapie Syst Lts | Hochflexibles Nikotin transdermales therapeutisches System mit Nikotin als Wirkstoff |
| US20040109869A1 (en) | 2001-03-19 | 2004-06-10 | Iomai Corporation | Transcutaneous immunostimulation |
| JP2004525803A (ja) | 2001-04-12 | 2004-08-26 | エーブリー デニソン コーポレイション | 金属被覆インクジェット基材およびそれを作製する方法 |
| DE10127134A1 (de) | 2001-06-05 | 2002-12-12 | Roehm Gmbh | verfahren zur Herstellung von Formkörpern aus (Meth)acrylat-Copolymeren mittels Spritzguß |
| CN1152067C (zh) | 2001-06-20 | 2004-06-02 | 山东大学 | 药物包衣用水性高分子薄膜材料制备工艺 |
| EP1416922A1 (en) | 2001-07-16 | 2004-05-12 | AstraZeneca AB | Pharmaceutical formulation comprising a proton pump inhibitor and antacids |
| AR034813A1 (es) | 2001-07-20 | 2004-03-17 | Novartis Ag | Composiciones farmaceuticas y uso de las mismas |
| CN1168797C (zh) | 2001-07-23 | 2004-09-29 | 广西南宁博世科工贸有限责任公司 | 纳米级纸质餐饮具防水剂及其生产方法 |
| US7055943B2 (en) | 2001-08-22 | 2006-06-06 | Canon Kabushiki Kaisha | Ink set for ink-jet recording, recording unit, ink-jet recording apparatus and ink-jet recording method |
| DE60204932T2 (de) | 2001-09-28 | 2006-05-18 | Canon K.K. | Toner und Bildaufzeichnungsmethode |
| US7048771B2 (en) | 2001-10-22 | 2006-05-23 | University Of California | Dyeing textiles using nanoparticles |
| CO5390081A1 (es) | 2001-11-28 | 2004-04-30 | Novartis Ag | Compuestos organicos |
| FR2832719B1 (fr) | 2001-11-29 | 2004-02-13 | Oreal | Copolymeres ethyleniques sequences adhesifs, compositions cosmetiques les contenant, et utilisation de ces copolymeres en cosmetique |
| FR2832720B1 (fr) | 2001-11-29 | 2004-02-13 | Oreal | Copolymeres ethyleniques sequences, compositions cosmetiques les contenant, et utilisation de ces copolymeres en cosmetique |
| DE10160720A1 (de) | 2001-12-11 | 2003-06-18 | Basf Ag | Kosmetisches Mittel enthaltend wenigstens ein Copolymer mit N-Vinyllactameinheiten |
| GB0130499D0 (en) | 2001-12-20 | 2002-02-06 | Unilever Plc | Polymers for laundry cleaning compositions |
| KR100619380B1 (ko) | 2002-03-28 | 2006-09-05 | 한미약품 주식회사 | 마크로라이드계 항생제의 경구투여용 조성물 및 이의제제화 방법 |
| KR20050023239A (ko) | 2002-03-29 | 2005-03-09 | 알자 코포레이션 | 용적 효율적인 조절된 방출 투여 형태 |
| US6924259B2 (en) | 2002-04-17 | 2005-08-02 | National Starch And Chemical Investment Holding Corporation | Amine copolymers for textile and fabric protection |
| WO2003090780A1 (en) | 2002-04-26 | 2003-11-06 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Direct cell target analysis |
| JP2003345095A (ja) | 2002-05-30 | 2003-12-03 | Canon Inc | 電子写真用部材の製造方法及び該方法により製造された電子写真用部材 |
| DE10239999A1 (de) | 2002-08-27 | 2004-03-04 | Röhm GmbH & Co. KG | Granulat oder Pulver zur Herstellung von Überzugs- und Bindemitteln für Arzneiformen |
| JP4213432B2 (ja) | 2002-08-28 | 2009-01-21 | 久光製薬株式会社 | 貼付剤 |
| WO2004041255A1 (en) | 2002-10-31 | 2004-05-21 | Alza Corporation | Dosage form providing ascending release of liquid formulation |
| DE10260921A1 (de) | 2002-12-20 | 2004-07-01 | Röhm GmbH & Co. KG | Verfahren zum Überziehen von Substraten für pharmazeutische Anwendungen mit einem Gemisch aus zwei filmbildenden Überzugsmitteln |
| DE10304403A1 (de) | 2003-01-28 | 2004-08-05 | Röhm GmbH & Co. KG | Verfahren zur Herstellung einer oralen Arzneiform mit unmittelbarem Zerfall und Wirkstofffreisetzung |
| AU2004228083B2 (en) | 2003-04-07 | 2009-03-26 | Rimon Therapeutics Ltd. | Ancient defense polymer |
| TR200300510A2 (tr) | 2003-04-18 | 2004-11-22 | Sanovel �La� Sanay� Ve T�Caret A.�. | Dağılan alendronat mikropartikül formülasyonu |
| WO2004096422A1 (en) | 2003-04-30 | 2004-11-11 | The University Of Sheffield | Particulate emulsifiers, emulsions and uses thereof |
| US20050090599A1 (en) | 2003-06-06 | 2005-04-28 | Spinelli Harry J. | Aqueous ionically stabilized dispersions |
| US8025899B2 (en) | 2003-08-28 | 2011-09-27 | Abbott Laboratories | Solid pharmaceutical dosage form |
| US20050048112A1 (en) | 2003-08-28 | 2005-03-03 | Jorg Breitenbach | Solid pharmaceutical dosage form |
| GB2407501A (en) | 2003-11-03 | 2005-05-04 | Ist Superiore Sanita | Nanoparticles for delivery of a pharmacologically active agent, comprising water insoluble (co)polymer core & hydrophilic acrylate-based (co)polymer shell |
| GB2407500A (en) | 2003-11-03 | 2005-05-04 | Ist Superiore Sanita | Use of microparticles for antigen delivery |
| US7829070B2 (en) | 2003-12-09 | 2010-11-09 | Basf Se | Ampholytic anionic copolymers |
| CN1909889B (zh) | 2004-01-09 | 2010-06-02 | 韩美药品株式会社 | 头孢呋辛酯颗粒及其制备方法 |
| US7670624B2 (en) | 2004-01-29 | 2010-03-02 | Astella Pharma Inc. | Gastrointestinal-specific multiple drug release system |
| JP4696107B2 (ja) | 2004-03-24 | 2011-06-08 | コグニス・フランス・ソシエテ・パール・アクシオン・サンプリフィエ | ブクホルジア属に属する植物の抽出物の化粧品および医薬品における使用 |
| US8652456B2 (en) | 2004-06-21 | 2014-02-18 | Basf Se | Aqueous preparations comprising at least one water-soluble or water-dispersible copolymer with cationgenic groups |
| DE102004035938A1 (de) | 2004-07-23 | 2006-02-16 | Röhm GmbH & Co. KG | Verfahren zur Herstellung von überzogenen Arzneiformen mit stabilem Wirkstofffreigabeprofil |
| DE102004051541A1 (de) | 2004-10-22 | 2006-05-04 | Basf Ag | Amphotere Ethylmethacrylat-Copolymere und deren Verwendung |
| DE102004051648A1 (de) | 2004-10-22 | 2006-04-27 | Basf Ag | Anionische Ethylmethacrylat-Copolymere und deren Verwendung |
| US7499209B2 (en) | 2004-10-26 | 2009-03-03 | Xerox Corporation | Toner compositions for dry-powder electrophoretic displays |
| DE102004059792A1 (de) | 2004-12-10 | 2006-06-14 | Röhm GmbH & Co. KG | Multipartikuläre Arzneiform, enthaltend mucoadhaesiv formulierte Nukleinsäure-Wirkstoffe, sowie ein Verfahren zur Herstellung der Arzneiform |
| WO2006079632A1 (de) | 2005-01-28 | 2006-08-03 | Basf Aktiengesellschaft | Verwendung von wasser-in-wasser-emulsionspolymerisaten als verdicker in kosmetischen zubereitungen |
| DE102005010255A1 (de) | 2005-03-07 | 2006-09-14 | Lts Lohmann Therapie-Systeme Ag | Faserfreies transdermales therapeutisches System und Verfahren zu seiner Herstellung |
| ES2421916T3 (es) | 2005-03-16 | 2013-09-06 | Nycomed Gmbh | Forma farmacéutica de sabor enmascarado que contiene roflumilast |
| US8445382B2 (en) | 2005-03-22 | 2013-05-21 | Nxp B.V. | Side wall pore sealing for low-k dielectrics |
| CN101232868A (zh) | 2005-04-19 | 2008-07-30 | 阿尔扎公司 | 曲马多和加巴喷丁的控释递药剂型 |
| WO2006122022A2 (en) | 2005-05-10 | 2006-11-16 | Novartis Ag | Modified release famciclovir pharmaceutical compositions |
| NZ585116A (en) | 2005-05-10 | 2011-12-22 | Novartis Ag | Extrusion process for making compositions with poorly compressible therapeutic compounds e.g. metformin hydrochloride |
| MY148074A (en) | 2005-05-10 | 2013-02-28 | Novartis Ag | Pharmaceutical compositions comprising imatinib and a release retardant |
| US7241805B2 (en) | 2005-06-27 | 2007-07-10 | Biovail Laboratories, Inc. | Modified release formulations of a bupropion salt |
| RU2423997C9 (ru) | 2005-07-05 | 2011-11-20 | Эббетт ГмбХ унд Ко. КГ | Композиция и лекарственная форма, содержащие твердую или полутвердую матрицу |
| US20070275060A1 (en) | 2005-08-05 | 2007-11-29 | Osmotica Costa Rica Sociedad Anonima | Extended release solid pharmaceutical composition containing carbidopa and levodopa |
| WO2007020187A1 (en) | 2005-08-12 | 2007-02-22 | Ciba Specialty Chemicals Holding Inc. | Strongly adherent coatings |
| GB0518059D0 (en) | 2005-09-06 | 2005-10-12 | Dow Corning | Delivery system for releasing active ingredients |
| US7642329B2 (en) | 2005-09-27 | 2010-01-05 | Council Of Scientific & Industrial Research | Oligomeric lactide macromer based copolymer and a process for the preparation thereof |
| PL116330U1 (en) | 2005-10-31 | 2007-04-02 | Alza Corp | Method for the reduction of alcohol provoked rapid increase in the released dose of the orally administered opioide with prolonged liberation |
| AU2006340003A1 (en) | 2005-11-09 | 2007-09-20 | Novartis Ag | Process for making pharmaceutical compositions with a transient plasticizer |
| WO2007060117A2 (de) | 2005-11-24 | 2007-05-31 | Basf Se | Chimäre keratinbindende effektorproteine |
| GB2432584A (en) | 2005-11-28 | 2007-05-30 | Univ Sheffield | Particle stabilised foam |
| CN1813683B (zh) | 2005-12-07 | 2011-08-31 | 范敏华 | 一种阿奇霉素的干混悬剂及其制备方法 |
| US7579504B2 (en) | 2005-12-07 | 2009-08-25 | Gilead Sciences, Inc. | ABCA1 elevating compounds |
| US9267937B2 (en) | 2005-12-15 | 2016-02-23 | Massachusetts Institute Of Technology | System for screening particles |
| US20110163469A1 (en) | 2005-12-16 | 2011-07-07 | Massachusetts Institute Of Technology | High-throughput fabrication of microparticles |
| GB0525864D0 (en) | 2005-12-20 | 2006-02-01 | Novartis Ag | Organic compounds |
| CN100450597C (zh) | 2005-12-27 | 2009-01-14 | 天津工业大学 | 一种复合纳滤膜及其制备方法 |
| EP1832281A1 (en) | 2006-03-10 | 2007-09-12 | Abbott GmbH & Co. KG | Process for producing a solid dispersion of an active ingredient |
| US20100233350A1 (en) | 2006-03-15 | 2010-09-16 | Boston Scientific Scimed, Inc. | Drug delivery composition and methods of making same using nanofabrication |
| KR20090005347A (ko) | 2006-03-31 | 2009-01-13 | 바스프 에스이 | 아크릴레이트 공중합체의 제조 방법 |
| US9085778B2 (en) | 2006-05-03 | 2015-07-21 | VL27, Inc. | Exosome transfer of nucleic acids to cells |
| CA2649848A1 (en) | 2006-05-04 | 2007-11-15 | Novartis Ag | Heated roller compaction process for making pharmaceutical compositions |
| CN101460156B (zh) | 2006-05-08 | 2011-06-08 | 帝国制药株式会社 | 抗痴呆药的经皮吸收制剂 |
| CN100500716C (zh) | 2006-06-21 | 2009-06-17 | 苏州大学 | 无规共聚阳离子大分子乳化剂及其制备方法 |
| AU2007265452A1 (en) | 2006-06-26 | 2008-01-03 | Mutual Pharmaceutical Company, Inc. | Active agent formulations, methods of making, and methods of use |
| KR100857724B1 (ko) | 2006-06-30 | 2008-09-10 | 한올제약주식회사 | 용해도와 용출률이 향상된 시부트라민 함유 경구투여용 고체분산체 |
| CN101484144A (zh) | 2006-07-06 | 2009-07-15 | 特瓦特药工业有限公司 | 具有受控药物动力学的组合物 |
| SI1880718T1 (sl) | 2006-07-10 | 2011-11-30 | Pfleger R Chem Fab | Farmacevtski pripravki za oralno dajanje z nadzorovanim sproščanjem zdravila v majhne intestinke kolone in postopek njihove priprave |
| EP1880715A1 (en) | 2006-07-19 | 2008-01-23 | Abbott GmbH & Co. KG | Pharmaceutically acceptable solubilizing composition and pharmaceutical dosage form containing same |
| KR100857411B1 (ko) | 2006-07-21 | 2008-09-08 | 한올제약주식회사 | 리파아제 저해제의 경구 투여용 방출조절 약학 제제 및이의 제조 방법 |
| ATE462416T1 (de) | 2006-08-04 | 2010-04-15 | Ethypharm Sa | Mehrschichtige im mund zerfallende tablette |
| WO2008021347A2 (en) | 2006-08-16 | 2008-02-21 | Novartis Ag | Method for making solid dispersions of highly crystalline therapeutic compounds |
| WO2008023869A1 (en) | 2006-08-24 | 2008-02-28 | Hanall Pharmaceutical Co., Ltd. | Combined pharmeceutical formulation with controlled-release comprising dihydropyridine calcium channel blockers and hmg-coa reductase inhibitors |
| CA2662911A1 (en) | 2006-09-19 | 2008-03-27 | Basf Se | Cosmetic preparations based on molecularly imprinted polymers |
| KR100812538B1 (ko) | 2006-10-23 | 2008-03-11 | 한올제약주식회사 | 약물 제어방출형 메트포르민-글리메피리드 복합제제 |
| WO2008054123A1 (en) | 2006-10-30 | 2008-05-08 | Hanall Pharmaceutical Company, Ltd. | Controlled release complex composition comprising angiotensin-ii-receptor blockers and hmg-coa reductase inhibitors |
| WO2008054121A1 (en) | 2006-10-30 | 2008-05-08 | Hanall Pharmaceutical Company. Ltd | Controlled release pharmaceutical composition containing thiazides and angiotensin-ii-receptor blockers |
| WO2008055966A1 (en) | 2006-11-09 | 2008-05-15 | Abbott Gmbh & Co. Kg | Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor |
| WO2008067164A2 (en) | 2006-11-15 | 2008-06-05 | Abbott Laboratories | Solid pharmaceutical dosage formulations |
| GB0624729D0 (en) | 2006-12-12 | 2007-01-17 | Univ Leeds | Reversible micelles and applications for their use |
| US20080153982A1 (en) | 2006-12-20 | 2008-06-26 | John Ta-Yuan Lai | Vinyl-Thiocarbonate and Polyol Containing Block Copolymers |
| WO2008093984A1 (en) | 2007-01-29 | 2008-08-07 | Hanall Pharmaceutical Company. Ltd | N, n- dimethyl imidodicarbonimidic diamide acetate, method for producing the same and pharmaceutical compositions comprising the same |
| US8298452B2 (en) | 2007-02-26 | 2012-10-30 | Dai Nippon Printing Co., Ltd. | Negative type resist composition for color filter, color filter using same, and liquid crystal display |
| WO2008117814A1 (ja) | 2007-03-26 | 2008-10-02 | Teikoku Seiyaku Co., Ltd. | 大腸送達用経口製剤 |
| JP5215642B2 (ja) | 2007-03-30 | 2013-06-19 | 富士フイルム株式会社 | インク組成物、並びに、それを用いた画像記録方法及び画像記録物 |
| JP5260943B2 (ja) | 2007-03-30 | 2013-08-14 | 富士フイルム株式会社 | 粒子分散物及びインク組成物、並びに、それを用いた画像記録方法及び画像記録物 |
| JP5215641B2 (ja) | 2007-03-30 | 2013-06-19 | 富士フイルム株式会社 | インク組成物、並びに、それを用いた画像記録方法及び画像記録物 |
| KR101128891B1 (ko) | 2007-05-03 | 2012-03-26 | 한올바이오파마주식회사 | 로라타딘 및 슈도에페드린을 함유하는 제어 방출 다층정 |
| US20080299391A1 (en) | 2007-05-31 | 2008-12-04 | White Scott R | Capsules, methods for making capsules, and self-healing composites including the same |
| CN101796186B (zh) | 2007-06-07 | 2013-05-22 | 韦克福里斯特大学健康科学院 | 喷墨基因打印 |
| KR100867639B1 (ko) | 2007-06-08 | 2008-11-10 | (주)다산메디켐 | 고미가 차폐된 염산 도네페질-함유 입자, 이를 포함하는약학 조성물, 및 이들의 제조방법 |
| WO2008157611A2 (en) | 2007-06-18 | 2008-12-24 | 3M Innovative Properties Company | Colored acrylic adhesive and marking film |
| JP2009016258A (ja) | 2007-07-06 | 2009-01-22 | Mitsubishi Electric Corp | 固体高分子型燃料電池 |
| JP5581208B2 (ja) | 2007-07-18 | 2014-08-27 | データレース リミテッド | レーザー感受性被覆配合物 |
| WO2009026461A2 (en) | 2007-08-21 | 2009-02-26 | Board Of Regents, The University Of Texas System | Thermo-kinetic mixing for pharmaceutical applications |
| KR101050015B1 (ko) | 2007-09-21 | 2011-07-19 | 동아제약주식회사 | 위체류약물전달시스템을 이용한 애엽 추출물의 약학조성물및 이를 이용한 서방성 경구용 제제 |
| AR066168A1 (es) | 2007-09-28 | 2009-07-29 | Novartis Ag | Formulaciones galenicas de compuestos organicos |
| FR2921835B1 (fr) | 2007-10-05 | 2012-05-04 | Soc Dexploitation De Produits Pour Les Industries Chimiques Seppic | Composition d'enrobage comprenant du polydextrose, procede pour sa preparation et utilisation pour enrober les formes solides ingerables |
| CN101932322A (zh) | 2007-10-10 | 2010-12-29 | 韩诺生物制约株式会社 | 用于治疗丙型肝炎病毒感染的包含HMG-CoA还原酶抑制剂和胆汁酸的药物组合物 |
| CN101444513B (zh) | 2007-11-27 | 2011-05-11 | 上官清 | 一种头孢克洛口腔崩解片及其制备方法 |
| US20100278899A1 (en) | 2007-12-06 | 2010-11-04 | Lintec Corporation | Edible film |
| US7932306B2 (en) | 2007-12-12 | 2011-04-26 | E. I. Du Pont De Nemours And Company | Amphoteric dispersants and their use in inkjet inks |
| DE102007060175A1 (de) | 2007-12-13 | 2009-06-18 | Johannes Gutenberg-Universität Mainz | Quartärnisierung des Zusatzstoffs Aminoalkyl Methacrylat Copolymer E zur Verbesserung der Permeabilität und Löslichkeit von Arzneistoffen |
| US8034254B2 (en) | 2007-12-21 | 2011-10-11 | 3M Innovative Properties Company | Optical adhesive for liquid crystal display |
| EP2224901A1 (en) | 2007-12-21 | 2010-09-08 | Basf Se | Anti-dandruff compositions containing peptides |
| KR101288294B1 (ko) | 2007-12-25 | 2013-07-26 | 닛뽕소다 가부시키가이샤 | 오늄염 함유 폴리머 |
| KR101104912B1 (ko) | 2008-01-08 | 2012-01-12 | 한올바이오파마주식회사 | N,n―디메틸 이미도디카르본이미딕 디아미드의 니코틴산염, 그의 제조방법 및 그를 포함하는 약제학적 조성물 |
| EP2246052B1 (en) | 2008-01-31 | 2017-03-08 | Kyorin Pharmaceutical Co., Ltd. | Orally rapidly disintegrating tablet comprising imidafenacin |
| CN101983055B (zh) | 2008-01-31 | 2013-05-08 | 杏林制药株式会社 | 以咪达那新为有效成分的口腔内速崩片的制造方法 |
| AU2009214307A1 (en) | 2008-02-13 | 2009-08-20 | Bayer Intellectual Property Gmbh | Drug delivery system with stabilising effect |
| WO2009103735A1 (de) | 2008-02-21 | 2009-08-27 | Basf Se | Zusammensetzung, enthaltend ein ampholytisches copolymer auf der basis quaternisierter stickstoffhaltiger monomere und mindestens ein hiervon verschiedenes polymer, und ihre verwendung |
| KR20090091075A (ko) | 2008-02-22 | 2009-08-26 | 한올제약주식회사 | 심혈관계 질환 치료용 약제학적 제제 |
| WO2009104939A2 (ko) | 2008-02-22 | 2009-08-27 | 한올제약주식회사 | 약제학적 제제 |
| KR101207618B1 (ko) | 2008-02-22 | 2012-12-04 | 한올바이오파마주식회사 | 심혈관계 질환 치료용 약제학적 제제 |
| EP2254556A2 (en) | 2008-03-11 | 2010-12-01 | Takeda Pharmaceutical Company Limited | Orally-disintegrating solid preparation |
| WO2009125981A2 (ko) | 2008-04-10 | 2009-10-15 | 한올제약주식회사 | 약제학적 제제 |
| WO2009125987A2 (ko) | 2008-04-10 | 2009-10-15 | 한올제약주식회사 | 약제학적 제제 |
| KR20090114190A (ko) | 2008-04-29 | 2009-11-03 | 한올제약주식회사 | 방출성이 제어된 HMG―CoA 환원 효소 억제제와안지오텐신―Ⅱ―수용체 차단제의 복합 조성물 |
| KR101209319B1 (ko) | 2008-04-29 | 2012-12-06 | 한올바이오파마주식회사 | 안지오텐신-ⅱ-수용체 차단제를 포함하는 약제학적 제제 |
| WO2009134053A2 (ko) | 2008-04-29 | 2009-11-05 | 한올제약주식회사 | 방출성이 제어된 차이자이드계 화합물과 안지오텐신 - ii - 수용체 차단제를 포함하는 약학적 조성물 |
| KR101230731B1 (ko) | 2008-04-29 | 2013-02-07 | 한올바이오파마주식회사 | 약제학적 제제 |
| CA2724014C (en) | 2008-05-13 | 2016-09-13 | University Of Washington | Micellic assemblies |
| WO2009140421A2 (en) * | 2008-05-13 | 2009-11-19 | University Of Washington | Polymeric carrier |
| WO2009142421A2 (ko) | 2008-05-17 | 2009-11-26 | 한올제약주식회사 | 약제학적 제제 |
| JP2011521085A (ja) | 2008-05-22 | 2011-07-21 | イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニー | インクジェットインクと共に用いられる定着インク |
| GB0809314D0 (en) | 2008-05-22 | 2008-07-02 | Summit Corp Plc | Compounds for treating muscular dystrophy |
| WO2009151295A2 (ko) | 2008-06-13 | 2009-12-17 | 한올제약주식회사 | 아젤니디핀과 HMG-CoA 환원효소 억제제 또는 안지오텐신 Ⅱ 수용체 차단제를 포함하는 약제학적 제제 |
| US8366600B2 (en) | 2008-06-19 | 2013-02-05 | Nupathe Inc. | Polyamine enhanced formulations for triptan compound iontophoresis |
| US8664324B2 (en) | 2008-06-23 | 2014-03-04 | Basf Se | Pigment dispersants with modified copolymers |
| WO2010008203A2 (ko) | 2008-07-15 | 2010-01-21 | 한올제약주식회사 | 칼슘채널길항제를 포함하는 약제학적 제제 |
| WO2010008244A2 (ko) | 2008-07-18 | 2010-01-21 | 한올제약주식회사 | 약제학적 제제 |
| JP5881292B2 (ja) | 2008-09-08 | 2016-03-09 | 国立大学法人京都大学 | リビングラジカル重合法のための触媒 |
| CA2776672A1 (en) | 2008-10-03 | 2010-04-08 | Chamelic Ltd | Ab diblock copolymers and applications for their use |
| US9267042B2 (en) | 2008-10-27 | 2016-02-23 | Datalase Ltd. | Coating composition for marking substrates |
| BRPI0921231A2 (pt) | 2008-11-05 | 2018-06-26 | Lubrizol Corp | composição contendo um copolímero em bloco e um método para lubrificação de um motor de combustão interna |
| JP2010111781A (ja) | 2008-11-06 | 2010-05-20 | Kao Corp | 非水系顔料分散剤 |
| DE102008043662A1 (de) | 2008-11-12 | 2010-05-20 | Evonik Röhm Gmbh | Verfahren zur Herstellung von Telechelen mit breiter Molekulargewichtsverteilung |
| CA2745926A1 (en) | 2008-12-08 | 2010-07-08 | Phaserx, Inc. | Omega-functionalized polymers, junction-functionalized block copolymers, polymer bioconjugates, and radical chain extension polymerization |
| US8820907B2 (en) | 2008-12-12 | 2014-09-02 | E I Du Pont De Nemours And Company | Amphoteric dispersants and their use in inkjet inks |
| TWI468191B (zh) | 2009-01-28 | 2015-01-11 | Novartis Ag | 有機化合物之調配物 |
| CN101643412B (zh) | 2009-03-17 | 2013-03-13 | 江苏工业学院 | 一种端羟基聚丙烯酸酯类齐聚物及制备方法与用途 |
| JP5654002B2 (ja) | 2009-05-13 | 2015-01-14 | ビーエーエスエフ ソシエタス・ヨーロピアBasf Se | ポリエーテルに基づくコポリマーを微水溶性ポリマーと組み合わせて含む固体医薬調製物 |
| US7992656B2 (en) | 2009-07-09 | 2011-08-09 | Halliburton Energy Services, Inc. | Self healing filter-cake removal system for open hole completions |
| KR101326900B1 (ko) | 2009-08-21 | 2013-11-11 | 이화여자대학교 산학협력단 | 신규한 항암제 보조용 화합물, 이의 제조방법 및 이를 포함하는 항암제 보조용 조성물 |
| KR101190953B1 (ko) | 2009-08-25 | 2012-10-12 | 한올바이오파마주식회사 | 메트포르민 타우린염, 그의 제조방법, 그를 포함하는 약학 조성물 및 그를 포함하는 복합제제 |
| WO2011025271A2 (ko) | 2009-08-25 | 2011-03-03 | 한올바이오파마주식회사 | 메트포르민 아스코르브산염, 그의 제조방법, 그를 포함하는 약학 조성물 및 그를 포함하는 복합제제 |
| KR101190957B1 (ko) | 2009-08-25 | 2012-10-15 | 한올바이오파마주식회사 | 메트포르민 카페익산염, 그의 제조방법, 그를 포함하는 약학 조성물 및 그를 포함하는 복합제제 |
| WO2011025267A2 (ko) | 2009-08-25 | 2011-03-03 | 한올바이오파마주식회사 | 메트포르민 메탄설폰산염, 그의 제조방법, 그를 포함하는 약학 조성물 및 그를 포함하는 복합제제 |
| EP2289971A1 (en) | 2009-08-27 | 2011-03-02 | Total Petrochemicals Research Feluy | Ring opening polymerisation of cyclic carbonates with organic catalyst systems |
| KR101630432B1 (ko) | 2009-08-28 | 2016-06-15 | 한국생명공학연구원 | 2, 6-위치가 치환된 3-니트로피리딘 유도체 화합물 또는 이의 약제학적으로 허용되는 염을 포함하는 암 예방 또는 치료용 약학 조성물 |
| KR101280160B1 (ko) | 2009-09-02 | 2013-06-28 | 이화여자대학교 산학협력단 | 피라졸 유도체, 이의 제조방법 및 이를 포함하는 골다공증 예방 및 치료용 조성물 |
| US8637674B2 (en) | 2009-09-02 | 2014-01-28 | Ewha University-Industry Collaboration Foundation | Pyrazole derivatives, preparation method thereof, and composition for prevention and treatment of osteoporosis containing same |
| JP5868319B2 (ja) | 2009-09-03 | 2016-02-24 | エボニック レーム ゲゼルシャフト ミット ベシュレンクテル ハフツングEvonik Roehm GmbH | 1つ以上の生物学的活性物質、調合補助物質および磁化可能粒子を包含する経口剤形 |
| CN102030871B (zh) | 2009-09-25 | 2012-10-10 | 天津大学 | 聚乙二醇嵌段可生物降解聚酯梳型接枝共聚物及其制备方法和应用 |
| CN102482546B (zh) | 2009-09-29 | 2015-11-25 | 琳得科株式会社 | 粘合剂以及粘合片 |
| JP5583379B2 (ja) | 2009-09-30 | 2014-09-03 | 富士フイルム株式会社 | 顔料分散物及びそれを用いたインク組成物 |
| KR101110845B1 (ko) | 2009-10-21 | 2012-02-15 | 주식회사 케이씨씨 | 내수성 및 내후성이 우수한 방담 코팅용 조성물 |
| CN102665671B (zh) | 2009-10-22 | 2015-06-10 | 欧莱雅 | 光照保护性组合物与薄膜及其制造方法 |
| WO2011062965A2 (en) | 2009-11-18 | 2011-05-26 | University Of Washington Through Its Center For Commercialization | Targeting monomers and polymers having targeting blocks |
| WO2011074637A1 (ja) | 2009-12-16 | 2011-06-23 | 後藤 武 | 抗認知症薬物の経皮吸収製剤 |
| JP2012236773A (ja) | 2009-12-16 | 2012-12-06 | Goto Takeshi | 抗認知症薬物の経皮吸収製剤 |
| US20120282303A1 (en) | 2009-12-16 | 2012-11-08 | Takeshi Ito | Percutaneous absorption preparation comprising anti-dementia drug |
| EA201200935A1 (ru) | 2009-12-23 | 2012-12-28 | Дефианте Фармасеутика С.А. | Комбинированная композиция, подходящая для лечения сердечно-сосудистых заболеваний |
| CN101735383B (zh) | 2009-12-25 | 2014-08-13 | 天津大学 | 聚甲基丙烯酸二甲胺基乙酯-聚甲基丙烯酸盐包裹氧化锌量子点及制备和应用 |
| EP2525780B1 (en) | 2010-01-19 | 2022-09-07 | Northwestern University | Synthetic nanostructures including nucleic acids and/or other entities |
| JP2011184582A (ja) | 2010-03-09 | 2011-09-22 | Three M Innovative Properties Co | 光学用粘着シート |
| GB201003970D0 (en) | 2010-03-10 | 2010-04-21 | Univ Sheffield | Polymer synthesis |
| US20110312973A1 (en) | 2010-03-10 | 2011-12-22 | Bernd Liepold | Solid compositions |
| US20130005874A1 (en) | 2010-03-15 | 2013-01-03 | Taisho Pharmaceutical Co., Ltd | Pigment composition |
| JP4620171B1 (ja) | 2010-03-19 | 2011-01-26 | 株式会社ツキオカ | 可食フィルム |
| US20130017245A1 (en) | 2010-03-23 | 2013-01-17 | Aska Pharmaceutical Co., Ltd. | Solid preparation |
| JP2011207963A (ja) | 2010-03-29 | 2011-10-20 | Fujifilm Corp | 顔料分散物、インク組成物、インクジェット記録方法、および印刷物 |
| JP2013527155A (ja) | 2010-04-16 | 2013-06-27 | ダボス ライフ サイエンス ピーティーイー. リミテッド | 皮膚科用途のための少なくとも1つのビタミンe成分およびチロシナーゼ阻害剤の相乗的相互作用 |
| KR20110117758A (ko) | 2010-04-22 | 2011-10-28 | 한올바이오파마주식회사 | 베타 아드레날린 차단제 및 HMG-CoA 환원 효소 억제제를 함유하는 약제학적 제제 |
| KR101324283B1 (ko) | 2010-04-27 | 2013-11-01 | 한올바이오파마주식회사 | 바이구아나이드 화합물의 신규 염, 그의 제조방법, 그를 포함하는 약제학적 조성물 |
| GB201008364D0 (en) | 2010-05-20 | 2010-07-07 | Geneve De | Composition and method |
| CN101890185B (zh) | 2010-05-21 | 2012-12-12 | 天津大学 | 含有ZnO量子点载体/DNA复合物的胶原基复合角膜替代物及其制备方法和应用 |
| RU2566716C2 (ru) | 2010-06-09 | 2015-10-27 | Эббви Бахамаз Лтд. | Твердые дисперсии, содержащие ингибиторы киназ |
| NZ605440A (en) | 2010-06-10 | 2014-05-30 | Abbvie Bahamas Ltd | Solid compositions comprising an hcv inhibitor |
| KR20110135018A (ko) | 2010-06-10 | 2011-12-16 | 연세대학교 산학협력단 | 암의 치료 또는 예방을 위한 약제학적 조성물 |
| WO2011154331A1 (en) | 2010-06-10 | 2011-12-15 | F. Hoffmann-La Roche Ag | Polymers for delivery of nucleic acids |
| KR101372721B1 (ko) | 2010-06-18 | 2014-03-14 | 이화여자대학교 산학협력단 | Interleukin―6 억제 작용을 갖는 신규한 벤즈옥사졸 유도체, 이의 제조 방법 및 이를 포함하는 약학적 조성물 |
| NZ605352A (en) | 2010-06-30 | 2013-10-25 | Nal Pharmaceuticals Ltd | Process for producing glycosaminoglycans |
| KR101463677B1 (ko) | 2010-06-30 | 2014-11-19 | 닛뽕소다 가부시키가이샤 | 신규 공중합체 |
| KR100994148B1 (ko) | 2010-07-14 | 2010-11-15 | (주)아팩 | 그라비아 인쇄용 양이온성 수성 수지 조성물 및 그의 제조방법 |
| US9121065B2 (en) | 2010-08-09 | 2015-09-01 | The Trustees Of The University Of Pennsylvania | Nanoparticle-oligonucleotide hybrid structures and methods of use thereof |
| KR101659785B1 (ko) | 2010-10-22 | 2016-09-26 | 한국생명공학연구원 | Il-6 활성 억제 작용을 갖는 화합물 또는 이의 약학적으로 허용되는 염을 유효성분으로 포함하는 il-6로 매개되는 질환의 예방 또는 치료용 조성물 |
| EP3974831A1 (en) | 2010-10-22 | 2022-03-30 | T2 Biosystems, Inc. | Methods for detecting the presence of a bacterium in a whole blood sample |
| WO2012058638A2 (en) | 2010-10-29 | 2012-05-03 | President And Fellows Of Harvard College | Nucleic acid nanostructure barcode probes |
| WO2012061719A2 (en) | 2010-11-04 | 2012-05-10 | President And Fellows Of Harvard College | Dna origami devices |
| GB201020032D0 (en) | 2010-11-25 | 2011-01-12 | Sigmoid Pharma Ltd | Composition |
| MX354210B (es) | 2010-12-16 | 2018-02-16 | Celgene Corp | Formas farmaceuticas orales de liberacion controlada de farmacos escasamente solubles y los usos de estas. |
| IE20100799A1 (en) | 2010-12-22 | 2012-08-01 | Eurand Pharmaceuticals Ltd | Pharmaceutical composites of poorly water soluble drugs and polymers |
| WO2012101235A1 (en) | 2011-01-26 | 2012-08-02 | Cenix Bioscience Gmbh | Delivery system and conjugates for compound delivery via naturally occurring intracellular transport routes |
| KR101730865B1 (ko) | 2011-02-11 | 2017-04-27 | 주식회사유한양행 | 레바프라잔-함유 나노입자를 포함하는 경구투여용 약학 조성물 및 그의 제조방법 |
| CN103391769A (zh) | 2011-02-17 | 2013-11-13 | 霍夫曼-拉罗奇有限公司 | 通过热熔挤出使活性药物成分从过冷液体状态受控结晶的方法 |
| KR20120098489A (ko) | 2011-02-28 | 2012-09-05 | 이화여자대학교 산학협력단 | 피라졸 유도체를 포함하는 심혈관 질환 예방 및 치료용 조성물 |
| KR20120098462A (ko) | 2011-02-28 | 2012-09-05 | 이화여자대학교 산학협력단 | 피라졸 유도체, 이의 제조방법 및 이를 포함하는 골다공증 예방 및 치료용 조성물 |
| CN103415284B (zh) | 2011-03-09 | 2016-12-07 | 巴斯夫欧洲公司 | 用于制备快速崩解的片剂的药物配制物 |
| KR101314579B1 (ko) | 2011-04-07 | 2013-10-10 | 광주과학기술원 | 파크리탁셀이 선적된 고분자 나노입자 및 그 제조방법 |
| GB201106433D0 (en) | 2011-04-15 | 2011-06-01 | Reckitt & Colman Overseas | Composition and method |
| EP2522689A1 (en) | 2011-05-13 | 2012-11-14 | Universität Bayreuth | Non-viral transfection systems |
| WO2012158610A1 (en) | 2011-05-13 | 2012-11-22 | William Marsh Rice University | Temperature-assisted migration of amphiphilic nanoparticles through liquid interfaces |
| EP2523002A1 (en) | 2011-05-13 | 2012-11-14 | Universität Bayreuth | Utilization of magnetic nanoparticles as intracellular pull-down system |
| CN102250278B (zh) | 2011-05-26 | 2013-04-10 | 华东理工大学 | 用于水溶性固定化纤维素酶的pH敏感再生型聚合物及其制备方法与应用 |
| KR101337672B1 (ko) | 2011-06-02 | 2013-12-31 | 경희대학교 산학협력단 | 베타―d―글루코스 펜타키스(3,4―디하이드록시―5―((3,4,5―트리하이드록시벤조일)옥시)벤조에이트)를 유효성분으로 포함하는 신장결석 예방 및 치료용 조성물 |
| KR101280720B1 (ko) | 2011-06-03 | 2013-07-26 | 경희대학교 산학협력단 | 1,2,3,4,6―펜타―오―갈로일―베타―디―글루코오스및 이마티니브를 유효성분으로 포함하는 만성 골수성 백혈병 치료용 조성물 |
| US20140235790A1 (en) | 2011-06-10 | 2014-08-21 | University Of Washington Through Its Center For Commercialization | Carbohydrate-based compositions and methods for targeted drug delivery |
| JP2013029832A (ja) | 2011-06-22 | 2013-02-07 | Dainippon Printing Co Ltd | カラーフィルタ用硬化性樹脂組成物、カラーフィルタ、液晶表示装置及び有機発光表示装置、並びにカラーフィルタ用顔料分散液 |
| GB201111216D0 (en) | 2011-07-01 | 2011-08-17 | Reckitt & Colman Overseas | Composition and method |
| WO2013003887A1 (en) | 2011-07-04 | 2013-01-10 | Commonwealth Scientific And Industrial Research Organisation | Nucleic acid complex |
| KR101302315B1 (ko) | 2011-07-19 | 2013-08-30 | 이화여자대학교 산학협력단 | 피라졸 유도체를 포함하는 호흡기 질환 예방 및 치료용 조성물 |
| KR101282847B1 (ko) | 2011-07-27 | 2013-07-05 | 조선대학교산학협력단 | 실로스타졸을 함유하는 고체분산체 및 이를 포함하는 약학 조성물 |
| JP5807438B2 (ja) | 2011-08-12 | 2015-11-10 | 富士ゼロックス株式会社 | 二成分現像剤用キャリア、二成分現像剤、画像形成方法、及び、画像形成装置 |
| CN102949342A (zh) | 2011-08-24 | 2013-03-06 | 天津金耀集团有限公司 | 一种含有睾酮的透皮吸收药物组合物 |
| EP2749577B1 (en) | 2011-08-25 | 2018-09-19 | Kyoto University | Living radical polymerization method |
| KR101454066B1 (ko) | 2011-09-08 | 2014-10-24 | 경희대학교 산학협력단 | 아스퍼질러스 나이저의 배양액에서 분리한 인삼 사포닌 전환활성을 갖는 효소, 이의 제조방법, 이를 이용한 효소처리 인삼 추출물, 효소처리 인삼 추출물의 제조방법 및 효소처리 인삼 추출물을 포함하는 피부미용 개선용 조성물 |
| KR101384873B1 (ko) | 2011-09-20 | 2014-04-16 | 경희대학교 산학협력단 | 인삼(Panax ginseng) 및 산사(Crataegis fructus) 추출물을 포함하는 피부미용 개선용 조성물 |
| US20130129869A1 (en) | 2011-11-23 | 2013-05-23 | Hooman Hafezi | Compositions comprising a shelf-life stability component |
| JP5735405B2 (ja) | 2011-11-30 | 2015-06-17 | 株式会社Dnpファインケミカル | 着色樹脂組成物、カラーフィルタ、及び液晶表示装置 |
| JP5781706B2 (ja) | 2011-12-29 | 2015-09-24 | アッヴィ・アイルランド・アンリミテッド・カンパニー | Hcv阻害剤を含む固体組成物 |
| WO2013135853A1 (en) | 2012-03-15 | 2013-09-19 | Boehringer Ingelheim Vetmedica Gmbh | Pharmaceutical packaging product for the veterinary medical sector |
| JP2013237821A (ja) | 2012-05-17 | 2013-11-28 | Teijin Ltd | (メタ)アクリル酸共重合体 |
| CA2874455C (en) | 2012-05-22 | 2016-10-11 | Kuhnil Pharm. Co., Ltd. | Multilayer coating form of orally administered pharmaceutical composition containing omega-3 fatty acid or alkyl ester thereof and statin based drug |
| CA2872446A1 (en) | 2012-05-22 | 2013-11-28 | Dsm Ip Assets B.V. | Composition and process for making a porous inorganic oxide coating |
| JP2014024537A (ja) | 2012-06-19 | 2014-02-06 | 3M Innovative Properties Co | ナンバープレート用シート、ナンバープレート用積層体、ナンバープレートおよびナンバープレート用装飾部材 |
| TWI506064B (zh) | 2012-07-23 | 2015-11-01 | Innocom Tech Shenzhen Co Ltd | 量子點高分子複合膜及其製造方法 |
| KR101633957B1 (ko) | 2012-08-27 | 2016-06-27 | 이화여자대학교 산학협력단 | 피라졸 유도체를 포함하는 신장질환 예방 또는 치료용 조성물 |
| BR112015006056A2 (pt) | 2012-09-18 | 2017-07-04 | Abbvie Inc | métodos para tratar hcv |
| EP2897609A1 (en) | 2012-09-18 | 2015-07-29 | AbbVie Inc. | Methods for treating hepatitis c |
| SMT201900683T1 (it) | 2012-09-18 | 2020-01-14 | Abbvie Inc | Metodi per il trattamento di epatite c |
| US10172956B2 (en) | 2012-10-26 | 2019-01-08 | Vanderbilt University | Polymeric nanoparticles |
| US8758860B1 (en) | 2012-11-07 | 2014-06-24 | Bayer Materialscience Llc | Process for incorporating an ion-conducting polymer into a polymeric article to achieve anti-static behavior |
| US9585826B2 (en) | 2012-11-07 | 2017-03-07 | Kimberly-Clark Worldwide, Inc. | Triggerable compositions for two-stage, controlled release of active chemistry |
| US9447220B2 (en) | 2012-11-19 | 2016-09-20 | Rohm And Haas Electronic Materials Llc | Self-assembled structures, method of manufacture thereof and articles comprising the same |
| KR101312286B1 (ko) | 2012-11-26 | 2013-09-27 | (주)비씨월드제약 | 즉시방출 및 조절방출 특성을 갖고 d-트레오-메틸페니데이트를 포함하는 약학 조성물 |
| CN104968333B (zh) | 2012-11-30 | 2018-07-10 | 阿库拉制药公司 | 活性药物成分的自调节释放 |
| RU2505286C1 (ru) | 2012-12-29 | 2014-01-27 | Открытое Акционерное Общество "Фармасинтез" | Фармацевтическая композиция для лечения вич-инфекции, способ ее получения и способ лечения |
| TW201434936A (zh) | 2013-01-11 | 2014-09-16 | Nippon Soda Co | 無機粒子用分散劑、含有該分散劑之組成物、硬化性組成物、硬化物及薄膜 |
| NZ708272A (en) | 2013-01-22 | 2020-07-31 | Hoffmann La Roche | Pharmaceutical composition with improved bioavailability |
| KR101431957B1 (ko) | 2013-01-25 | 2014-08-19 | 경희대학교 산학협력단 | 피세틴 및 설퍼레틴을 유효성분으로 포함하는 염증성 질환 개선용 조성물 |
| CN103113509B (zh) | 2013-01-30 | 2016-05-04 | 华东理工大学 | 以l-甲状腺素为亲和配基的再生型亲和沉淀剂及制备方法和应用以及相关再生型聚合物 |
| KR20140105941A (ko) | 2013-02-25 | 2014-09-03 | 건양대학교산학협력단 | 어류 양식용 부상성(浮上性) 사료 및 그 제조 방법 |
| JP6309980B2 (ja) | 2013-02-25 | 2018-04-11 | ユニバーシティ オブ ロチェスター | 抗バイオフィルム剤を制御放出するためのナノ粒子及びその使用方法 |
| CN105142616B (zh) | 2013-03-01 | 2018-02-13 | Bpsi控股有限责任公司 | 含有硅酸钙的延迟释放薄膜包衣及其包被的底物 |
| WO2014159340A1 (en) | 2013-03-13 | 2014-10-02 | Tris Pharma, Inc. | Benzonatate modified release solid tablets and capsules |
| HK1216862A1 (zh) | 2013-03-26 | 2016-12-09 | 橘生药品工业株式会社 | 西洛多辛苦味被掩蔽的口服给药制剂 |
| KR101502588B1 (ko) | 2013-05-01 | 2015-03-16 | 한국유나이티드제약 주식회사 | 클로피도그렐 및 아스피린의 복합제제 |
| CN103255174B (zh) | 2013-05-02 | 2015-10-28 | 天津大学 | 以聚乙二醇接枝的透明质酸为外层的三元复合物及三元复合物的液体与应用 |
| CN103319668B (zh) | 2013-06-25 | 2015-11-11 | 常州大学 | 一种甲基丙烯酸丁酯-甲基丙烯酸二甲氨基乙酯嵌段共聚物的制备方法 |
| KR101458468B1 (ko) | 2013-06-27 | 2014-11-10 | 한국화학연구원 | 신규한 공중합체를 함유하는 제조가 용이한 리튬 이차전지용 겔 고분자 전해질 |
| CN103536972B (zh) | 2013-07-05 | 2016-01-13 | 北京大学 | 磁共振成像可检测的液体栓塞组合物及其制备和应用 |
| CN103333283B (zh) | 2013-07-15 | 2015-09-09 | 华东理工大学 | 可形成偏碱性两水相体系的两种pH响应再生型聚合物及其制备方法与应用 |
| US20150045353A1 (en) | 2013-08-09 | 2015-02-12 | Neurogenetic Pharmaceuticals, Inc. | Formulations containing gamma secretase modulators, methods for preparation and delivery thereof |
| US20140161893A1 (en) | 2013-08-16 | 2014-06-12 | University Of Washington Through Its Center For Commercialization | Polymer blend particles for intracellular delivery of agents |
| EP2842548A1 (en) | 2013-08-29 | 2015-03-04 | Universite De Liege | Polymeric synthetic antidote |
| CA2923029A1 (en) | 2013-09-03 | 2015-03-12 | Moderna Therapeutics, Inc. | Chimeric polynucleotides |
| WO2015034925A1 (en) | 2013-09-03 | 2015-03-12 | Moderna Therapeutics, Inc. | Circular polynucleotides |
| RU2646501C2 (ru) | 2013-09-11 | 2018-03-05 | 3М Инновейтив Пропертиз Компани | Композиции для полости рта |
| US9970040B2 (en) * | 2013-09-26 | 2018-05-15 | Massachusetts Institute Of Technology | Engineering DNA assembly in vivo and methods of making and using the reverse transcriptase technology |
| EP3052150B1 (en) | 2013-09-30 | 2021-02-17 | Lucite International Speciality Polymers and Resins Limited | A hardenable multi-part acrylic composition |
| GB201317299D0 (en) | 2013-09-30 | 2013-11-13 | Lucite Int Uk Ltd | A hardenable multi-part acrylic composition |
| US10023626B2 (en) | 2013-09-30 | 2018-07-17 | Modernatx, Inc. | Polynucleotides encoding immune modulating polypeptides |
| KR20160067219A (ko) | 2013-10-03 | 2016-06-13 | 모더나 세라퓨틱스, 인코포레이티드 | 저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드 |
| CN105658211A (zh) | 2013-10-07 | 2016-06-08 | 怡百克制药公司 | 左旋多巴和/或左旋多巴的酯的粘膜粘附性、控制释放调配物和其用途 |
| US9085618B2 (en) | 2013-10-18 | 2015-07-21 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same |
| US20160243221A1 (en) | 2013-10-18 | 2016-08-25 | Moderna Therapeutics, Inc. | Compositions and methods for tolerizing cellular systems |
| US9119780B2 (en) | 2013-10-30 | 2015-09-01 | Kimberly-Clark Worldwide, Inc. | Triggerable compositions for two-stage, controlled release of proactive chemistry |
| EP3068378A4 (en) | 2013-11-12 | 2017-05-03 | University Of Washington Through Its Center For Commercialization | Random copolymer therapeutic agent carriers and assemblies thereof |
| CA2929991A1 (en) * | 2013-11-28 | 2015-06-04 | Commonwealth Scientific And Industrial Research Organisation | Mikto-arm branched polymers |
| US20170173128A1 (en) | 2013-12-06 | 2017-06-22 | Moderna TX, Inc. | Targeted adaptive vaccines |
| WO2015089419A2 (en) | 2013-12-12 | 2015-06-18 | The Broad Institute Inc. | Delivery, use and therapeutic applications of the crispr-cas systems and compositions for targeting disorders and diseases using particle delivery components |
| CN106061292B (zh) | 2013-12-16 | 2020-01-21 | 麻省理工学院 | 强化的微量营养素盐调配物 |
| EP3208651A1 (en) | 2013-12-23 | 2017-08-23 | 3M Innovative Properties Company | Optical article |
| WO2015103490A1 (en) | 2014-01-03 | 2015-07-09 | Abbvie, Inc. | Solid antiviral dosage forms |
| CN103755870B (zh) | 2014-01-06 | 2016-10-26 | 苏州大学 | 一种含多巴胺无规共聚物及其精细制备方法和应用 |
| US20170002060A1 (en) | 2014-01-08 | 2017-01-05 | Moderna Therapeutics, Inc. | Polynucleotides for the in vivo production of antibodies |
| US20150232729A1 (en) | 2014-02-20 | 2015-08-20 | Georgia Southern Research and Service Foundation | Antifogging compositions and methods of making the same |
| CA2941612A1 (en) | 2014-03-05 | 2015-09-11 | Adaptive Biotechnologies Corporation | Methods using randomer-containing synthetic molecules |
| KR101663791B1 (ko) | 2014-03-07 | 2016-10-10 | 한국과학기술원 | 생체분자를 타겟팅하는 하이브리드 나노구조체 |
| US9750814B2 (en) | 2014-03-12 | 2017-09-05 | University Of Washington | Polypeptides to inhibit epstein barr viral protein BHRF1 and B cell lymphoma family proteins |
| HRP20220070T1 (hr) | 2014-04-23 | 2022-04-01 | Modernatx, Inc. | Cjepiva nukleinske kiseline |
| JP6573913B2 (ja) | 2014-05-20 | 2019-09-11 | エルテーエス ローマン テラピー−ジステーメ アーゲー | ロチゴチンを含む経皮送達システム |
| CN106456567A (zh) | 2014-05-20 | 2017-02-22 | Lts勒曼治疗系统股份公司 | 在经皮递送系统中调节活性剂释放的方法 |
| ES2954087T3 (es) | 2014-05-20 | 2023-11-20 | Lts Lohmann Therapie Systeme Ag | Sistema de administración transdérmica que incluye un mediador de interfase |
| CN103976972B (zh) | 2014-05-26 | 2017-09-12 | 中国药科大学 | 酒石酸唑吡坦口服脉冲控释给药系统及其制备方法 |
| IL291842A (en) | 2014-06-10 | 2022-06-01 | Afyx Therapeutics As | Compositions comprising electrohydrodynamically obtained fibres for administration of specific dosages of an active substance to skin or mucosa |
| RU2706791C2 (ru) | 2014-07-03 | 2019-11-21 | Пфайзер Инк. | Направленно доставляемые терапевтические наночастицы и способы их получения и использования |
| GB201412955D0 (en) | 2014-07-22 | 2014-09-03 | Aqdot Ltd | Supramolecular capsules |
| WO2016025747A1 (en) * | 2014-08-13 | 2016-02-18 | Stayton Patrick S | Nonlinear copolymers as intracellular delivery vehicles and related methods |
| JP6265093B2 (ja) | 2014-09-22 | 2018-01-24 | Jsr株式会社 | 着色組成物、着色硬化膜、並びに表示素子及び固体撮像素子 |
| CN107075274B (zh) | 2014-10-21 | 2019-12-13 | 帝斯曼知识产权资产管理有限公司 | 聚合物、方法和用途 |
| WO2016065306A1 (en) | 2014-10-23 | 2016-04-28 | The Brigham And Women's Hospital, Inc. | Amphiphile-polymer particles |
| FR3027802B1 (fr) | 2014-10-31 | 2018-03-02 | Ethypharm | Granules de principe actif a double masquage de gout, leur procede de preparation et comprimes orodispersibles les contenant |
| KR20170083071A (ko) | 2014-11-11 | 2017-07-17 | 시오노기 앤드 컴파니, 리미티드 | 광에 대해서 불안정한 약물을 함유하는 다층 정제 |
| RU2582704C1 (ru) | 2014-12-15 | 2016-04-27 | Общество с ограниченной ответственностью "СКИФ Спешиал Кемикалз" | Состав для поверхностной проклейки бумаги и картона |
| CN104479064B (zh) | 2014-12-18 | 2016-08-24 | 中国海洋石油总公司 | 一种聚驱采出液处理用反相破乳剂及其制备方法 |
| JP2016126154A (ja) | 2014-12-26 | 2016-07-11 | 花王株式会社 | カラーフィルター用顔料分散体 |
| EP3247328B1 (en) | 2015-01-21 | 2026-01-07 | Genevant Sciences Gmbh | Methods, compositions, and systems for delivering therapeutic and diagnostic agents into cells |
| WO2016134121A1 (en) | 2015-02-20 | 2016-08-25 | Cytec Industries Inc. | Dialkyl sulfosuccinate compositions, method of making, and method of use |
| CN104772051A (zh) | 2015-03-25 | 2015-07-15 | 浙江工业大学 | 一种共聚物亲水改性超滤膜及其制备方法与应用 |
| WO2016164762A1 (en) | 2015-04-08 | 2016-10-13 | Moderna Therapeutics, Inc. | Polynucleotides encoding low density lipoprotein receptor egf-a and intracellular domain mutants and methods of using the same |
| CN104784155B (zh) | 2015-05-15 | 2018-02-23 | 中国药科大学 | 一种盐酸普拉克索组合微丸胶囊及其制备方法 |
| KR101764785B1 (ko) | 2015-05-29 | 2017-08-07 | 한국유나이티드제약 주식회사 | 약제학적 복합제제 |
| CN104971073B (zh) | 2015-05-29 | 2018-01-12 | 西南药业股份有限公司 | 法莫替丁钙镁咀嚼片的制备方法及其产品 |
| EA201890068A1 (ru) | 2015-06-17 | 2018-09-28 | Байоджен Ма Инк. | Частицы диметилфумарата и фармацевтические композиции на их основе |
| CN104922078B (zh) | 2015-06-23 | 2018-10-23 | 上海市计划生育科学研究所 | 非诺贝特迟释微丸、制备方法及应用 |
| US20160375017A1 (en) | 2015-06-26 | 2016-12-29 | Abbvie Inc. | Solid Pharmaceutical Compositions for Treating HCV |
| WO2017009865A1 (en) | 2015-07-10 | 2017-01-19 | Sun Pharma Advanced Research Company Ltd. | Multiple pill abuse-resistant immediate release solid dosage form of hydrocodone |
| JP2017058405A (ja) | 2015-09-14 | 2017-03-23 | 富士ゼロックス株式会社 | 静電荷像現像剤、現像剤カートリッジ、プロセスカートリッジ、画像形成装置、及び、画像形成方法 |
| US20180237800A1 (en) | 2015-09-21 | 2018-08-23 | The Regents Of The University Of California | Compositions and methods for target nucleic acid modification |
| BR112018006206A2 (pt) | 2015-09-29 | 2018-10-09 | Achillion Pharmaceuticals Inc | composição, uso de uma combinação, forma de dosagem fixa farmacêutica, combinação de dosagem fixa, embalagem, e, uso de uma combinação de dose fixa |
| JP6954648B2 (ja) | 2015-10-19 | 2021-10-27 | シージー オンコロジー, インコーポレイテッド | 併用療法による固形腫瘍又はリンパ系腫瘍の治療方法 |
| US20180230489A1 (en) | 2015-10-28 | 2018-08-16 | Voyager Therapeutics, Inc. | Regulatable expression using adeno-associated virus (aav) |
| KR102435996B1 (ko) | 2015-11-19 | 2022-08-25 | 에이에프와이엑스 테라퓨틱스 에스에이 | 전기수력학적으로 수득된 섬유를 포함하는 약학적 조성물, 적용 부위에서 향상된 체류 시간을 갖는 조성물 |
| US20170296484A1 (en) | 2015-11-23 | 2017-10-19 | Grace Therapeutics Llc | Topical Film-Forming Spray |
| US10874991B2 (en) | 2015-11-27 | 2020-12-29 | Queen's University At Kingston | Functional filters for hydrophobic liquid/hydrophilic liquid separations |
| CN105504923B (zh) | 2015-12-07 | 2017-11-21 | 常州大学 | 一种快干型无溶剂涂料及其制备方法 |
| KR102408645B1 (ko) | 2015-12-24 | 2022-06-14 | (주)휴온스 | 안정성이 증가된 에스오메프라졸 함유 이중코팅정 조성물 및 이의 제조방법 |
| CA3007577A1 (en) | 2015-12-28 | 2017-07-06 | Nippon Shinyaku Co., Ltd. | Compression-molded preparation |
| JP7156945B2 (ja) | 2016-02-03 | 2022-10-19 | ノバルティス アーゲー | 有機化合物のガレヌス製剤 |
| PL4049660T3 (pl) | 2016-02-29 | 2025-06-09 | F. Hoffmann-La Roche Ag | Kompozycje postaci dawkowania zawierające inhibitor kinazy tyrozynowej Brutona |
| FR3048700B1 (fr) | 2016-03-08 | 2019-11-08 | Arkema France | Films poreux obtenus a partir de latex de polymeres |
| US11497781B2 (en) | 2016-03-10 | 2022-11-15 | Cg Oncology, Inc. | Methods of treating bladder cancer by combination therapy comprising the oncolytic adenovirus CG0070 and an immune checkpoint inhibitor |
| ES2935158T3 (es) | 2016-03-17 | 2023-03-02 | Sun Pharmaceutical Ind Ltd | Composición farmacéutica de nilotinib |
| KR102304478B1 (ko) | 2016-04-04 | 2021-09-24 | 주식회사 바오밥에이바이오 | Ras를 분해하는 이종원자고리화합물 및 이의 용도 |
| WO2017180587A2 (en) | 2016-04-11 | 2017-10-19 | Obsidian Therapeutics, Inc. | Regulated biocircuit systems |
| KR20260004568A (ko) | 2016-04-19 | 2026-01-08 | 더 브로드 인스티튜트, 인코퍼레이티드 | 신규한 crispr 효소 및 시스템 |
| CN105833272B (zh) | 2016-04-20 | 2020-08-21 | 国家纳米科学中心 | 一种多功能纳米药物组合物及其制备方法与应用 |
| CN105833287B (zh) | 2016-04-20 | 2020-07-10 | 国家纳米科学中心 | 一种缓释纳米药物载体及其制备方法与应用 |
| EP3448874A4 (en) | 2016-04-29 | 2020-04-22 | Voyager Therapeutics, Inc. | COMPOSITIONS FOR TREATING A DISEASE |
| EP3448987A4 (en) | 2016-04-29 | 2020-05-27 | Voyager Therapeutics, Inc. | COMPOSITIONS FOR TREATING A DISEASE |
| WO2017189963A1 (en) | 2016-04-29 | 2017-11-02 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
| TWI753910B (zh) | 2016-05-16 | 2022-02-01 | 美商拜歐斯瑞克斯公司 | 吡啶硫酮、其醫藥組合物及其治療增生性、炎性、神經退化性或免疫介導疾病之治療用途 |
| US12109305B2 (en) | 2016-05-27 | 2024-10-08 | Lyndra Therapeutics, Inc. | Materials architecture for gastric residence systems |
| CN105949365B (zh) | 2016-05-30 | 2018-10-19 | 山东鲁岳化工有限公司 | 一种珠状超高粘度水溶性阳离子聚合物及其制备方法 |
| WO2017210666A2 (en) | 2016-06-03 | 2017-12-07 | Stemgenics, Inc. | Functionalized nanoparticles for the intracellular delivery of biologically active molecules and methods for their manufacture and use |
| CN106117580A (zh) | 2016-06-23 | 2016-11-16 | 广州新克力生物科技有限公司 | 一种用于滤除白细胞的滤膜改性剂及其改性方法 |
| US9910353B2 (en) | 2016-07-29 | 2018-03-06 | Dow Global Technologies Llc | Method of negative tone development using a copolymer multilayer electrolyte and articles made therefrom |
| US9910355B2 (en) | 2016-07-29 | 2018-03-06 | Rohm And Haas Electronic Materials Llc | Method of negative tone development using a copolymer multilayer electrolyte and articles made therefrom |
| US20210330599A1 (en) | 2016-08-01 | 2021-10-28 | University Of Rochester | Nanoparticles for Controlled Release of Anti-Biofilm Agents and Methods of Use |
| JP6638706B2 (ja) | 2016-08-03 | 2020-01-29 | 東ソー株式会社 | ブロック共重合体およびそれを用いた表面処理剤 |
| CN106236785B (zh) | 2016-08-28 | 2019-08-27 | 福州海王金象中药制药有限公司 | 多糖蛋白片制备工艺 |
| KR101847604B1 (ko) | 2016-09-09 | 2018-04-11 | 주식회사 웨피 | 자외선 차단 성능이 우수한 수성 열반사 보온 단열도료 및 그 제조방법 |
| CN106478904B (zh) | 2016-09-26 | 2018-10-26 | 同济大学 | 一种具有温度和pH敏感性的多嵌段共聚物材料的制备方法 |
| KR20190065344A (ko) | 2016-10-03 | 2019-06-11 | 회가내스 아베 (피유비엘) | 백색 철 식품 첨가제 |
| KR102072546B1 (ko) | 2016-10-14 | 2020-02-04 | 주식회사 삼양바이오팜 | 레날리도마이드의 경구용 정제 조성물 |
| WO2018079573A1 (ja) | 2016-10-26 | 2018-05-03 | 味の素株式会社 | 消化管における吸収低下の改善用組成物、および消化管における吸収の促進用組成物 |
| KR101827744B1 (ko) | 2016-10-31 | 2018-02-09 | 부광약품 주식회사 | 톨리미돈의 대량 제조 방법 |
| US20200086616A1 (en) | 2016-12-16 | 2020-03-19 | Basf Se | Multi-layered film , method for the production and use thereof |
| WO2018112555A1 (en) | 2016-12-22 | 2018-06-28 | Commonwealth Scientific And Industrial Research Organisation | Aqueous polymer composition |
| JP2020502226A (ja) * | 2016-12-23 | 2020-01-23 | コモンウェルス サイエンティフィック アンド インダストリアル リサーチ オーガナイゼーション | 薬物の標的送達のための生体適合性の親水性ポリマーコンジュゲート |
| KR101850629B1 (ko) | 2016-12-28 | 2018-04-20 | 연세대학교 원주산학협력단 | 항균제가 담지된 금속이중층수산화물 나노구조체를 함유하는 신선편이 농산물의 선도 유지용 조성물 |
| BR112019015107A2 (pt) | 2017-01-23 | 2020-03-10 | Dong Wha Pharm. Co., Ltd. | Formulação de complexo compreendendo inibidor de hmg-coa redutase e clopidogrel |
| AU2018212273B2 (en) | 2017-01-26 | 2023-12-21 | Triastek, Inc. | Dosage forms of controlled release at specific gastrointestinal sites |
| WO2018139626A1 (ja) | 2017-01-30 | 2018-08-02 | 塩野義製薬株式会社 | キナゾリン誘導体を含有する固形製剤 |
| CN106811998B (zh) | 2017-02-15 | 2019-09-24 | 山东聚发生物科技有限公司 | 一种交联型无醛固色剂乳液及其制备方法 |
| WO2018155555A1 (ja) | 2017-02-27 | 2018-08-30 | Jsr株式会社 | 基材表面の選択的修飾方法 |
| KR20180099263A (ko) | 2017-02-28 | 2018-09-05 | 경남대학교 산학협력단 | 피세틴을 포함하는 피부건강용 조성물 |
| JP2018154752A (ja) | 2017-03-17 | 2018-10-04 | 東ソー株式会社 | 共重合体およびその製造方法 |
| JP7127330B2 (ja) | 2017-04-12 | 2022-08-30 | 東ソー株式会社 | ブロック共重合体およびそれを用いた表面処理剤 |
| KR102542711B1 (ko) | 2017-04-13 | 2023-06-12 | 오지 홀딩스 가부시키가이샤 | 가식 성형용 점착 시트 |
| WO2018192910A2 (en) | 2017-04-18 | 2018-10-25 | Dsm Ip Assets B.V. | Process for making an anti-soiling coating composition and a coating made therefrom |
| EP3615147B1 (de) | 2017-04-28 | 2024-09-11 | Symrise AG | Schafgarbe frischpflanzenpresssaft konzentrat, herstellung und verwendung |
| KR102082775B1 (ko) | 2017-05-02 | 2020-02-28 | 주식회사 삼양바이오팜 | 수용해도 및 생체이용율이 개선된 조성물 |
| WO2018213361A1 (en) | 2017-05-15 | 2018-11-22 | Vanderbilt University | LONG-CIRCULATING ZWITTERIONIC POLYPLEXES FOR siRNA DELIVERY |
| JP2018203987A (ja) | 2017-05-30 | 2018-12-27 | 東ソー株式会社 | 表面処理剤のコート方法 |
| KR20200014353A (ko) | 2017-06-02 | 2020-02-10 | 사우디 아라비안 오일 컴퍼니 | 코팅된 실리카 입자 |
| CN107173546A (zh) | 2017-06-12 | 2017-09-19 | 揭阳市润达肠衣有限公司 | 一种含大蒜精油的掩味控释颗粒及其制备方法和应用 |
| JOP20190269A1 (ar) | 2017-06-15 | 2019-11-20 | Voyager Therapeutics Inc | بولي نوكليوتيدات aadc لعلاج مرض باركنسون |
| FR3068704B1 (fr) | 2017-07-06 | 2021-02-19 | Centre Nat Rech Scient | Materiau solide organique antibacterien |
| WO2019027767A1 (en) | 2017-07-31 | 2019-02-07 | Illumina Inc. | SEQUENCING SYSTEM COMPRISING AGGREGATION OF MULTIPLEXED BIOLOGICAL SAMPLES |
| US11512327B2 (en) | 2017-08-03 | 2022-11-29 | Voyager Therapeutics, Inc. | Compositions and methods for delivery of AAV |
| EP3668484B1 (en) | 2017-08-17 | 2022-07-13 | F. Hoffmann-La Roche AG | Novel pharmaceutical compositions for basic or neutral, low molecular weight compounds |
| US11013695B2 (en) | 2017-08-28 | 2021-05-25 | Wisconsin Alumni Research Foundation | Nanocapsule delivery system for ribonucleoproteins |
| KR102394794B1 (ko) | 2017-09-01 | 2022-05-04 | 현대자동차주식회사 | 탄소섬유 강화 고분자 복합재료 및 이의 제조방법 |
| US11125748B2 (en) | 2017-09-01 | 2021-09-21 | University Of British Columbia | Method for organizing individual molecules on a patterned substrate and structures assembled thereby |
| WO2019048962A1 (en) | 2017-09-08 | 2019-03-14 | 3M Innovative Properties Company | AQUEOUS FLUORIDE TREATMENT COMPOSITIONS FOR ORAL CARE, AND METHODS |
| MA50189A (fr) | 2017-09-22 | 2021-05-19 | Dispersol Technologies Llc | Formulations pharmaceutiques d'oligomère cyclique et d'abiratérone et procédés de formation et d'administration de celles-ci |
| CN107596368B (zh) | 2017-10-11 | 2020-02-14 | 华南师范大学 | 一种细菌靶向纳米粒子的制备及其抑杀细菌的应用 |
| MX2020004491A (es) | 2017-10-30 | 2020-08-13 | Kaken Pharma Co Ltd | Preparacion externa para tratar tinea unguium. |
| KR102184117B1 (ko) | 2017-10-31 | 2020-11-30 | 주식회사 삼양바이오팜 | 수용해도 및 생체이용율이 개선된 소라페닙 나노입자 경구용 조성물 및 이의 제조 방법 |
| EP3705118B1 (en) | 2017-10-31 | 2024-02-14 | Samyang Holdings Corporation | Oral solid dosage form composition having improved disintegration and preparation method therefor |
| KR101840702B1 (ko) | 2017-11-01 | 2018-03-22 | 압타바이오 주식회사 | 간질환 치료제 |
| US20210163933A1 (en) | 2017-12-11 | 2021-06-03 | University Of Massachusetts | Arc protein extracellular vesicle nucleic acid delivery platform |
| US10920061B2 (en) | 2017-12-29 | 2021-02-16 | Kyungpook National University Industry-Academic Cooperation Foundation | Self-healing acrylic copolymer, crosslinked copolymer prepared from the acrylic copolymer and method for low-temperature self-healing of the crosslinked copolymer |
| US10201503B1 (en) | 2018-01-09 | 2019-02-12 | Triastek, Inc. | Precision pharmaceutical 3D printing device |
| JP6959154B2 (ja) | 2018-01-23 | 2021-11-02 | 大阪有機化学工業株式会社 | 化粧料組成物 |
| US11253484B2 (en) | 2018-01-30 | 2022-02-22 | Nitto Denko Corporation | Transdermal absorption preparation |
| EP3759225A1 (en) * | 2018-03-02 | 2021-01-06 | Sixfold Bioscience Ltd. | Compositions for delivery of cargo to cells |
| KR20190111448A (ko) | 2018-03-23 | 2019-10-02 | 주식회사 제이와이에스앤텍 | 부착용 방담필름 |
| JP7581052B2 (ja) | 2018-04-13 | 2024-11-12 | サムヤン ホールディングス コーポレイション | レナリドミドの経口用コーティング錠剤組成物 |
| GB201807853D0 (en) | 2018-05-15 | 2018-06-27 | Univ College Cardiff Consultants Ltd | Polymers |
| US11702653B2 (en) | 2018-05-21 | 2023-07-18 | Battelle Memorial Institute | Control compositions and methods for sequencing |
| KR101923028B1 (ko) | 2018-05-28 | 2018-11-29 | (주)무량기술 | 용융형 도로 표시용 조성물 및 이의 시공 방법 |
| BR112020024269A2 (pt) | 2018-05-31 | 2021-02-23 | Hua Medicine (Shanghai) Ltd. | combinação farmacêutica, composição e formulação de combinação contendo ativador de glucoquinase e ativador de receptor ppar e métodos de preparação e usos dos mesmos |
| US11344506B2 (en) | 2018-07-11 | 2022-05-31 | Cure Pharmaceutical Holding Corp. | Rapidly disintegrating oral dissolvable film |
| KR102120720B1 (ko) | 2018-07-16 | 2020-06-10 | 연성정밀화학(주) | 날푸라핀 함유 구강붕해정 |
| KR101943270B1 (ko) | 2018-07-17 | 2019-01-28 | 코오롱제약주식회사 | 맛차폐된 시나칼셋 구강붕해정 및 그 제조방법 |
| KR20200009744A (ko) | 2018-07-20 | 2020-01-30 | 크리스탈지노믹스(주) | Fab I 저해제를 포함하는 경구투여용 약제학적 조성물 및 그 제조방법 |
| WO2020023612A1 (en) | 2018-07-24 | 2020-01-30 | Voyager Therapeutics, Inc. | Systems and methods for producing gene therapy formulations |
| CN112912420A (zh) | 2018-08-16 | 2021-06-04 | 巴斯夫欧洲公司 | 聚合物组合物 |
| JP2021533177A (ja) | 2018-08-23 | 2021-12-02 | チョン クン ダン ファーマシューティカル コーポレイション | エソメプラゾール及び炭酸水素ナトリウムを含む、優れた溶解特性を備えた薬学的製剤 |
| US20200069696A1 (en) | 2018-08-30 | 2020-03-05 | Yunxiang Liu | Ophthalmic injectable formulation preparing and oculopathy treating and preventing |
| US20210371470A1 (en) | 2018-10-12 | 2021-12-02 | Voyager Therapeutics, Inc. | Compositions and methods for delivery of aav |
| KR102300335B1 (ko) | 2018-10-19 | 2021-09-10 | 주식회사 삼양홀딩스 | 아프레피탄트의 경구용 조성물 |
| CN112955130A (zh) | 2018-10-30 | 2021-06-11 | 佩洛通治疗公司 | 包含取代茚满的固体分散体和药物组合物及其制备和使用方法 |
| BR112021007656A2 (pt) | 2018-10-30 | 2021-07-27 | Basf Se | processo para produzir micropartículas carregadas com pelo menos um ativo orgânico de baixo peso molecular, composição de micropartículas preenchidas com pelo menos um ativo, produto, e, uso da composição. |
| US12508233B2 (en) | 2018-10-30 | 2025-12-30 | Vanderbilt University | Graft copolymers, methods of forming graft copolymers, and methods of use thereof |
| EP3873440A4 (en) | 2018-11-01 | 2022-08-17 | Molecular Infusions, LLC | POLYMER-BASED ORAL CANNABINOID AND/OR TERPEN FORMULATIONS |
| JP7262206B2 (ja) | 2018-11-07 | 2023-04-21 | 東ソー株式会社 | 溶出物試験方法 |
| MX2021005997A (es) | 2018-11-21 | 2021-08-11 | Vectores virales recombinantes y acidos nucleicos para producirlos. | |
| WO2020123661A1 (en) | 2018-12-11 | 2020-06-18 | Farokhzad Omid C | Methods for treating cancer |
| KR20200090359A (ko) | 2019-01-21 | 2020-07-29 | 크리스탈지노믹스(주) | Fab I 저해제를 포함하는 주사제용 조성물 및 그 제조방법 |
| WO2020154595A1 (en) | 2019-01-24 | 2020-07-30 | Massachusetts Institute Of Technology | Nucleic acid nanostructure platform for antigen presentation and vaccine formulations formed therefrom |
| CN121081491A (zh) | 2019-03-04 | 2025-12-09 | 旗舰创业创新第六有限责任公司 | 环状多核糖核苷酸及其药物组合物 |
| KR102107332B1 (ko) | 2019-03-20 | 2020-05-07 | (주)제이비바이오텍 | CRISPR/Cas9 기반 Bacillus subtillis 유전체 편집 메커니즘을 이용한 콜레라 백신 |
| US20200308331A1 (en) | 2019-03-28 | 2020-10-01 | Penn Color, Inc. | Water compatible cationic graft copolymers and ink compositions comprising same |
| KR102349029B1 (ko) | 2019-04-18 | 2022-01-10 | 한양대학교 에리카산학협력단 | 자극 반응성을 가진 양친성 노보넨 기반 블럭 공중합체, 이의 고분자 브러쉬, 이의 초분자 자가조립 나노구조체, 이의 제조 방법 및 이의 응용 |
| US20220243225A1 (en) | 2019-04-29 | 2022-08-04 | Voyager Therapeutics, Inc. | SYSTEMS AND METHODS FOR PRODUCING BACULOVIRAL INFECTED INSECT CELLS (BIICs) IN BIOREACTORS |
| JP7568380B2 (ja) | 2019-05-28 | 2024-10-16 | トイメディカル株式会社 | ナトリウム排出粒子 |
| US20220233459A1 (en) | 2019-06-05 | 2022-07-28 | Guide Therapeutics, Inc. | Analysis of materials for tissue delivery |
| KR102157964B1 (ko) | 2019-06-13 | 2020-09-22 | (주)제이비바이오텍 | CRISPR/Cas9 기반 Bacillus subtilis 유전체 편집 메커니즘을 이용한 돼지의 아프리카 돼지열병 백신 |
| WO2021007382A1 (en) | 2019-07-09 | 2021-01-14 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of parkinson's disease |
| AU2020315401B2 (en) | 2019-07-16 | 2025-05-22 | The Regents Of The University Of Michigan | Imidazopyrimidines as EED inhibitors and the use thereof |
| KR102207353B1 (ko) | 2019-08-28 | 2021-01-27 | (주)제이비바이오텍 | CRISPR/Cas9 기반 Bacillus subtilis 유전체 편집 메커니즘을 이용한 돼지의 괴사성장염 백신 |
| KR102207354B1 (ko) | 2019-09-02 | 2021-01-27 | (주)제이비바이오텍 | CRISPR/Cas9 기반 Bacillus subtilis 유전체 편집 메커니즘을 이용한 닭의 괴사성장염 백신 |
| US11564884B2 (en) | 2019-09-09 | 2023-01-31 | Regents Of The University Of Minnesota | Cationic block polymer micelles for delivery of biological agents |
| EP4045655A4 (en) | 2019-10-16 | 2024-02-28 | King Abdullah University Of Science And Technology | METHOD FOR MODULATING HUMAN L1 RETRO TRANSPOSON RNA AND COMPOSITIONS FOR USE THEREIN |
| KR102212504B1 (ko) | 2019-10-28 | 2021-02-08 | 주식회사 제이비바이오텍 농업회사법인 | CRISPR/Cas9 기반 Bacillus subtilis 유전체 편집 메커니즘을 이용한 개의 켄넬코프 백신 |
| KR102212505B1 (ko) | 2019-10-28 | 2021-02-05 | 주식회사 제이비바이오텍 농업회사법인 | CRISPR/Cas9 기반 Bacillus subtilis 유전체 편집 메커니즘을 이용한 벌의 낭충봉아부패 백신 |
| KR102212503B1 (ko) | 2019-10-28 | 2021-02-05 | 주식회사 제이비바이오텍 농업회사법인 | CRISPR/Cas9 기반 Bacillus subtilis 유전체 편집 메커니즘을 이용한 넙치의 스쿠티카증 백신 |
| KR102842351B1 (ko) | 2019-11-05 | 2025-08-04 | 아주대학교산학협력단 | 레바미피드 또는 이의 약학적으로 허용가능한 염을 포함하는 경구투여용 서방성 약학 조성물 |
| CN115175668A (zh) | 2019-12-20 | 2022-10-11 | 三养控股公司 | 具有改善的奥拉帕尼的溶解度和生物利用率的组合物 |
| WO2021145655A1 (ko) | 2020-01-13 | 2021-07-22 | 압타바이오 주식회사 | 신규한 피라졸 유도체 |
| JP2023511282A (ja) | 2020-01-14 | 2023-03-17 | シンロジック オペレーティング カンパニー インコーポレイテッド | シュウ酸塩が有害となる障害を治療するための遺伝子改変細菌 |
| KR102366598B1 (ko) | 2020-03-20 | 2022-02-24 | 광주과학기술원 | 양쪽 이온성 관능기를 가지는 랜덤 공중합체를 포함하는 공기 필터용 나노섬유 및 그 제조방법 |
| KR20210119906A (ko) | 2020-03-25 | 2021-10-06 | 주식회사 삼양홀딩스 | 포말리도마이드의 경구용 정제 조성물 및 이의 제조 방법 |
| KR102672103B1 (ko) | 2020-04-01 | 2024-06-04 | 연세대학교 산학협력단 | 노로바이러스성 질환의 치료용 조성물 |
| DE102020002360A1 (de) | 2020-04-18 | 2021-10-21 | Friedrich-Schiller-Universität Jena | Nanopartikel enthaltend Komplexe aus Nukleinsäuren und kationischen Copolymeren, Verfahren zu deren Herstellung und deren Verwendung zum Gentransfer in Zellen |
| WO2021255262A1 (en) | 2020-06-19 | 2021-12-23 | Sylentis Sau | siRNA AND COMPOSITIONS FOR PROPHYLACTIC AND THERAPEUTIC TREATMENT OF VIRUS DISEASES |
| EP3960203A1 (en) | 2020-08-25 | 2022-03-02 | Université de Liège | Complexes for the delivery of proteinaceous agents |
| JP7533087B2 (ja) | 2020-09-30 | 2024-08-14 | 日油株式会社 | 共重合体、共重合体の製造方法、細胞凍結保存材及び細胞凍結保存液 |
| CA3196560A1 (en) | 2020-10-27 | 2022-05-05 | Mitsubishi Pencil Company, Limited | Marker composition for skin |
| JP2022076360A (ja) | 2020-11-09 | 2022-05-19 | 日本電信電話株式会社 | 形状記憶性高分子積層膜およびその製造方法 |
| IL303390A (en) | 2020-12-03 | 2023-08-01 | Battelle Memorial Institute | Compositions of polymer nanoparticles and DNA nanostructures and methods for non-viral transport |
| EP4015634A1 (en) | 2020-12-15 | 2022-06-22 | Sylentis, S.A.U. | Sirna and compositions for prophylactic and therapeutic treatment of virus diseases |
| WO2022139687A1 (en) | 2020-12-23 | 2022-06-30 | Croda Singapore Pte Limited | Soot dispersant comprising block copolymer and lubricant composition containing the same |
| JP2022117407A (ja) | 2021-01-29 | 2022-08-10 | 花王株式会社 | 外用剤組成物 |
| IL305336B2 (en) | 2021-03-11 | 2025-09-01 | Nautilus Subsidiary Inc | Systems and methods for preserving biomolecules |
| WO2022197654A1 (en) | 2021-03-15 | 2022-09-22 | E Ink Corporation | Switchable light modulator having regions of varying opacity |
| WO2022216977A1 (en) | 2021-04-07 | 2022-10-13 | Batelle Memorial Institute | Rapid design, build, test, and learn technologies for identifying and using non-viral carriers |
| EP4340847A4 (en) | 2021-05-21 | 2024-07-17 | ILKO Ilaç Sanayi ve Ticaret A.S. | MESALAZIN-BASED ENTERIC TABLET FORMULATION COMPOSITION |
| CN117677708A (zh) | 2021-06-09 | 2024-03-08 | 麻省理工学院 | 序列控制聚合物存储 |
| WO2022266119A1 (en) | 2021-06-16 | 2022-12-22 | Edwards Lifesciences Corporation | Multifunctional sealing member for improved endothelialization and paravalvular leakage |
| WO2023023055A1 (en) | 2021-08-16 | 2023-02-23 | Renagade Therapeutics Management Inc. | Compositions and methods for optimizing tropism of delivery systems for rna |
| WO2023107574A2 (en) | 2021-12-07 | 2023-06-15 | The Brigham And Women’S Hospital, Inc. | Lipid-based compositions and methods thereof |
| PL245677B1 (pl) | 2022-02-23 | 2024-09-16 | Podkarpackie Centrum Innowacji Spolka Z Ograniczona Odpowiedzialnoscia | Polimery gwiaździste, sposób otrzymywania polimerów gwiaździstych oraz ich zastosowanie |
| CN118660707A (zh) | 2022-04-08 | 2024-09-17 | 北京睿创康泰医药研究院有限公司 | 超分子自组装体系 |
| CA3258934A1 (en) | 2022-06-09 | 2023-12-14 | Battelle Memorial Institute | NON-VIRAL ADMINISTRATION OF SMALL MOLECULE THERAPEUTIC AGENTS |
| AU2023285047A1 (en) | 2022-06-09 | 2024-12-12 | Battelle Memorial Institute | Non-viral delivery compositions and screening methods |
| WO2024036356A1 (en) * | 2022-08-15 | 2024-02-22 | Newsouth Innovations Pty Limited | Additive manufacturing method |
| CN115714187A (zh) | 2022-10-12 | 2023-02-24 | 池州学院 | 一种中间催化层改性的双极膜及其制备方法 |
-
2021
- 2021-12-03 IL IL303390A patent/IL303390A/en unknown
- 2021-12-03 US US17/542,055 patent/US20220175812A1/en not_active Abandoned
- 2021-12-03 EP EP21901543.5A patent/EP4255495A4/en active Pending
- 2021-12-03 AU AU2021391823A patent/AU2021391823A1/en active Pending
- 2021-12-03 JP JP2023534084A patent/JP2023553010A/ja active Pending
- 2021-12-03 CN CN202180092894.XA patent/CN116887866A/zh active Pending
- 2021-12-03 CA CA3203975A patent/CA3203975A1/en active Pending
- 2021-12-03 WO PCT/US2021/061846 patent/WO2022120194A1/en not_active Ceased
-
2024
- 2024-02-16 US US18/444,146 patent/US12109223B2/en active Active
- 2024-08-27 US US18/816,696 patent/US12433910B2/en active Active
-
2025
- 2025-09-17 US US19/331,773 patent/US20260014186A1/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120251583A1 (en) * | 2005-06-14 | 2012-10-04 | The California Institute Of Technology | Methods of making nucleic acid nanostructures |
| US20150104408A1 (en) * | 2012-04-18 | 2015-04-16 | Arrowhead Madison Inc. | Poly(acrylate) Polymers for In Vivo Nucleic Acid Delivery |
| WO2019126627A1 (en) * | 2017-12-22 | 2019-06-27 | Rensselaer Polytechnic Institute | Dna origami nanoparticle delivery of programmed chromosome breakage machinery |
| WO2019152957A1 (en) * | 2018-02-02 | 2019-08-08 | Arizona Board Of Regents On Behalf Of Arizona State University | Dna-chimeric antigen receptor t cells for immunotherapy |
| WO2020051507A1 (en) * | 2018-09-06 | 2020-03-12 | The Broad Institute, Inc. | Nucleic acid assemblies for use in targeted delivery |
Non-Patent Citations (1)
| Title |
|---|
| See also references of EP4255495A4 * |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12109223B2 (en) | 2020-12-03 | 2024-10-08 | Battelle Memorial Institute | Polymer nanoparticle and DNA nanostructure compositions and methods for non-viral delivery |
| US12433910B2 (en) | 2020-12-03 | 2025-10-07 | Battelle Memorial Institute | Polymer nanoparticle and DNA nanostructure compositions and methods for non-viral delivery |
| US12031128B2 (en) | 2021-04-07 | 2024-07-09 | Battelle Memorial Institute | Rapid design, build, test, and learn technologies for identifying and using non-viral carriers |
| US12709747B2 (en) | 2023-09-27 | 2026-08-18 | Battelle Memorial Institute | Rapid design, build, test, and learn technologies for identifying and using non-viral carriers |
| WO2025072893A1 (en) * | 2023-09-29 | 2025-04-03 | Battelle Memorial Institute | Polymer nanoparticle compositions for non-viral gene delivery |
| WO2025072751A1 (en) * | 2023-09-29 | 2025-04-03 | Battelle Memorial Institute | Polymer nanoparticle compositions for in vivo expression of polypeptides |
| WO2025072801A1 (en) * | 2023-09-29 | 2025-04-03 | Battelle Memorial Institute | Polymer nanoparticle compositions for non-viral gene delivery to the central nervous system |
| US12458606B2 (en) | 2023-09-29 | 2025-11-04 | Battelle Memorial Institute | Polymer nanoparticle compositions for in vivo expression of polypeptides |
| WO2025250979A1 (en) * | 2024-05-31 | 2025-12-04 | Battelle Memorial Institute | Polymer nanoparticle compositions for non-viral gene delivery |
Also Published As
| Publication number | Publication date |
|---|---|
| US20240415865A1 (en) | 2024-12-19 |
| EP4255495A1 (en) | 2023-10-11 |
| US20220175812A1 (en) | 2022-06-09 |
| CN116887866A (zh) | 2023-10-13 |
| US20260014186A1 (en) | 2026-01-15 |
| IL303390A (en) | 2023-08-01 |
| US20240189338A1 (en) | 2024-06-13 |
| US12433910B2 (en) | 2025-10-07 |
| AU2021391823A9 (en) | 2024-10-10 |
| AU2021391823A1 (en) | 2023-06-29 |
| US12109223B2 (en) | 2024-10-08 |
| JP2023553010A (ja) | 2023-12-20 |
| CA3203975A1 (en) | 2022-06-09 |
| EP4255495A4 (en) | 2025-10-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12433910B2 (en) | Polymer nanoparticle and DNA nanostructure compositions and methods for non-viral delivery | |
| Yang et al. | Self-assembled double-bundle DNA tetrahedron for efficient antisense delivery | |
| Cho et al. | Synthesis of biocompatible PEG-based star polymers with cationic and degradable core for siRNA delivery | |
| Huh et al. | pH-sensitive polymers for drug delivery | |
| Yang et al. | Impact of PEG chain length on the physical properties and bioactivity of PEGylated chitosan/siRNA nanoparticles in vitro and in vivo | |
| Jain et al. | Comparison of avidin, neutravidin, and streptavidin as nanocarriers for efficient siRNA delivery | |
| Sunshine et al. | Poly (β-amino ester)-nanoparticle mediated transfection of retinal pigment epithelial cells in vitro and in vivo | |
| Taranejoo et al. | Bioreducible PEI-functionalized glycol chitosan: A novel gene vector with reduced cytotoxicity and improved transfection efficiency | |
| US8936907B2 (en) | Neural transfection reagents | |
| Sunasee et al. | Biodegradable and nontoxic nanogels as nonviral gene delivery systems | |
| Haladjova et al. | Polymeric nanoparticle engineering: from temperature-responsive polymer mesoglobules to gene delivery systems | |
| Peterson et al. | Controlling self‐assembly of DNA‐polymer conjugates for applications in imaging and drug delivery | |
| WO2022216977A1 (en) | Rapid design, build, test, and learn technologies for identifying and using non-viral carriers | |
| Street et al. | Length-controlled nanofiber micelleplexes as efficient nucleic acid delivery vehicles | |
| Fay et al. | Gene delivery using dimethyldidodecylammonium bromide-coated PLGA nanoparticles | |
| Helal et al. | Non-viral gene delivery systems: hurdles for bench-to-bedside transformation | |
| Xiong et al. | Engineered Aptamer‐Organic Amphiphile Self‐Assemblies for Biomedical Applications: Progress and Challenges | |
| CN115715186A (zh) | 含核酸与阳离子共聚物的复合物的纳米粒子及其制备方法、用于基因转移至细胞中的用途 | |
| Kly et al. | Hierarchical self-assembly route to “polyplex-in-hydrophobic-core” micelles for gene delivery | |
| Patnaik et al. | PEI-alginate nanocomposites: efficient non-viral vectors for nucleic acids | |
| Thomas et al. | Dextran–glycidyltrimethylammonium chloride conjugate/DNA nanoplex: A potential non-viral and haemocompatible gene delivery system | |
| Yang et al. | Synthetic conjugated Oligoelectrolytes are effective siRNA transfection carriers: relevance to pancreatic cancer gene therapy | |
| Chen et al. | αvβ3 Receptor-targeted acid-responsive controlled-release endosome escape doxorubicin-loaded liposomes for A549/ADR treatment | |
| Lawson et al. | The spatial distribution of lipophilic cations in gradient copolymers regulates polymer–pDNA complexation, polyplex aggregation, and intracellular pDNA delivery | |
| Bristow et al. | Aptamer-targeted dendrimersomes assembled from azido-modified Janus dendrimers “clicked” to DNA |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21901543 Country of ref document: EP Kind code of ref document: A1 |
|
| ENP | Entry into the national phase |
Ref document number: 3203975 Country of ref document: CA |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2023534084 Country of ref document: JP |
|
| ENP | Entry into the national phase |
Ref document number: 2021391823 Country of ref document: AU Date of ref document: 20211203 Kind code of ref document: A |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| ENP | Entry into the national phase |
Ref document number: 2021901543 Country of ref document: EP Effective date: 20230703 |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 202180092894.X Country of ref document: CN |